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Overview {#bph13354-sec-0003}
========

Enzymes are protein catalysts facilitating the conversion of substrates into products. The Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC‐IUBMB) classifies enzymes into families, using a four number code, on the basis of the reactions they catalyse. There are six main families:

EC 1.‐.‐.‐ Oxidoreductases;

EC 2.‐.‐.‐ Transferases;

EC 3.‐.‐.‐ Hydrolases;

EC 4.‐.‐.‐ Lyases;

EC 5.‐.‐.‐ Isomerases;

EC 6.‐.‐.‐ Ligases.

Although there are many more enzymes than receptors in biology, and many drugs that target prokaryotic enzymes are effective medicines, overall the number of enzyme drug targets is relatively small \[[367](http://www.ncbi.nlm.nih.gov/pubmed/17139284?dopt=AbstractPlus), [401](http://www.ncbi.nlm.nih.gov/pubmed/24016212?dopt=AbstractPlus)\], which is not to say that they are of modest importance.

The majority of drugs which act on enzymes act as inhibitors; one exception is metformin, which appears to stimulate activity of AMP‐activated protein kinase, albeit through an imprecisely‐defined mechanism. Kinetic assays allow discrimination of competitive, non‐competitive, and un‐competitive inhibitors. The majority of inhibitors are competitive (acting at the enzyme\'s ligand recognition site), non‐competitive (acting at a distinct site; potentially interfering with co‐factor or co‐enzyme binding) or of mixed type. One rare example of an uncompetitive inhibitor is lithium ions, which are effective inhibitors at inositol monophosphatase only in the presence of high substrate concentrations. Some inhibitors are irreversible, including a group known as suicide substrates, which bind to the ligand recognition site and then couple covalently to the enzyme. It is beyond the scope of the Guide to give mechanistic information about the inhibitors described, although generally this information is available from the indicated literature.

Many enzymes require additional entities for functional activity. Some of these are used in the catalytic steps, while others promote a particular conformational change. Co‐factors are tightly bound to the enzyme and include metal ions and heme groups. Co‐enzymes are typically small molecules which accept or donate functional groups to assist in the enzymatic reaction. Examples include ATP, NAD, NADP and S‐adenosylmethionine, as well as a number of vitamins, such as riboflavin (vitamin B1) and thiamine (vitamin B2). Where co‐factors/co‐enzymes have been identified, the Guide indicates their involvement.

Family structure {#bph13354-sec-0004}
================

This is a complete listing of enzyme families included in the online IUPHAR/BPS Guide to PHARMACOLOGY database. Summary information is provided for a subset of enzyme families (those with page numbers) in the tables below. Family members judged to be of significant pharmacological interest have been included, with further enzymes listed in the database.

[6028 Protein Kinases (EC 2.7.x.x)](#bph13354-sec-0005){ref-type="sec"}

[‐ AGC: Containing PKA, PKC, PKG families](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=677)

[‐ DMPK family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=454)

[‐ GEK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=500)

[‐ Other DMPK family kinases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=573)

[6028 Rho kinase](#bph13354-sec-0008){ref-type="sec"}

[‐ G protein‐coupled receptor kinases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=283)

[‐ BARK/GRK2 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=507)

[‐ GRK1/3 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=508)

[‐ MAST family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=583)

[‐ NDR family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=587)

[‐ PDK1 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=604)

[‐ Protein kinase A](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=284)

[‐ Akt (Protein kinase B)](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=285)

[6029 Protein kinase C (PKC)](#bph13354-sec-0010){ref-type="sec"}

[6029 Alpha subfamily](#bph13354-sec-0012){ref-type="sec"}

[6029 Delta subfamily](#bph13354-sec-0013){ref-type="sec"}

[6030 Eta subfamily](#bph13354-sec-0014){ref-type="sec"}

[‐ Iota subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=535)

[‐ Protein kinase G (PKG)](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=287)

[‐ Protein kinase N (PKN) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=601)

[‐ RSK family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=466)

[‐ MSK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=539)

[‐ p70 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=540)

[‐ RSK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=541)

[‐ RSKR subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=705)

[‐ RSKL family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=614)

[‐ SGK family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=616)

[‐ YANK family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=644)

[‐ Atypical](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=678)

[‐ ABC1 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=448)

[‐ ABC1‐A subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=468)

[‐ ABC1‐B subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=469)

[‐ Alpha kinase family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=450)

[‐ ChaK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=471)

[‐ eEF2K subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=472)

[‐ Other alpha kinase family kinases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=556)

[‐ BCR family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=874)

[‐ Bromodomain kinase (BRDK) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=558)

[‐ G11 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=576)

[‐ Phosphatidyl inositol 3\' kinase‐related kinases (PIKK) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=463)

[‐ ATR subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=528)

[6030 FRAP subfamily](#bph13354-sec-0015){ref-type="sec"}

[‐ SMG1 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=530)

[‐ TRRAP subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=531)

[‐ Other PIKK family kinases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=598)

[‐ RIO family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=465)

[‐ RIO1 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=536)

[‐ RIO2 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=537)

[‐ RIO3 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=538)

[‐ PDHK family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=596)

[‐ Pyruvate dehydrogenase kinase (PDHK) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=608)

[‐ TAF1 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=626)

[‐ TIF1 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=631)

[‐ CAMK: Calcium/calmodulin‐dependent protein kinases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=679)

[‐ CAMK‐like (CAMKL) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=452)

[‐ AMPK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=474)

[‐ BRSK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=475)

[‐ CHK1 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=476)

[‐ HUNK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=477)

[‐ LKB subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=478)

[‐ MARK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=479)

[‐ MELK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=480)

[‐ NIM1 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=700)

[‐ NuaK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=481)

[‐ PASK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=482)

[‐ QIK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=483)

[‐ SNRK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=484)

[‐ CAMK‐unique family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=563)

[‐ CASK family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=566)

[‐ DCAMKL family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=571)

[‐ Death‐associated kinase (DAPK) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=572)

[‐ MAPK‐Activated Protein Kinase (MAPKAPK) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=459)

[‐ MAPKAPK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=512)

[‐ MKN subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=513)

[‐ Myosin Light Chain Kinase (MLCK) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=585)

[‐ Phosphorylase kinase (PHK) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=599)

[‐ PIM family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=600)

[‐ Protein kinase D (PKD) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=605)

[‐ PSK family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=607)

[‐ RAD53 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=609)

[‐ Trbl family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=635)

[‐ Trio family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=636)

[‐ CK1: Casein kinase 1](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=680)

[‐ Casein kinase 1 (CK1) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=564)

[‐ Tau tubulin kinase (TTBK) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=627)

[‐ Vaccina related kinase (VRK) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=640)

[‐ CMGC: Containing CDK, MAPK, GSK3, CLK families](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=681)

[‐ CLK family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=568)

[‐ Cyclin‐dependent kinase (CDK) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=453)

[‐ CCRK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=485)

[‐ CDK1 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=492)

[6031 CDK4 subfamily](#bph13354-sec-0016){ref-type="sec"}

[‐ CDK5 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=495)

[‐ CDK7 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=496)

[‐ CDK8 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=497)

[‐ CDK9 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=489)

[‐ CDK10 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=494)

[‐ CRK7 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=490)

[‐ PITSLRE subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=498)

[‐ TAIRE subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=491)

[‐ Cyclin‐dependent kinase‐like (CDKL) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=570)

[‐ Dual‐specificity tyrosine‐(Y)‐phosphorylation regulated kinase (DYRK) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=455)

[‐ Dyrk1 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=503)

[‐ Dyrk2 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=504)

[‐ HIPK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=505)

[‐ PRP4 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=506)

[‐ Glycogen synthase kinase (GSK) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=457)

[6031 GSK subfamily](#bph13354-sec-0017){ref-type="sec"}

[‐ Mitogen‐activated protein kinases (MAP kinases)](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=288)

[‐ ERK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=514)

[‐ Erk7 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=515)

[‐ JNK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=518)

[‐ p38 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=519)

[‐ nmo subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=520)

[‐ RCK family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=612)

[‐ SRPK family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=620)

[‐ Other protein kinases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=683)

[‐ CAMKK family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=451)

[‐ Meta subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=473)

[‐ Aurora kinase (Aur) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=557)

[‐ Bub family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=559)

[‐ Bud32 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=560)

[‐ Casein kinase 2 (CK2) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=565)

[‐ CDC7 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=567)

[‐ Haspin family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=577)

[‐ IKK family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=578)

[‐ IRE family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=580)

[‐ MOS family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=584)

[‐ NAK family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=586)

[‐ NIMA (never in mitosis gene a)‐ related kinase (NEK) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=588)

[‐ NKF1 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=589)

[‐ NKF2 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=590)

[‐ NKF4 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=591)

[‐ NKF5 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=592)

[‐ NRBP family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=593)

[‐ Numb‐associated kinase (NAK) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=594)

[‐ Other‐unique family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=595)

[6032 Polo‐like kinase (PLK) family](#bph13354-sec-0018){ref-type="sec"}

[‐ PEK family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=462)

[‐ GCN2 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=526)

[‐ PEK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=527)

[‐ Other PEK family kinases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=597)

[‐ SgK493 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=617)

[‐ Slob family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=618)

[‐ TBCK family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=628)

[‐ TOPK family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=633)

[‐ Tousled‐like kinase (TLK) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=634)

[‐ TTK family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=637)

[‐ Unc‐51‐like kinase (ULK) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=639)

[‐ VPS15 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=641)

[‐ WEE family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=642)

[‐ Wnk family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=643)

[‐ Miscellaneous protein kinases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=684)

[‐ actin‐binding proteins ADF family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=449)

[‐ Twinfilin subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=470)

[‐ SCY1 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=615)

[‐ Hexokinases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=890)

[‐ STE: Homologs of yeast Sterile 7, Sterile 11, Sterile 20 kinases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=685)

[6032 STE7 family](#bph13354-sec-0019){ref-type="sec"}

[‐ STE11 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=621)

[‐ STE20 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=467)

[‐ FRAY subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=542)

[‐ MSN subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=544)

[‐ NinaC subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=546)

[‐ PAKA subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=547)

[‐ PAKB subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=548)

[‐ STLK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=550)

[‐ TAO subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=551)

[‐ STE20 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=622)

[‐ STE‐unique family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=624)

[‐ TK: Tyrosine kinase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=686)

[6033 Abl family](#bph13354-sec-0020){ref-type="sec"}

[6033 Ack family](#bph13354-sec-0021){ref-type="sec"}

[‐ Csk family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=569)

[‐ Fak family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=574)

[‐ Fer family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=575)

[6034 Janus kinase (JakA) family](#bph13354-sec-0022){ref-type="sec"}

[6034 Src family](#bph13354-sec-0023){ref-type="sec"}

[‐ Syk family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=625)

[6035 Tec family](#bph13354-sec-0024){ref-type="sec"}

[‐ TKL: Tyrosine kinase‐like](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=687)

[‐ Interleukin‐1 receptor‐associated kinase (IRAK) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=579)

[‐ Leucine‐rich repeat kinase (LRRK) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=582)

[‐ LIM domain kinase (LISK) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=458)

[‐ LIMK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=510)

[‐ TESK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=511)

[‐ Mixed Lineage Kinase (MLK) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=461)

[‐ HH498 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=521)

[‐ ILK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=522)

[‐ LZK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=523)

[‐ MLK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=524)

[‐ TAK1 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=525)

[6035 RAF family](#bph13354-sec-0025){ref-type="sec"}

[‐ Receptor interacting protein kinase (RIPK) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=613)

[‐ TKL‐unique family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=632)

[6036 Peptidases and proteinases](#bph13354-sec-0026){ref-type="sec"}

[‐ AA: Aspartic (A) Peptidases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=707)

[6036 A1: Pepsin](#bph13354-sec-0028){ref-type="sec"}

[‐ AD: Aspartic (A) Peptidases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=708)

[6037 A22: Presenilin](#bph13354-sec-0029){ref-type="sec"}

[‐ CA: Cysteine (C) Peptidases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=709)

[‐ C1: Papain](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=728)

[‐ C2: Calpain](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=731)

[‐ C12: Ubiquitin C‐terminal hydrolase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=729)

[‐ C19: Ubiquitin‐specific protease](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=730)

[‐ C54: Aut2 peptidase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=732)

[‐ CD: Cysteine (C) Peptidases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=710)

[‐ C13: Legumain](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=733)

[6037 C14: Caspase](#bph13354-sec-0031){ref-type="sec"}

[‐ CE: Cysteine (C) Peptidases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=711)

[‐ C48: Ulp1 endopeptidase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=735)

[‐ M‐: Metallo (M) Peptidases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=712)

[‐ M79: Prenyl protease 2](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=736)

[‐ MA: Metallo (M) Peptidases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=713)

[6037 M1: Aminopeptidase N](#bph13354-sec-0034){ref-type="sec"}

[6038 M2: Angiotensin‐converting (ACE and ACE2)](#bph13354-sec-0036){ref-type="sec"}

[6038 M10: Matrix metallopeptidase](#bph13354-sec-0037){ref-type="sec"}

[6039 M12: Astacin/Adamalysin](#bph13354-sec-0040){ref-type="sec"}

[‐ M13: Neprilysin](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=740)

[‐ M49: Dipeptidyl‐peptidase III](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=742)

[‐ MC: Metallo (M) Peptidases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=714)

[‐ M14: Carboxypeptidase A](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=743)

[‐ ME: Metallo (M) Peptidases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=715)

[‐ M16: Pitrilysin](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=744)

[‐ MF: Metallo (M) Peptidases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=716)

[‐ M17: Leucyl aminopeptidase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=745)

[‐ MG: Metallo (M) Peptidases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=717)

[‐ M24: Methionyl aminopeptidase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=746)

[‐ MH: Metallo (M) Peptidases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=718)

[‐ M18: Aminopeptidase I](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=747)

[‐ M20: Carnosine dipeptidase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=860)

[6039 M28: Aminopeptidase Y](#bph13354-sec-0043){ref-type="sec"}

[‐ MJ: Metallo (M) Peptidases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=719)

[6040 M19: Membrane dipeptidase](#bph13354-sec-0045){ref-type="sec"}

[‐ MP: Metallo (M) Peptidases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=720)

[‐ M67: PSMD14 peptidase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=750)

[‐ PA: Serine (S) Peptidases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=721)

[6040 S1: Chymotrypsin](#bph13354-sec-0046){ref-type="sec"}

[‐ PB: Threonine (T) Peptidases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=722)

[6041 T1: Proteasome](#bph13354-sec-0047){ref-type="sec"}

[‐ T2: Glycosylasparaginase precursor](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=753)

[‐ PC: Cysteine (C) Peptidases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=723)

[‐ C26: Gamma‐glutamyl hydrolase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=754)

[‐ SB: Serine (S) Peptidases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=724)

[6042 S8: Subtilisin](#bph13354-sec-0049){ref-type="sec"}

[‐ SC: Serine (S) Peptidases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=725)

[6042 S9: Prolyl oligopeptidase](#bph13354-sec-0051){ref-type="sec"}

[‐ S10: Carboxypeptidase Y](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=756)

[‐ S28: Lysosomal Pro‐Xaa carboxypeptidase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=757)

[‐ S33: prolyl aminopeptidase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=917)

[6042 Acetylcholine turnover](#bph13354-sec-0052){ref-type="sec"}

[6044 Adenosine turnover](#bph13354-sec-0056){ref-type="sec"}

[6045 Amino acid hydroxylases](#bph13354-sec-0060){ref-type="sec"}

[6046 L‐Arginine turnover](#bph13354-sec-0063){ref-type="sec"}

[6047 Arginase](#bph13354-sec-0066){ref-type="sec"}

[6047 Arginine:glycine amidinotransferase](#bph13354-sec-0069){ref-type="sec"}

[6047 Dimethylarginine dimethylaminohydrolases](#bph13354-sec-0070){ref-type="sec"}

[6048 Nitric oxide synthases](#bph13354-sec-0072){ref-type="sec"}

[6048 Carboxylases and decarboxylases](#bph13354-sec-0075){ref-type="sec"}

[6049 Carboxylases](#bph13354-sec-0076){ref-type="sec"}

[6050 Decarboxylases](#bph13354-sec-0079){ref-type="sec"}

[6052 Catecholamine turnover](#bph13354-sec-0082){ref-type="sec"}

[6055 Ceramide turnover](#bph13354-sec-0085){ref-type="sec"}

[6055 Serine palmitoyltransferase](#bph13354-sec-0087){ref-type="sec"}

[‐ 3‐ketodihydrosphingosine reductase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=791)

[6056 Ceramide synthase](#bph13354-sec-0089){ref-type="sec"}

[6057 Sphingolipid *Δ* ^14^‐desaturase](#bph13354-sec-0091){ref-type="sec"}

[6058 Sphingomyelin synthase](#bph13354-sec-0094){ref-type="sec"}

[6058 Sphingomyelin phosphodiesterase](#bph13354-sec-0096){ref-type="sec"}

[6059 Neutral sphingomyelinase coupling factors](#bph13354-sec-0098){ref-type="sec"}

[6059 Ceramide glucosyltransferase](#bph13354-sec-0100){ref-type="sec"}

[6060 Acid ceramidase](#bph13354-sec-0101){ref-type="sec"}

[6060 Neutral ceramidases](#bph13354-sec-0103){ref-type="sec"}

[6061 Alkaline ceramidases](#bph13354-sec-0106){ref-type="sec"}

[6061 Ceramide kinase](#bph13354-sec-0108){ref-type="sec"}

[6062 Chromatin modifying enzymes](#bph13354-sec-0111){ref-type="sec"}

[‐ Enzymatic bromodomain‐containing proteins](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=884)

[‐ Bromodomain kinase (BRDK) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=558)

[‐ TAF1 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=626)

[‐ TIF1 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=631)

[‐ 1.14.11.‐ Histone demethylases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=869)

[‐ 2.1.1.43 Histone methyltransferases (HMTs)](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=871)

[‐ 2.3.1.48 Histone acetyltransferases (HATs)](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=872)

[‐ 3.6.1.3 ATPases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=873)

[6062 2.1.1.‐ Protein arginine N‐methyltransferases](#bph13354-sec-0113){ref-type="sec"}

[6062 3.5.1.‐ Histone deacetylases (HDACs)](#bph13354-sec-0115){ref-type="sec"}

[6063 Cyclic nucleotide turnover](#bph13354-sec-0117){ref-type="sec"}

[6063 Adenylyl cyclases](#bph13354-sec-0119){ref-type="sec"}

[6064 Soluble guanylyl cyclase](#bph13354-sec-0122){ref-type="sec"}

[6065 Exchange protein activated by cyclic AMP (Epac)](#bph13354-sec-0126){ref-type="sec"}

[6066 Phosphodiesterases, 3\',5\'‐cyclic nucleotide](#bph13354-sec-0128){ref-type="sec"}

[6069 Cytochrome P450](#bph13354-sec-0132){ref-type="sec"}

[6069 CYP1 family](#bph13354-sec-0134){ref-type="sec"}

[6070 CYP2 family](#bph13354-sec-0135){ref-type="sec"}

[6070 CYP3 family](#bph13354-sec-0136){ref-type="sec"}

[6071 CYP4 family](#bph13354-sec-0137){ref-type="sec"}

[6072 CYP5, CYP7 and CYP8 families](#bph13354-sec-0138){ref-type="sec"}

[6072 CYP11, CYP17, CYP19, CYP20 and CYP21 families](#bph13354-sec-0139){ref-type="sec"}

[6073 CYP24, CYP26 and CYP27 families](#bph13354-sec-0140){ref-type="sec"}

[6074 CYP39, CYP46 and CYP51 families](#bph13354-sec-0141){ref-type="sec"}

[6076 Eicosanoid turnover](#bph13354-sec-0143){ref-type="sec"}

[6075 Endocannabinoid turnover](#bph13354-sec-0145){ref-type="sec"}

[6077 Cyclooxygenase](#bph13354-sec-0149){ref-type="sec"}

[6077 Prostaglandin synthases](#bph13354-sec-0151){ref-type="sec"}

[6079 Lipoxygenases](#bph13354-sec-0154){ref-type="sec"}

[6080 Leukotriene and lipoxin metabolism](#bph13354-sec-0157){ref-type="sec"}

[6081 GABA turnover](#bph13354-sec-0161){ref-type="sec"}

[6082 Glycerophospholipid turnover](#bph13354-sec-0164){ref-type="sec"}

[‐ Lipid modifying kinases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=682)

[6083 1‐phosphatidylinositol 4‐kinase family](#bph13354-sec-0166){ref-type="sec"}

[6083 Phosphatidylinositol‐4‐phosphate 3‐kinase family](#bph13354-sec-0167){ref-type="sec"}

[6084 Phosphatidylinositol 3‐kinase family](#bph13354-sec-0168){ref-type="sec"}

[6084 Phosphatidylinositol‐4,5‐bisphosphate 3‐kinase family](#bph13354-sec-0169){ref-type="sec"}

[6085 1‐phosphatidylinositol‐3‐phosphate 5‐kinase family](#bph13354-sec-0170){ref-type="sec"}

[6085 Type I PIP kinases (1‐phosphatidylinositol‐4‐phosphate 5‐kinase family)](#bph13354-sec-0171){ref-type="sec"}

[6086 Type II PIP kinases (1‐phosphatidylinositol‐5‐phosphate 4‐kinase family)](#bph13354-sec-0173){ref-type="sec"}

[6100 Sphingosine kinase](#bph13354-sec-0176){ref-type="sec"}

[6087 Phosphoinositide‐specific phospholipase C](#bph13354-sec-0178){ref-type="sec"}

[6088 Phospholipase A~2~](#bph13354-sec-0181){ref-type="sec"}

[6089 Phosphatidylcholine‐specific phospholipase D](#bph13354-sec-0184){ref-type="sec"}

[6090 Lipid phosphate phosphatases](#bph13354-sec-0187){ref-type="sec"}

[6082 Phosphatidylinositol kinases](#bph13354-sec-0190){ref-type="sec"}

[6091 Haem oxygenase](#bph13354-sec-0192){ref-type="sec"}

[6092 Hydrogen sulphide synthesis](#bph13354-sec-0196){ref-type="sec"}

[6093 Hydrolases](#bph13354-sec-0199){ref-type="sec"}

[6093 Inositol phosphate turnover](#bph13354-sec-0202){ref-type="sec"}

[6094 Inositol 1,4,5‐trisphosphate 3‐kinases](#bph13354-sec-0204){ref-type="sec"}

[6094 Inositol polyphosphate phosphatases](#bph13354-sec-0206){ref-type="sec"}

[6094 Inositol monophosphatase](#bph13354-sec-0209){ref-type="sec"}

[6095 Lanosterol biosynthesis pathway](#bph13354-sec-0213){ref-type="sec"}

[6097 Nucleoside synthesis and metabolism](#bph13354-sec-0216){ref-type="sec"}

[6099 Sphingosine 1‐phosphate turnover](#bph13354-sec-0220){ref-type="sec"}

[6100 Sphingosine kinase](#bph13354-sec-0176){ref-type="sec"}

[6100 Sphingosine 1‐phosphate phosphatase](#bph13354-sec-0223){ref-type="sec"}

[6101 Sphingosine 1‐phosphate lyase](#bph13354-sec-0224){ref-type="sec"}

[6101 Thyroid hormone turnover](#bph13354-sec-0226){ref-type="sec"}

[‐ 1.4.3.13 Lysyl oxidases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=912)

[‐ 1.13.11.‐ Dioxygenases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=899)

[6103 1.14.11.29 2‐oxoglutarate oxygenases transferases](#bph13354-sec-0229){ref-type="sec"}

[‐ 2.3.‐.‐ Acyltransferases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=844)

[6103 2.4.2.30 poly(ADP‐ribose)polymerases](#bph13354-sec-0231){ref-type="sec"}

[6104 2.5.1.58 Protein farnesyltransferase](#bph13354-sec-0234){ref-type="sec"}

[‐ 3.1.‐.‐ Ester bond enzymes](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=880)

[‐ 3.1.1.‐ Carboxylic Ester Hydrolases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=850)

[‐ 3.2.1.‐ Glycosidases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=841)

[‐ 3.4.21.46 Complement factor D](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=909)

[6062 3.5.1.‐ Histone deacetylases (HDACs)](#bph13354-sec-0115){ref-type="sec"}

[6104 3.5.3.15 Peptidyl arginine deiminases (PADI)](#bph13354-sec-0238){ref-type="sec"}

[‐ 3.6.5.2 Small monomeric GTPases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=896)

[6104 RAS subfamily](#bph13354-sec-0240){ref-type="sec"}

[6105 4.2.1.1 Carbonate dehydratases](#bph13354-sec-0242){ref-type="sec"}

[‐ 5.‐.‐.‐ Isomerases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=849)

[‐ 5.2.‐.‐ Cis‐trans‐isomerases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=845)

[6105 5.99.1.2 DNA Topoisomerases](#bph13354-sec-0245){ref-type="sec"}

[Protein Kinases (EC 2.7.x.x)](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=698) {#bph13354-sec-0005}
=========================================================================================================

Overview {#bph13354-sec-0006}
--------

Protein kinases ([E.C. 2.7.11.‐](http://www.genome.jp/kegg-bin/search_brite?option=-a&search_string=2.7.11.1)) use the co‐substrate [ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713) to phosphorylate serine and/or threonine residues on target proteins. Analysis of the human genome suggests the presence of 518 protein kinases in man, with over 100 protein kinase‐like pseudogenes \[[313](http://www.ncbi.nlm.nih.gov/pubmed/12471243?dopt=AbstractPlus)\]. It is beyond the scope of the Concise Guide to list all these protein kinase activities; the full listing may be seen at [www.GuidetoPHARMACOLOGY.org](http://www.GuidetoPHARMACOLOGY.org).

Most inhibitors of these enzymes have been assessed in cell‐free investigations and so may appear to 'lose' potency and selectivity in intact cell assays. In particular, ambient [ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713) concentrations may be influential in responses to inhibitors, since the majority are directed at the ATP binding site \[[103](http://www.ncbi.nlm.nih.gov/pubmed/10998351?dopt=AbstractPlus)\].

Further Reading {#bph13354-sec-0007}
---------------

Eglen R *et al*. (2011) Drug discovery and the human kinome: recent trends. *Pharmacol. Ther.* **130**: 144‐56 [\[PMID:21256157\]](http://www.ncbi.nlm.nih.gov/pubmed/21256157?dopt=AbstractPlus)

Graves LM *et al*. (2013) The dynamic nature of the kinome. *Biochem. J.* **450**: 1‐8 [\[PMID:23343193\]](http://www.ncbi.nlm.nih.gov/pubmed/23343193?dopt=AbstractPlus)

Liu Q *et al*. (2013) Developing irreversible inhibitors of the protein kinase cysteinome. *Chem. Biol.* **20**: 146‐59 [\[PMID:23438744\]](http://www.ncbi.nlm.nih.gov/pubmed/23438744?dopt=AbstractPlus)

Martin KJ *et al*. (2012) Selective kinase inhibitors as tools for neuroscience research. *Neuropharmacology* **63**: 1227‐37 [\[PMID:22846224\]](http://www.ncbi.nlm.nih.gov/pubmed/22846224?dopt=AbstractPlus)

Tarrant MK *et al*. (2009) The chemical biology of protein phosphorylation. *Annu. Rev. Biochem.* **78**: 797‐825 [\[PMID:19489734\]](http://www.ncbi.nlm.nih.gov/pubmed/19489734?dopt=AbstractPlus)

Wu‐Zhang AX *et al*. (2013) Protein kinase C pharmacology: refining the toolbox. *Biochem. J.* **452**: 195‐209 [\[PMID:23662807\]](http://www.ncbi.nlm.nih.gov/pubmed/23662807?dopt=AbstractPlus)

[Rho kinase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=289) {#bph13354-sec-0008}
=======================================================================================

Overview {#bph13354-sec-0009}
--------

Rho kinase (also known as P160ROCK, Rho‐activated kinase) is activated by members of the Rho small G protein family, which are activated by GTP exchange factors, such as [*ARHGEF1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=681)([Q92888](http://www.uniprot.org/uniprot/Q92888), p115‐RhoGEF), which in turn may be activated by G*α* ~12/13~ subunits \[[269](http://www.ncbi.nlm.nih.gov/pubmed/9641915?dopt=AbstractPlus)\].

Nomenclature[Rho‐associated, coiled‐coil containing protein kinase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1503)[Rho‐associated, coiled‐coil containing protein kinase 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1504)Systematic nomenclatureROCK1ROCK2Common abreviationRho kinase 1Rho kinase 2HGNC, UniProt[*ROCK1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10251), [Q13464](http://www.uniprot.org/uniprot/Q13464)[*ROCK2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10252), [O75116](http://www.uniprot.org/uniprot/O75116)EC number[2.7.11.1](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.11.1)[2.7.11.1](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.11.1)Inhibitors[RKI‐1447](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8152) (pIC~50~\>9) \[[387](http://www.ncbi.nlm.nih.gov/pubmed/23275831?dopt=AbstractPlus)\], [Y27632](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5290) (pIC~50~ 7.3) \[[529](http://www.ncbi.nlm.nih.gov/pubmed/20462760?dopt=AbstractPlus)\], [fasudil](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5181) (p*K* ~i~ 7) \[[403](http://www.ncbi.nlm.nih.gov/pubmed/21145740?dopt=AbstractPlus)\], [Y27632](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5290) (p*K* ~i~ 6.8) \[[496](http://www.ncbi.nlm.nih.gov/pubmed/9353125?dopt=AbstractPlus)\], [fasudil](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5181) (pIC~50~ 5.5) \[[403](http://www.ncbi.nlm.nih.gov/pubmed/21145740?dopt=AbstractPlus)\][RKI‐1447](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8152) (pIC~50~\>9) \[[387](http://www.ncbi.nlm.nih.gov/pubmed/23275831?dopt=AbstractPlus)\], [compound 11d \[DOI: 10.1039/c0md00194e\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8197) (pIC~50~\>9) \[[77](#bph13354-bib-0077){ref-type="ref"}\], [GSK269962A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8037) (pIC~50~ 8.4) \[[118](http://www.ncbi.nlm.nih.gov/pubmed/17018693?dopt=AbstractPlus)\], [compound 32 \[PMID: 20471253\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8184) (pIC~50~ 8.4) \[[45](http://www.ncbi.nlm.nih.gov/pubmed/20471253?dopt=AbstractPlus)\], [compound 22 \[PMID: 20462760\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8205) (pIC~50~ 7.7) \[[529](http://www.ncbi.nlm.nih.gov/pubmed/20462760?dopt=AbstractPlus)\], [Y27632](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5290) (pIC~50~ 7.2) \[[529](http://www.ncbi.nlm.nih.gov/pubmed/20462760?dopt=AbstractPlus)\], [Y27632](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5290) (p*K* ~i~ 6.8) \[[496](http://www.ncbi.nlm.nih.gov/pubmed/9353125?dopt=AbstractPlus)\], [fasudil](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5181) (pIC~50~ 5.9) \[[403](http://www.ncbi.nlm.nih.gov/pubmed/21145740?dopt=AbstractPlus)\]Selective inhibitors[GSK269962A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8037) (pIC~50~ 8.8) \[[118](http://www.ncbi.nlm.nih.gov/pubmed/17018693?dopt=AbstractPlus)\]--

[Protein kinase C (PKC)](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=286) {#bph13354-sec-0010}
===================================================================================================

Overview {#bph13354-sec-0011}
--------

Protein kinase C is the target for the tumour‐promoting phorbol esters, such as tetradecanoyl‐*β*‐phorbol acetate (TPA, also known as [phorbol 12‐myristate 13‐acetate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2341)).

*Classical protein kinase C isoforms:* **PKC*α*, PKC*β*, PKC*γ***. Members of the classical protein kinase C family are activated by [Ca^2+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707) and diacylglycerol, and may be inhibited by [GF109203X](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5193), [calphostin C](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5156), [GÖ 6983](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5192), [chelerythrine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5953) and [Ro31‐8220](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5259).

*Novel protein kinase C isoforms:* **PKC*δ*, PKC*ε*, PKC*η*, PKC*θ* and PKC*μ***. Members of the classical protein kinase C family are activated by diacylglycerol and may be inhibited by [calphostin C](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5156), [GÖ 6983](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5192) and [chelerythrine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5953).

*Atypical protein kinase C isoforms:* **PKC*ι*, PKC*ζ***.

[Alpha subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=532) {#bph13354-sec-0012}
============================================================================================

Nomenclature[protein kinase C, beta](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1483)[protein kinase C, gamma](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1484)Common abreviationPKC*β*PKC*γ*HGNC, UniProt[*PRKCB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9395), [P05771](http://www.uniprot.org/uniprot/P05771)[*PRKCG*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9402), [P05129](http://www.uniprot.org/uniprot/P05129)EC number[2.7.11.13](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.11.13)[2.7.11.13](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.11.13)Inhibitors[sotrastaurin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7946) (pIC~50~ 8.7) \[[506](http://www.ncbi.nlm.nih.gov/pubmed/19827831?dopt=AbstractPlus)\], [GÖ 6983](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5192) (pIC~50~ 8.1) \[[183](http://www.ncbi.nlm.nih.gov/pubmed/8772178?dopt=AbstractPlus)\], [GF109203X](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5193) (pIC~50~ 7.8) \[[490](http://www.ncbi.nlm.nih.gov/pubmed/1874734?dopt=AbstractPlus)\] -- Bovine, [7‐hydroxystaurosporine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7907) (pIC~50~ 7.5) \[[431](http://www.ncbi.nlm.nih.gov/pubmed/8022414?dopt=AbstractPlus)\][GÖ 6983](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5192) (pIC~50~ 8.2) \[[183](http://www.ncbi.nlm.nih.gov/pubmed/8772178?dopt=AbstractPlus)\], [7‐hydroxystaurosporine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7907) (pIC~50~ 7.5) \[[431](http://www.ncbi.nlm.nih.gov/pubmed/8022414?dopt=AbstractPlus)\]Selective inhibitors[ruboxistaurin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5263) (pIC~50~ 8.2) \[[238](http://www.ncbi.nlm.nih.gov/pubmed/8709095?dopt=AbstractPlus)\], [enzastaurin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5693) (pIC~50~ 7.5) \[[132](http://www.ncbi.nlm.nih.gov/pubmed/12749884?dopt=AbstractPlus)\], [CGP53353](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5163) (pIC~50~ 6.4) \[[70](http://www.ncbi.nlm.nih.gov/pubmed/9121494?dopt=AbstractPlus)\]--

[Delta subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=533) {#bph13354-sec-0013}
============================================================================================

Nomenclature[protein kinase C, alpha](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1482)[protein kinase C, delta](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1485)Common abreviationPKC*α*PKC*δ*HGNC, UniProt[*PRKCA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9393), [P17252](http://www.uniprot.org/uniprot/P17252)[*PRKCD*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9399), [Q05655](http://www.uniprot.org/uniprot/Q05655)EC number[2.7.11.13](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.11.13)[2.7.11.13](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.11.13)Activators--[ingenol mebutate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7443) (p*K* ~i~ 9.4) \[[252](http://www.ncbi.nlm.nih.gov/pubmed/15126366?dopt=AbstractPlus)\]Inhibitors[sotrastaurin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7946) (pIC~50~ 8.7) \[[506](http://www.ncbi.nlm.nih.gov/pubmed/19827831?dopt=AbstractPlus)\], [GÖ 6983](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5192) (pIC~50~ 8.1) \[[183](http://www.ncbi.nlm.nih.gov/pubmed/8772178?dopt=AbstractPlus)\], [7‐hydroxystaurosporine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7907) (pIC~50~ 7.5) \[[431](http://www.ncbi.nlm.nih.gov/pubmed/8022414?dopt=AbstractPlus)\][sotrastaurin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7946) (pIC~50~ 8.9) \[[506](http://www.ncbi.nlm.nih.gov/pubmed/19827831?dopt=AbstractPlus)\], [GÖ 6983](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5192) (pIC~50~ 8) \[[183](http://www.ncbi.nlm.nih.gov/pubmed/8772178?dopt=AbstractPlus)\]

[Eta subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=534) {#bph13354-sec-0014}
==========================================================================================

Nomenclature[protein kinase C, epsilon](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1486)Common abreviationPKC*ε*HGNC, UniProt[*PRKCE*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9401), [Q02156](http://www.uniprot.org/uniprot/Q02156)EC number[2.7.11.13](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.11.13)Inhibitors[sotrastaurin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7946) (pIC~50~ 8.2) \[[506](http://www.ncbi.nlm.nih.gov/pubmed/19827831?dopt=AbstractPlus)\]

[FRAP subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=529) {#bph13354-sec-0015}
===========================================================================================

Nomenclature[mechanistic target of rapamycin (serine/threonine kinase)](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109)Common abreviationmTORHGNC, UniProt[*MTOR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3942), [P42345](http://www.uniprot.org/uniprot/P42345)EC number[2.7.11.1](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.11.1)Inhibitors[ridaforolimus](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7884) (pIC~50~ 9.7) \[[408](http://www.ncbi.nlm.nih.gov/pubmed/21482695?dopt=AbstractPlus)\], [torin 1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8004) (pIC~50~ 9.5) \[[291](http://www.ncbi.nlm.nih.gov/pubmed/20860370?dopt=AbstractPlus)\], [INK‐128](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7933) (pIC~50~ 9) \[[219](http://www.ncbi.nlm.nih.gov/pubmed/22367541?dopt=AbstractPlus)\], [INK‐128](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7933) (p*K* ~i~ 8.9) \[[219](http://www.ncbi.nlm.nih.gov/pubmed/22367541?dopt=AbstractPlus)\], [gedatolisib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7940) (pIC~50~ 8.8) \[[500](http://www.ncbi.nlm.nih.gov/pubmed/20166697?dopt=AbstractPlus)\], [dactolisib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950) (pIC~50~ 8.2) \[[310](http://www.ncbi.nlm.nih.gov/pubmed/18606717?dopt=AbstractPlus)\], [PP‐242](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5704) (pIC~50~ 8.1) \[[14](http://www.ncbi.nlm.nih.gov/pubmed/18849971?dopt=AbstractPlus)\], [PP121](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8013) (pIC~50~ 8) \[[14](http://www.ncbi.nlm.nih.gov/pubmed/18849971?dopt=AbstractPlus)\], [XL388](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7973) (pIC~50~ 8) \[[472](http://www.ncbi.nlm.nih.gov/pubmed/23394126?dopt=AbstractPlus)\], [PF‐04691502](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7936) (p*K* ~i~ 7.8) \[[290](http://www.ncbi.nlm.nih.gov/pubmed/24900269?dopt=AbstractPlus)\], [apitolisib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888) (p*K* ~i~ 7.8) \[[467](http://www.ncbi.nlm.nih.gov/pubmed/21981714?dopt=AbstractPlus)\]Selective inhibitors[everolimus](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5889) (pIC~50~ 8.7) \[[427](http://www.ncbi.nlm.nih.gov/pubmed/9723437?dopt=AbstractPlus)\], [temsirolimus](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5892) (pIC~50~ 5.8) \[[266](http://www.ncbi.nlm.nih.gov/pubmed/21438579?dopt=AbstractPlus)\]

[CDK4 subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=488) {#bph13354-sec-0016}
===========================================================================================

Nomenclature[cyclin‐dependent kinase 4](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1976)[cyclin‐dependent kinase 6](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1978)Common abreviationCDK4CDK6HGNC, UniProt[*CDK4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1773), [P11802](http://www.uniprot.org/uniprot/P11802)[*CDK6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1777), [Q00534](http://www.uniprot.org/uniprot/Q00534)EC number[2.7.11.22](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.11.22)[2.7.11.22](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.11.22)Inhibitors[R547](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5707) (p*K* ~i~ 9) \[[107](http://www.ncbi.nlm.nih.gov/pubmed/17121911?dopt=AbstractPlus)\], [palbociclib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7380) (pIC~50~ 8) \[[151](http://www.ncbi.nlm.nih.gov/pubmed/15542782?dopt=AbstractPlus)\], [Ro‐0505124](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8203) (pIC~50~ 7.7) \[[115](#bph13354-bib-0115){ref-type="ref"}\], [riviciclib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7934) (pIC~50~ 7.2) \[[246](http://www.ncbi.nlm.nih.gov/pubmed/17363486?dopt=AbstractPlus)\], [alvocidib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5680) (p*K* ~i~ 7.2) \[[64](http://www.ncbi.nlm.nih.gov/pubmed/8674031?dopt=AbstractPlus)\][palbociclib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7380) (pIC~50~ 7.8) \[[151](http://www.ncbi.nlm.nih.gov/pubmed/15542782?dopt=AbstractPlus)\]

[GSK subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=509) {#bph13354-sec-0017}
==========================================================================================

Nomenclature[glycogen synthase kinase 3 beta](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2030)Common abreviationGSK3BHGNC, UniProt[*GSK3B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4617), [P49841](http://www.uniprot.org/uniprot/P49841)EC number[2.7.11.26](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.11.26)Inhibitors[CHIR‐98014](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8016) (pIC~50~ 9.2) \[[407](http://www.ncbi.nlm.nih.gov/pubmed/12606497?dopt=AbstractPlus)\], [LY2090314](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7958) (pIC~50~ 9) \[[125](http://www.ncbi.nlm.nih.gov/pubmed/15267232?dopt=AbstractPlus)\], [CHIR‐99021](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8014) (pIC~50~ 8.2) \[[407](http://www.ncbi.nlm.nih.gov/pubmed/12606497?dopt=AbstractPlus)\], [SB 216763](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8015) (pIC~50~∼8.1) \[[88](http://www.ncbi.nlm.nih.gov/pubmed/11033082?dopt=AbstractPlus)\], [1‐azakenpaullone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8018) (pIC~50~ 7.7) \[[272](http://www.ncbi.nlm.nih.gov/pubmed/14698171?dopt=AbstractPlus)\], [SB‐415286](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8019) (pIC~50~∼7.4) \[[88](http://www.ncbi.nlm.nih.gov/pubmed/11033082?dopt=AbstractPlus)\], [IM‐12](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8017) (pIC~50~ 7.3) \[[424](http://www.ncbi.nlm.nih.gov/pubmed/20708937?dopt=AbstractPlus)\]Selective inhibitors[AZD2858](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8478) (p*K* ~i~ 8.3) \[[29](http://www.ncbi.nlm.nih.gov/pubmed/22489897?dopt=AbstractPlus)\]CommentsDue to its Tau phosphorylating activity, small molecule inhibitors of GSK‐3*β* are being investigated as potential treatments for Alzheimer\'s disease (AD) \[[29](http://www.ncbi.nlm.nih.gov/pubmed/22489897?dopt=AbstractPlus)\]. GSK‐3*β* also plays a role in canonical Wnt pathway signalling, the normal activity of which is crucial for the maintenance of normal bone mass. It is hypothesised that small molecule inhibitors of GSK‐3*β* may provide effective therapeutics for the treatment of diseases characterised by low bone mass \[[317](http://www.ncbi.nlm.nih.gov/pubmed/22142634?dopt=AbstractPlus)\].

[Polo‐like kinase (PLK) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=602) {#bph13354-sec-0018}
==========================================================================================================

Nomenclature[polo‐like kinase 4](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2171)Common abreviationPLK4HGNC, UniProt[*PLK4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11397), [O00444](http://www.uniprot.org/uniprot/O00444)EC number[2.7.11.21](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.11.21)Inhibitors[CFI‐400945](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8063) (pIC~50~ 8.6) \[[320](http://www.ncbi.nlm.nih.gov/pubmed/25043604?dopt=AbstractPlus)\]

[STE7 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=623) {#bph13354-sec-0019}
========================================================================================

Nomenclature[mitogen‐activated protein kinase kinase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2062)[mitogen‐activated protein kinase kinase 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2063)Common abreviationMEK1MEK2HGNC, UniProt[*MAP2K1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6840), [Q02750](http://www.uniprot.org/uniprot/Q02750)[*MAP2K2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6842), [P36507](http://www.uniprot.org/uniprot/P36507)EC number[2.7.12.2](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.12.2)[2.7.12.2](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.12.2)Inhibitors[trametinib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6495) (pIC~50~ 9--9.1) \[[173](http://www.ncbi.nlm.nih.gov/pubmed/21245089?dopt=AbstractPlus), [536](http://www.ncbi.nlm.nih.gov/pubmed/21523318?dopt=AbstractPlus)\], [PD 0325901](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7935) (pIC~50~ 8.1) \[[195](http://www.ncbi.nlm.nih.gov/pubmed/23474388?dopt=AbstractPlus)\], [binimetinib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7921) (pIC~50~ 7.9) \[[382](#bph13354-bib-0382){ref-type="ref"}\], [refametinib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7942) (pIC~50~ 7.7) \[[229](http://www.ncbi.nlm.nih.gov/pubmed/19706763?dopt=AbstractPlus)\], [CI‐1040](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5676) (p*K* ~d~ 6.9) \[[105](http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus)\][trametinib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6495) (pIC~50~ 8.7) \[[536](http://www.ncbi.nlm.nih.gov/pubmed/21523318?dopt=AbstractPlus)\], [binimetinib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7921) (pIC~50~ 7.9) \[[382](#bph13354-bib-0382){ref-type="ref"}\], [refametinib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7942) (pIC~50~ 7.3) \[[229](http://www.ncbi.nlm.nih.gov/pubmed/19706763?dopt=AbstractPlus)\]

[Abl family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=553) {#bph13354-sec-0020}
=======================================================================================

Nomenclature[ABL proto‐oncogene 1, non‐receptor tyrosine kinase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1923)Common abreviationAblHGNC, UniProt[*ABL1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=76), [P00519](http://www.uniprot.org/uniprot/P00519)EC number[2.7.10.2](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.10.2)Inhibitors[compound 8h](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8170) (pIC~50~ 9.7) \[[487](http://www.ncbi.nlm.nih.gov/pubmed/21561767?dopt=AbstractPlus)\], [dasatinib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5678) (pIC~50~ 9.6) \[[258](http://www.ncbi.nlm.nih.gov/pubmed/23279183?dopt=AbstractPlus)\], [compound 24](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8147) (pIC~50~ 9.3) \[[110](http://www.ncbi.nlm.nih.gov/pubmed/23441572?dopt=AbstractPlus)\], [PD‐173955](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5699) (p*K* ~d~ 9.2) \[[105](http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus)\], [bosutinib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5710) (pIC~50~ 9) \[[176](http://www.ncbi.nlm.nih.gov/pubmed/12543790?dopt=AbstractPlus)\], [PD‐173955](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5699) (pIC~50~∼8.3) \[[346](http://www.ncbi.nlm.nih.gov/pubmed/12154025?dopt=AbstractPlus)\], [bafetinib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7906) (pIC~50~ 7.6--8.2) \[[216](http://www.ncbi.nlm.nih.gov/pubmed/17376680?dopt=AbstractPlus), [257](http://www.ncbi.nlm.nih.gov/pubmed/16105974?dopt=AbstractPlus)\], [ponatinib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5890) (pIC~50~ 8.1) \[[220](http://www.ncbi.nlm.nih.gov/pubmed/20513156?dopt=AbstractPlus)\], [nilotinib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5697) (pIC~50~ 7.8) \[[356](http://www.ncbi.nlm.nih.gov/pubmed/15930265?dopt=AbstractPlus)\], [PP121](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8013) (pIC~50~ 7.7) \[[14](http://www.ncbi.nlm.nih.gov/pubmed/18849971?dopt=AbstractPlus)\], [imatinib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5687) (pIC~50~ 6.7) \[[216](http://www.ncbi.nlm.nih.gov/pubmed/17376680?dopt=AbstractPlus)\], [GNF‐5](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8065) (pIC~50~ 6.7) \[[549](http://www.ncbi.nlm.nih.gov/pubmed/20072125?dopt=AbstractPlus)\]

[Ack family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=554) {#bph13354-sec-0021}
=======================================================================================

Nomenclature[tyrosine kinase, non‐receptor, 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2246)Common abreviationAckHGNC, UniProt[*TNK2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19297), [Q07912](http://www.uniprot.org/uniprot/Q07912)EC number[2.7.10.2](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.10.2)Inhibitors[compound 30](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8193) (pIC~50~ 9) \[[114](http://www.ncbi.nlm.nih.gov/pubmed/17280833?dopt=AbstractPlus)\]

[anus kinase (JakA) family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=581) {#bph13354-sec-0022}
======================================================================================================

Nomenclature[Janus kinase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2047)[Janus kinase 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2048)[Janus kinase 3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2049)[tyrosine kinase 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2269)Common abreviationJAK1JAK2JAK3Tyk2HGNC, UniProt[*JAK1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6190), [P23458](http://www.uniprot.org/uniprot/P23458)[*JAK2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6192), [O60674](http://www.uniprot.org/uniprot/O60674)[*JAK3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6193), [P52333](http://www.uniprot.org/uniprot/P52333)[*TYK2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12440), [P29597](http://www.uniprot.org/uniprot/P29597)EC number[2.7.10.2](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.10.2)[2.7.10.2](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.10.2)[2.7.10.2](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.10.2)[2.7.10.2](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.10.2)Inhibitors[ruxolitinib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5688) (pIC~50~ 8.5--10.1) \[[191](http://www.ncbi.nlm.nih.gov/pubmed/23061660?dopt=AbstractPlus), [395](http://www.ncbi.nlm.nih.gov/pubmed/20130243?dopt=AbstractPlus)\], [filgotinib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7913) (pIC~50~ 8) \[[497](http://www.ncbi.nlm.nih.gov/pubmed/24006460?dopt=AbstractPlus)\][NS‐018](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7839) (pIC~50~ 9.1) \[[350](http://www.ncbi.nlm.nih.gov/pubmed/22829185?dopt=AbstractPlus)\], [BMS‐911543](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7954) (pIC~50~ 9) \[[393](http://www.ncbi.nlm.nih.gov/pubmed/22015772?dopt=AbstractPlus)\], [AT‐9283](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7949) (pIC~50~ 8.9) \[[218](http://www.ncbi.nlm.nih.gov/pubmed/19143567?dopt=AbstractPlus)\], [XL019](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7971) (pIC~50~ 8.7) \[[143](http://www.ncbi.nlm.nih.gov/pubmed/23127890?dopt=AbstractPlus)\], [fedratinib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5716) (pIC~50~ 8.5) \[[311](http://www.ncbi.nlm.nih.gov/pubmed/21106455?dopt=AbstractPlus), [521](http://www.ncbi.nlm.nih.gov/pubmed/18394554?dopt=AbstractPlus)\], [gandotinib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7909) (pIC~50~ 8.4) \[[308](http://www.ncbi.nlm.nih.gov/pubmed/23584399?dopt=AbstractPlus)\][AT‐9283](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7949) (pIC~50~ 9) \[[218](http://www.ncbi.nlm.nih.gov/pubmed/19143567?dopt=AbstractPlus)\]--Selective inhibitors--[compound 1d](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8123) (pIC~50~\>9) \[[509](http://www.ncbi.nlm.nih.gov/pubmed/21493067?dopt=AbstractPlus)\]----Comments--The JAK2^V617F^ mutation, which causes constitutive activation, plays an oncogenic role in the pathogenesis of the myeloproliferative disorders, polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis \[[58](http://www.ncbi.nlm.nih.gov/pubmed/17151367?dopt=AbstractPlus), [109](http://www.ncbi.nlm.nih.gov/pubmed/17131059?dopt=AbstractPlus)\]. Small molecule compounds which inhibit aberrant JAK2 activity are being developed as novel anti‐cancer pharmaceuticals.----

[Src family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=619) {#bph13354-sec-0023}
=======================================================================================

Nomenclature[BLK proto‐oncogene, Src](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1940)[fyn‐related Src family](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2025)[FYN proto‐oncogene, Src](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2026)[LYN proto‐oncogene, Src](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2060)[SRC proto‐oncogene,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2206)[Src family tyrosine kinase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)[tyrosine kinase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)[family tyrosine kinase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)[family tyrosine kinase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)[non-receptor tyrosine kinase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)Common abreviationBlkFRKFynLynSrcHGNC, UniProt[*BLK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1057), [P51451](http://www.uniprot.org/uniprot/P51451)[*FRK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3955), [P42685](http://www.uniprot.org/uniprot/P42685)[*FYN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4037), [P06241](http://www.uniprot.org/uniprot/P06241)[*LYN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6735), [P07948](http://www.uniprot.org/uniprot/P07948)[*SRC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11283), [P12931](http://www.uniprot.org/uniprot/P12931)EC number[2.7.10.2](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.10.2)[2.7.10.2](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.10.2)[2.7.10.2](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.10.2)[2.7.10.2](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.10.2)[2.7.10.2](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.10.2)Inhibitors------[bafetinib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7906) (pIC~50~ 8) \[[216](http://www.ncbi.nlm.nih.gov/pubmed/17376680?dopt=AbstractPlus)\][WH‐4‐023](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8068) (pIC~50~ 8.2) \[[318](http://www.ncbi.nlm.nih.gov/pubmed/16884310?dopt=AbstractPlus)\], [PD166285](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8183) (p*K* ~i~ 8.1) \[[371](http://www.ncbi.nlm.nih.gov/pubmed/9400019?dopt=AbstractPlus)\], [PP121](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8013) (pIC~50~ 7.8) \[[14](http://www.ncbi.nlm.nih.gov/pubmed/18849971?dopt=AbstractPlus)\], [ENMD‐2076](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7885) (pIC~50~ 7.7) \[[389](http://www.ncbi.nlm.nih.gov/pubmed/19320489?dopt=AbstractPlus)\]

[Tec family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=629) {#bph13354-sec-0024}
=======================================================================================

Nomenclature[BMX non‐receptor tyrosine kinase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1942)[Bruton agammaglobulinemia tyrosine kinase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1948)[TXK tyrosine kinase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2268)Common abreviationEtkBtkTXKHGNC, UniProt[*BMX*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1079), [P51813](http://www.uniprot.org/uniprot/P51813)[*BTK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1133), [Q06187](http://www.uniprot.org/uniprot/Q06187)[*TXK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12434), [P42681](http://www.uniprot.org/uniprot/P42681)EC number[2.7.10.2](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.10.2)[2.7.10.2](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.10.2)[2.7.10.2](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.10.2)Inhibitors--[ibrutinib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6912) (pIC~50~ 9.3) \[[370](http://www.ncbi.nlm.nih.gov/pubmed/17154430?dopt=AbstractPlus)\], [compound 31 \[PMID: 24915291\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8148) (pIC~50~ 8.4) \[[285](http://www.ncbi.nlm.nih.gov/pubmed/24915291?dopt=AbstractPlus)\], [compound 38 \[PMID: 24915291\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8145) (pIC~50~\>8.4) \[[285](http://www.ncbi.nlm.nih.gov/pubmed/24915291?dopt=AbstractPlus)\]--Selective inhibitors--[CGI1746](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8066) (pIC~50~ 8.7) \[[112](http://www.ncbi.nlm.nih.gov/pubmed/21113169?dopt=AbstractPlus)\]--

[RAF family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=610) {#bph13354-sec-0025}
=======================================================================================

Nomenclature[B‐Raf proto‐oncogene, serine/threonine kinase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1943)[Raf‐1 proto‐oncogene, serine/threonine kinase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2184)Common abreviationB‐Rafc‐RafHGNC, UniProt[*BRAF*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1097), [P15056](http://www.uniprot.org/uniprot/P15056)[*RAF1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9829), [P04049](http://www.uniprot.org/uniprot/P04049)EC number[2.7.11.1](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.11.1)[2.7.11.1](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.11.1)Inhibitors[GDC‐0879](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5681) (pIC~50~ 9.7--9.9) \[[105](http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus), [193](http://www.ncbi.nlm.nih.gov/pubmed/18676143?dopt=AbstractPlus)\], [dabrafenib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6494) (pIC~50~ 8.5) \[[277](#bph13354-bib-0277){ref-type="ref"}\], [regorafenib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5891) (pIC~50~ 7.6) \[[545](http://www.ncbi.nlm.nih.gov/pubmed/22222036?dopt=AbstractPlus)\], [vemurafenib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5893) (pIC~50~ 7) \[[510](http://www.ncbi.nlm.nih.gov/pubmed/22808911?dopt=AbstractPlus)\], [PLX‐4720](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5703) (p*K* ~d~ 6.5) \[[105](http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus)\], [compound 2 \[PMID: 26061392\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8548) (p*K* ~d~ 6.3) \[[215](http://www.ncbi.nlm.nih.gov/pubmed/26061392?dopt=AbstractPlus)\], [CHIR‐265](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5674) (p*K* ~d~ 5.9) \[[105](http://www.ncbi.nlm.nih.gov/pubmed/22037378?dopt=AbstractPlus)\]--Selective inhibitors--[GW5074](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8072) (pIC~50~ 8.1) \[[80](http://www.ncbi.nlm.nih.gov/pubmed/15255937?dopt=AbstractPlus)\]

25. [Peptidases and proteinases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=759) {#bph13354-sec-0216}
===========================================================================================================

Overview {#bph13354-sec-0217}
--------

Peptidases and proteinases hydrolyse peptide bonds, and can be simply divided on the basis of whether terminal peptide bonds are cleaved (exopeptidases and exoproteinases) at the amino terminus (aminopeptidases) or carboxy terminus (carboxypeptidases). Non‐terminal peptide bonds are cleaved by endopeptidases and endoproteinases, which are divided into serine endopeptidases (EC 3.4.21.‐), cysteine endopeptidases (EC 3.4.22.‐), aspartate endopeptidases (EC 3.4.23.‐), metalloendopeptidases (EC 3.4.24.‐) and threonine endopeptidases (EC 3.4.25.‐).

It is beyond the scope of the Guide to list all peptidase and proteinase activities; this summary focuses on selected enzymes of significant pharmacological interest.

[A1: Pepsin](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=726) {#bph13354-sec-0026}
=======================================================================================

Nomenclature[renin](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2413)HGNC, UniProt[*REN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9958), [P00797](http://www.uniprot.org/uniprot/P00797)EC number[3.4.23.15](http://www.genome.jp/dbget-bin/www_bget?ec:3.4.23.15)Inhibitors[aliskiren](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4812) (pIC~50~ 9.2) \[[532](http://www.ncbi.nlm.nih.gov/pubmed/18307734?dopt=AbstractPlus)\]

[A22: Presenilin](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=727) {#bph13354-sec-0027}
============================================================================================

Overview {#bph13354-sec-0028}
--------

Presenilin (PS)‐1 or ‐2 act as the catalytic component/essential co‐factor of the *γ*‐secretase complex responsible for the final carboxy‐terminal cleavage of amyloid precursor protein (APP) \[[249](http://www.ncbi.nlm.nih.gov/pubmed/2881207?dopt=AbstractPlus)\] in the generation of amyloid beta (A*β*) \[[6](http://www.ncbi.nlm.nih.gov/pubmed/21115843?dopt=AbstractPlus), [471](http://www.ncbi.nlm.nih.gov/pubmed/12660785?dopt=AbstractPlus)\]. Given that the accumulation and aggregation of A*β* in the brain is pivotal in the development of Alzheimer\'s disease (AD), inhibition of PS activity is one mechanism being investigated as a therapeutic option for AD \[[177](http://www.ncbi.nlm.nih.gov/pubmed/11378516?dopt=AbstractPlus)\]. Several small molecule inhibitors of PS‐1 have been investigated, with some reaching early clinical trials, but none have been formally approved. Dewji *et al* (2015) have reported that small peptide fragments of human PS‐1 can significantly inhibit A*β* production (total A*β*, A*β*40 and A*β*42) both *in vitro* and when infused in to the brains of APP transgenic mice \[[111](http://www.ncbi.nlm.nih.gov/pubmed/25923432?dopt=AbstractPlus)\]. The most active small peptides in this report were [P4 \[PMID: 25923432\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8344) and [P8 \[PMID: 25923432\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8345), from the amino‐terminal domain of PS‐1.

[C14: Caspase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=734) {#bph13354-sec-0029}
=========================================================================================

Overview {#bph13354-sec-0030}
--------

Caspases, ([E.C. 3.4.22.‐](http://www.genome.jp/kegg-bin/search_brite?option=-a&search_string=3.4.22.-)) which derive their name from Cysteine ASPartate‐specific proteASES, include at least two families; initiator caspases (caspases 2, 8, 9 and 10), which are able to hydrolyse and activate a second family of effector caspases (caspases 3, 6 and 7), which themselves are able to hydrolyse further cellular proteins to bring about programmed cell death. Caspases are heterotetrameric, being made up of two pairs of subunits, generated by a single gene product, which is proteolysed to form the mature protein. Members of the mammalian inhibitors of apoptosis proteins (IAP) are able to bind the procaspases, thereby preventing maturation to active proteinases.

Comments {#bph13354-sec-0031}
--------

CARD16 (Caspase recruitment domain‐containing protein 16, caspase‐1 inhibitor COP, CARD only domain‐containing protein 1, pseudo interleukin‐1*β* converting enzyme, pseudo‐ICE, [ENSG00000204397](http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000204397;r=11:104912053-104972158)) shares sequence similarity with some of the caspases.

[M1: Aminopeptidase N](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=737) {#bph13354-sec-0032}
=================================================================================================

Overview {#bph13354-sec-0033}
--------

Aminopeptidases catalyze the cleavage of amino acids from the amino (N) terminus of protein or peptide substrates, and are involved in many essential cellular functions. Members of this enzyme family may be monomeric or multi‐subunit complexes, and many are zinc metalloenzymes \[[480](http://www.ncbi.nlm.nih.gov/pubmed/8440407?dopt=AbstractPlus)\].

[M2: Angiotensin‐converting (ACE and ACE2)](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=741) {#bph13354-sec-0034}
======================================================================================================================

Nomenclature[Angiotensin‐converting enzyme](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1613)Common abreviationACEHGNC, UniProt[*ACE*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2707), [P12821](http://www.uniprot.org/uniprot/P12821)EC number[3.4.15.1](http://www.genome.jp/dbget-bin/www_bget?ec:3.4.15.1)Endogenous substrates[angiotensin I](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=583) ([*AGT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=333), [P01019](http://www.uniprot.org/uniprot/P01019)) \>[angiotensin II](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2504) ([*AGT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=333), [P01019](http://www.uniprot.org/uniprot/P01019))Inhibitors[zofenoprilat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6463) (p*K* ~i~ 9.4) \[[270](http://www.ncbi.nlm.nih.gov/pubmed/2836590?dopt=AbstractPlus)\] -- Rabbit, [captopril](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5158) (p*K* ~i~ 8.4) \[[331](http://www.ncbi.nlm.nih.gov/pubmed/9187274?dopt=AbstractPlus)\], [zofenopril](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6462)Selective inhibitors[perindoprilat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6373) (pIC~50~ 9) \[[67](http://www.ncbi.nlm.nih.gov/pubmed/17716647?dopt=AbstractPlus)\], [cilazaprilat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6461) (pIC~50~ 8.7) \[[514](http://www.ncbi.nlm.nih.gov/pubmed/2527528?dopt=AbstractPlus)\] -- Rabbit, [imidaprilat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6378) (pIC~50~ 8.7) \[[409](http://www.ncbi.nlm.nih.gov/pubmed/17547476?dopt=AbstractPlus)\], [lisinopril‐tryptophan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7893) (C‐domain assay) (pIC~50~ 8.2) \[[515](http://www.ncbi.nlm.nih.gov/pubmed/20233165?dopt=AbstractPlus)\], [RXP‐407](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7894) (N‐domain selective inhibition) (pIC~50~ 8.1) \[[434](http://www.ncbi.nlm.nih.gov/pubmed/22628311?dopt=AbstractPlus)\], [fosinoprilat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6457) (pIC~50~ 8) \[[106](http://www.ncbi.nlm.nih.gov/pubmed/2481187?dopt=AbstractPlus)\] -- Rabbit, [enalaprilat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6332) (pIC~50~ 7.5) \[[79](http://www.ncbi.nlm.nih.gov/pubmed/7527095?dopt=AbstractPlus)\], [benazeprilat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6375) (pIC~50~ 6.6) \[[282](http://www.ncbi.nlm.nih.gov/pubmed/17506720?dopt=AbstractPlus)\]CommentsReports of ACE GPI hydrolase activity \[[265](http://www.ncbi.nlm.nih.gov/pubmed/15665832?dopt=AbstractPlus)\] have been refuted \[[283](http://www.ncbi.nlm.nih.gov/pubmed/16270062?dopt=AbstractPlus)\]

[M10: Matrix metallopeptidase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=738) {#bph13354-sec-0035}
=========================================================================================================

Overview {#bph13354-sec-0036}
--------

Matrix metalloproteinases (MMP) are calcium‐ and zinc‐dependent proteinases regulating the extracellular matrix and are often divided (*e.g*. \[[501](http://www.ncbi.nlm.nih.gov/pubmed/17275314?dopt=AbstractPlus)\]) on functional and structural bases into gelatinases, collagenases, stromyelinases and matrilysins, as well as membrane type‐MMP (MT‐MMP).

Nomenclature[MMP2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1629)[MMP8](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1632)HGNC, UniProt[*MMP2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7166), [P08253](http://www.uniprot.org/uniprot/P08253)[*MMP8*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7175), [P22894](http://www.uniprot.org/uniprot/P22894)EC number[3.4.24.24](http://www.genome.jp/dbget-bin/www_bget?ec:3.4.24.24)[3.4.24.34](http://www.genome.jp/dbget-bin/www_bget?ec:3.4.24.34)Selective inhibitors[ARP100](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5140) \[[493](http://www.ncbi.nlm.nih.gov/pubmed/16483784?dopt=AbstractPlus)\]--

Comments {#bph13354-sec-0037}
--------

A number of small molecule 'broad spectrum' inhibitors of MMP have been described, including [marimastat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5220) and [batimastat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5145).

**Tissue inhibitors of metalloproteinase (TIMP)** proteins are endogenous inhibitors acting to chelate MMP proteins: [TIMP1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5309)([*TIMP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11820), [P01033](http://www.uniprot.org/uniprot/P01033)), [TIMP2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5310)([*TIMP2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11821), [P16035](http://www.uniprot.org/uniprot/P16035)), [TIMP3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5311)([*TIMP3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11822), [P35625](http://www.uniprot.org/uniprot/P35625)), [TIMP4](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5312)([*TIMP4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11823), [Q99727](http://www.uniprot.org/uniprot/Q99727))

[M12: Astacin/Adamalysin](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=739) {#bph13354-sec-0038}
====================================================================================================

Overview {#bph13354-sec-0039}
--------

ADAM (A Disintegrin And Metalloproteinase domain containing proteins) metalloproteinases cleave cell‐surface or transmembrane proteins to generate soluble and membrane‐limited products.

ADAMTS (with thrombospondin motifs) metalloproteinases cleave cell‐surface or transmembrane proteins to generate soluble and membrane‐limited products.

Comments {#bph13354-sec-0040}
--------

Additional ADAM family members include AC123767.2 (cDNA FLJ58962, moderately similar to mouse ADAM3, ENSG00000231168), AL160191.3 (ADAM21‐like protein, [ENSG00000235812](http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000235812;r=14:70712470-70714518)), AC136428.3‐2 (ENSG00000185520) and ADAMDEC1 (decysin 1, [ENSG00000134028](http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000134028;r=8:24241798-24263526)).

Other ADAMTS family members include AC104758.12‐5 (FLJ00317 protein Fragment ENSG00000231463), AC139425.3‐1 (ENSG00000225577), and AC126339.6‐1 (ENSG00000225734).

[M28: Aminopeptidase Y](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=748) {#bph13354-sec-0041}
==================================================================================================

Nomenclature[Folate hydrolase (prostate‐specific membrane antigen) 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1606)HGNC, UniProt[*FOLH1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3788), [Q04609](http://www.uniprot.org/uniprot/Q04609)EC number[3.4.17.21](http://www.genome.jp/dbget-bin/www_bget?ec:3.4.17.21)Antibodies[capromab](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6878) (Binding)

Comment {#bph13354-sec-0042}
-------

folate hydrolase is also known as NAALADase as it is responsible for the hydrolysis of N‐acetaspartylglutamate to form N‐acetylaspartate and L‐glutamate. In the gut, the enzyme assists in the assimilation of folate by hydrolysing dietary poly‐gamma‐glutamylfolate. The enzyme is highly expressed in the prostate, and its expression is up‐regulated in cancerous tissue. A tagged version of the antibody capromab has been used for imaging purposes.

[M19: Membrane dipeptidase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=749) {#bph13354-sec-0043}
======================================================================================================

Nomenclature[Dipeptidase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1393)HGNC, UniProt[*DPEP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3002), [P16444](http://www.uniprot.org/uniprot/P16444)EC number[3.4.13.19](http://www.genome.jp/dbget-bin/www_bget?ec:3.4.13.19): [LTD~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353) + H~2~O = [LTE~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3352) + [glycine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727)Inhibitors[cilastatin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5166) (p*K* ~i~ 6) \[[179](http://www.ncbi.nlm.nih.gov/pubmed/3495664?dopt=AbstractPlus)\] -- Unknown

[S1: Chymotrypsin](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=751) {#bph13354-sec-0044}
=============================================================================================

Nomenclature[complement component 1, r subcomponent](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2334)[coagulation factor II (thrombin)](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362)[coagulation factor X](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2359)[elastase, neutrophil expressed](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2358)HGNC, UniProt[*C1R*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1246), [P00736](http://www.uniprot.org/uniprot/P00736)[*F2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3535), [P00734](http://www.uniprot.org/uniprot/P00734)[*F10*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3528), [P00742](http://www.uniprot.org/uniprot/P00742)[*ELANE*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3309), [P08246](http://www.uniprot.org/uniprot/P08246)EC number[3.4.21.41](http://www.genome.jp/dbget-bin/www_bget?ec:3.4.21.41)[3.4.21.5](http://www.genome.jp/dbget-bin/www_bget?ec:3.4.21.5)[3.4.21.6](http://www.genome.jp/dbget-bin/www_bget?ec:3.4.21.6)[3.4.21.37](http://www.genome.jp/dbget-bin/www_bget?ec:3.4.21.37)Inhibitors[nafamostat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262) (pIC~50~ 4.9) \[[203](http://www.ncbi.nlm.nih.gov/pubmed/9544206?dopt=AbstractPlus)\][lepirudin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6469) (p*K* ~i~ 13) \[[511](http://www.ncbi.nlm.nih.gov/pubmed/16363236?dopt=AbstractPlus)\], [desirudin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6458) (p*K* ~i~ 12.7) \[[242](http://www.ncbi.nlm.nih.gov/pubmed/1894196?dopt=AbstractPlus)\], [AZ12971554](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7727) (p*K* ~i~ 9.5) \[[16](#bph13354-bib-0016){ref-type="ref"}\], [melagatran](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6382) (p*K* ~i~ 8.7) \[[186](http://www.ncbi.nlm.nih.gov/pubmed/9459334?dopt=AbstractPlus)\], [bivalirudin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6470) (p*K* ~i~ 8.6) \[[527](http://www.ncbi.nlm.nih.gov/pubmed/1290488?dopt=AbstractPlus)\], [dabigatran](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6380) (p*K* ~i~ 8.3) \[[198](http://www.ncbi.nlm.nih.gov/pubmed/11960487?dopt=AbstractPlus)\], [argatroban](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6385) (p*K* ~i~ 7.7) \[[225](http://www.ncbi.nlm.nih.gov/pubmed/9361377?dopt=AbstractPlus)\][rivaroxaban](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6388) (p*K* ~i~ 9.4) \[[380](http://www.ncbi.nlm.nih.gov/pubmed/20139357?dopt=AbstractPlus)\], [edoxaban](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7575) (p*K* ~i~ 9.2) \[[385](http://www.ncbi.nlm.nih.gov/pubmed/20503967?dopt=AbstractPlus)\], [apixaban](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6390) (p*K* ~i~ 9.1) \[[528](http://www.ncbi.nlm.nih.gov/pubmed/18315548?dopt=AbstractPlus)\][alvelestat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6476) (p*K* ~i~ 8) \[[463](http://www.ncbi.nlm.nih.gov/pubmed/21791628?dopt=AbstractPlus)\], [sivelestat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6441) (pIC~50~ 7.4) \[[96](http://www.ncbi.nlm.nih.gov/pubmed/21741848?dopt=AbstractPlus)\]Selective inhibitors--[AR‐H067637](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7688) (pIC~50~ 8.4) \[[108](http://www.ncbi.nlm.nih.gov/pubmed/19492147?dopt=AbstractPlus)\]----

Nomenclature[plasminogen](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2394)[plasminogen activator, tissue](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2392)[protease, serine, 1 (trypsin 1)](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2397)[tryptase alpha/beta 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2424)HGNC, UniProt[*PLG*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9071), [P00747](http://www.uniprot.org/uniprot/P00747)[*PLAT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9051), [P00750](http://www.uniprot.org/uniprot/P00750)[*PRSS1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9475), [P07477](http://www.uniprot.org/uniprot/P07477)[*TPSAB1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12019), [Q15661](http://www.uniprot.org/uniprot/Q15661)EC number[3.4.21.7](http://www.genome.jp/dbget-bin/www_bget?ec:3.4.21.7)[3.4.21.68](http://www.genome.jp/dbget-bin/www_bget?ec:3.4.21.68)[3.4.21.4](http://www.genome.jp/dbget-bin/www_bget?ec:3.4.21.4)[3.4.21.59](http://www.genome.jp/dbget-bin/www_bget?ec:3.4.21.59)Inhibitors[aprotinin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6570) {Bovine} (Binding) (pIC~50~ 6.8) \[[454](http://www.ncbi.nlm.nih.gov/pubmed/17666018?dopt=AbstractPlus)\], [tranexamic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6573) (Binding) (pIC~50~ 3.6) \[[454](http://www.ncbi.nlm.nih.gov/pubmed/17666018?dopt=AbstractPlus)\], [6‐aminocaproic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6574) (Binding)[6‐aminocaproic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6574)[nafamostat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262) (pIC~50~ 7.8) \[[203](http://www.ncbi.nlm.nih.gov/pubmed/9544206?dopt=AbstractPlus)\][nafamostat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4262) (pIC~50~ 10) \[[342](http://www.ncbi.nlm.nih.gov/pubmed/12939527?dopt=AbstractPlus)\]Selective inhibitors------[gabexate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7863) (pIC~50~ 8.5) \[[127](http://www.ncbi.nlm.nih.gov/pubmed/11172730?dopt=AbstractPlus)\]

[T1: Proteasome](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=752) {#bph13354-sec-0045}
===========================================================================================

Overview {#bph13354-sec-0046}
--------

The T1 macropain beta subunits form the catalytic proteinase core of the 20S proteasome complex \[[86](http://www.ncbi.nlm.nih.gov/pubmed/16142822?dopt=AbstractPlus)\]. This catalytic core enables the degradation of peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the cleavage site. The *β*5 subunit is the principal target of the approved drug proteasome inhibitor [bortezomib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6391).

Nomenclature[proteasome (prosome, macropain) subunit, beta type, 5](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2406)HGNC, UniProt[*PSMB5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9542), [P28074](http://www.uniprot.org/uniprot/P28074)EC number[3.4.25.1](http://www.genome.jp/dbget-bin/www_bget?ec:3.4.25.1)Inhibitors[bortezomib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6391) (pIC~50~ 7.7) \[[347](http://www.ncbi.nlm.nih.gov/pubmed/19428245?dopt=AbstractPlus)\]Selective inhibitors[ixazomib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8450) (p*K* ~i~ 9) \[[273](http://www.ncbi.nlm.nih.gov/pubmed/20160034?dopt=AbstractPlus)\]

[S8: Subtilisin](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=755) {#bph13354-sec-0047}
===========================================================================================

Overview {#bph13354-sec-0048}
--------

One member of this family has garnered intense interest as a clinical drug target. As liver PCSK9 acts to maintain cholesterol homeostasis, it has become a target of intense interest for clinical drug development. Inhibition of PCSK9 can lower low‐density cholesterol (LDL‐C) by clearing LDLR‐bound LDL particles, thereby lowering circulating cholesterol levels. It is hypothesised that this action may improve outcomes in patients with atherosclerotic cardiovascular disease \[[297](http://www.ncbi.nlm.nih.gov/pubmed/18836590?dopt=AbstractPlus), [416](http://www.ncbi.nlm.nih.gov/pubmed/25083925?dopt=AbstractPlus), [462](http://www.ncbi.nlm.nih.gov/pubmed/19506257?dopt=AbstractPlus)\]. Therapeutics which inhibit PCSK9 are viewed as potentially lucrative replacements for statins, upon statin patent expiry. Several monoclonal antibodies including [alirocumab](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6744), [evolocumab](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7343), [bococizumab](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7730), RG‐7652 and LY3015014 are under development. One RNAi therapeutic, code named ALN‐PCS02, is also in development \[[99](http://www.ncbi.nlm.nih.gov/pubmed/24145894?dopt=AbstractPlus), [139](http://www.ncbi.nlm.nih.gov/pubmed/24094767?dopt=AbstractPlus), [146](http://www.ncbi.nlm.nih.gov/pubmed/18695239?dopt=AbstractPlus)\].

[S9: Prolyl oligopeptidase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=758) {#bph13354-sec-0049}
======================================================================================================

Nomenclature[dipeptidyl‐peptidase 4](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612)HGNC, UniProt[*DPP4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3009), [P27487](http://www.uniprot.org/uniprot/P27487)EC number[3.4.14.5](http://www.genome.jp/dbget-bin/www_bget?ec:3.4.14.5)Endogenous substrates[glucagon‐like peptide 1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5194) ([*GCG*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4191), [P01275](http://www.uniprot.org/uniprot/P01275))Inhibitors[saxagliptin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6316) (p*K* ~i~ 9.2) \[[184](http://www.ncbi.nlm.nih.gov/pubmed/19149538?dopt=AbstractPlus)\], [linagliptin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6318) (p*K* ~i~ 9) \[[122](http://www.ncbi.nlm.nih.gov/pubmed/18052023?dopt=AbstractPlus)\], [sitagliptin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6286) (pIC~50~ 8.1) \[[104](http://www.ncbi.nlm.nih.gov/pubmed/20927248?dopt=AbstractPlus)\], [vildagliptin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6310) (p*K* ~i~ 7.8) \[[184](http://www.ncbi.nlm.nih.gov/pubmed/19149538?dopt=AbstractPlus)\]

[Acetylcholine turnover](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=765) {#bph13354-sec-0050}
===================================================================================================

Overview {#bph13354-sec-0051}
--------

Acetylcholine is familiar as a neurotransmitter in the central nervous system and in the periphery. In the somatic nervous system, it activates [nicotinic acetylcholine receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=76) at the skeletal neuromuscular junction. It is also employed in the autonomic nervous system, in both parasympathetic and sympathetic branches; in the former, at the smooth muscle neuromuscular junction, activating [muscarinic acetylcholine receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=2). In the latter, acetylcholine is involved as a neurotransmitter at the ganglion, activating nicotinic acetylcholine receptors. Acetylcholine is synthesised in neurones through the action of choline O‐acetyltransferase and metabolised after release through the extracellular action of acetylcholinesterase and cholinesterase. Choline is accumulated from the extracellular medium by selective transporters (see [SLC5A7](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=143#show_object_914) and the [SLC44](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=233) family). Acetylcholine is accumulated in synaptic vesicles through the action of the vesicular acetylcholine transporter [SLC18A3](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=193).

Nomenclature[choline O‐acetyltransferase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2480)[acetylcholinesterase (Yt blood group)](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2465)[butyrylcholinesterase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2471)Common abreviationChATAChEBChEHGNC, UniProt[*CHAT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1912), [P28329](http://www.uniprot.org/uniprot/P28329)[*ACHE*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=108), [P22303](http://www.uniprot.org/uniprot/P22303)[*BCHE*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=983), [P06276](http://www.uniprot.org/uniprot/P06276)EC number[2.3.1.6](http://www.genome.jp/dbget-bin/www_bget?ec:2.3.1.6): [acetyl CoA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038) + [choline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4551) = [acetylcholine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=294) + [coenzyme A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044)[3.1.1.7](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.1.7): [acetylcholine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=294) + H~2~O = [acetic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1058) + [choline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4551) + H^+^[3.1.1.7](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.1.7): [acetylcholine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=294) + H~2~O = [acetic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1058) + [choline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4551) + H^+^Inhibitors--[tacrine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6687) (p*K* ~i~ 7.5) \[[52](http://www.ncbi.nlm.nih.gov/pubmed/18479118?dopt=AbstractPlus)\], [galantamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6693) (pIC~50~ 6.3) \[[87](http://www.ncbi.nlm.nih.gov/pubmed/12182861?dopt=AbstractPlus)\], [rivastigmine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6602) (pIC~50~ 5.4) \[[305](http://www.ncbi.nlm.nih.gov/pubmed/16570913?dopt=AbstractPlus)\][rivastigmine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6602) (pIC~50~ 7.4) \[[305](http://www.ncbi.nlm.nih.gov/pubmed/16570913?dopt=AbstractPlus)\], [tacrine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6687) (p*K* ~i~ 7.2) \[[52](http://www.ncbi.nlm.nih.gov/pubmed/18479118?dopt=AbstractPlus)\](Sub)family‐selective inhibitors--[physostigmine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6598) (pIC~50~ 7.6--7.8) \[[305](http://www.ncbi.nlm.nih.gov/pubmed/16570913?dopt=AbstractPlus)\][physostigmine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6598) (pIC~50~ 7.6--7.8) \[[305](http://www.ncbi.nlm.nih.gov/pubmed/16570913?dopt=AbstractPlus)\]Selective inhibitors--[donepezil](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6599) (pIC~50~ 7.7--8.3) \[[62](http://www.ncbi.nlm.nih.gov/pubmed/1738151?dopt=AbstractPlus), [160](http://www.ncbi.nlm.nih.gov/pubmed/8039548?dopt=AbstractPlus), [305](http://www.ncbi.nlm.nih.gov/pubmed/16570913?dopt=AbstractPlus)\], [BW284C51](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6600) (pIC~50~ 7.7) \[[172](http://www.ncbi.nlm.nih.gov/pubmed/12675140?dopt=AbstractPlus)\][bambuterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6601) (pIC~50~ 8.5) \[[172](http://www.ncbi.nlm.nih.gov/pubmed/12675140?dopt=AbstractPlus)\]CommentsSplice variants of choline O‐acetyltransferase are suggested to be differentially distributed in the periphery and CNS (see \[[28](http://www.ncbi.nlm.nih.gov/pubmed/21382474?dopt=AbstractPlus)\]).----

Comments {#bph13354-sec-0052}
--------

A number of organophosphorus compounds inhibit acetylcholinesterase and cholinesterase irreversibly, including pesticides such as chlorpyrifos‐oxon, and nerve agents such as tabun, soman and sarin. AChE is unusual in its exceptionally high turnover rate which has been calculated at 740 000/min/molecule \[[505](http://www.ncbi.nlm.nih.gov/pubmed/13785664?dopt=AbstractPlus)\].

Further Reading {#bph13354-sec-0053}
---------------
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[Adenosine turnover](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=248) {#bph13354-sec-0054}
===============================================================================================

Overview {#bph13354-sec-0055}
--------

A multifunctional, ubiquitous molecule, [adenosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844) acts at cell‐surface G protein‐coupled receptors, as well as numerous enzymes, including protein kinases and adenylyl cyclase. Extracellular adenosine is thought to be produced either by export or by metabolism, predominantly through ecto‐5\'‐nucleotidase activity (also producing inorganic phosphate). It is inactivated either by extracellular metabolism *via*adenosine deaminase (also producing ammonia) or, following uptake by nucleoside transporters, *via*adenosine deaminase or adenosine kinase (requiring [ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713) as co‐substrate). Intracellular adenosine may be produced by cytosolic 5\'‐nucleotidases or through S‐adenosylhomocysteine hydrolase (also producing [L‐homocysteine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5198)).

Nomenclature[Adenosine deaminase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1230)[Adenosine kinase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1231)[Ecto‐5\'‐Nucleotidase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1232)[S‐Adenosylhomocysteine hydrolase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1233)Common abreviationADAADKNT5ESAHHHGNC, UniProt[*ADA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=186), [P00813](http://www.uniprot.org/uniprot/P00813)[*ADK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=257), [P55263](http://www.uniprot.org/uniprot/P55263)[*NT5E*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8021), [P21589](http://www.uniprot.org/uniprot/P21589)[*AHCY*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=343), [P23526](http://www.uniprot.org/uniprot/P23526)EC number[3.5.4.4](http://www.genome.jp/dbget-bin/www_bget?ec:3.5.4.4): [adenosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844) + H~2~O = [inosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4554) + NH~3~[2.7.1.20](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.1.20)[3.1.3.5](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.3.5)[3.3.1.1](http://www.genome.jp/dbget-bin/www_bget?ec:3.3.1.1)Endogenous substrates------[S‐adenosylhomocysteine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5265)Rank order of affinity[2\'‐deoxyadenosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5109)\>[adenosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844)[adenosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844)[adenosine 5\'‐monophosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2455), [5\'‐GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5123), [5\'‐inosine monophosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5124), [5\'‐UMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5125)\>[5\'‐dAMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5120), [5\'‐dGMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5122)--Products[2\'‐deoxyinosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5110), [inosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4554)[adenosine 5\'‐monophosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2455)[uridine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4566), [inosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4554), [guanine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4556), [adenosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844)[adenosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844)Inhibitors------[DZNep](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8392) (p*K* ~i~ 12.3) \[[174](http://www.ncbi.nlm.nih.gov/pubmed/3457563?dopt=AbstractPlus)\] -- HamsterSelective inhibitors[pentostatin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4805) (pIC~50~ 10.8) \[[3](http://www.ncbi.nlm.nih.gov/pubmed/849330?dopt=AbstractPlus)\], [EHNA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5179) (p*K* ~i~ 8.8) \[[3](http://www.ncbi.nlm.nih.gov/pubmed/849330?dopt=AbstractPlus)\][A134974](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5130) (pIC~50~ 10.2) \[[325](http://www.ncbi.nlm.nih.gov/pubmed/11160637?dopt=AbstractPlus)\], [ABT702](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5131) (pIC~50~ 8.8) \[[236](http://www.ncbi.nlm.nih.gov/pubmed/11082453?dopt=AbstractPlus)\][*αβ*‐methyleneADP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5092) (pIC~50~ 8.7) \[[50](http://www.ncbi.nlm.nih.gov/pubmed/1169962?dopt=AbstractPlus)\][3‐deazaadenosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5115) (pIC~50~ 8.5) \[[185](http://www.ncbi.nlm.nih.gov/pubmed/7470463?dopt=AbstractPlus)\]

Comments {#bph13354-sec-0056}
--------

An extracellular adenosine deaminase activity, termed ADA2 or adenosine deaminase growth factor (ADGF, [*CECR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1839), [Q9NZK5](http://www.uniprot.org/uniprot/Q9NZK5)) has been identified \[[94](http://www.ncbi.nlm.nih.gov/pubmed/24933472?dopt=AbstractPlus), [309](http://www.ncbi.nlm.nih.gov/pubmed/16245011?dopt=AbstractPlus)\], which is insensitive to [EHNA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5179)\[[546](http://www.ncbi.nlm.nih.gov/pubmed/20147294?dopt=AbstractPlus)\]. Other forms of adenosine deaminase act on ribonucleic acids and may be divided into two families: [*ADAT1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=228)([Q9BUB4](http://www.uniprot.org/uniprot/Q9BUB4)) deaminates transfer RNA; [*ADAR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=225)([EC 3.5.4.37](http://www.genome.jp/dbget-bin/www_bget?ec:3.5.4.37), also known as 136 kDa double‐stranded RNA‐binding protein, P136, K88DSRBP, Interferon‐inducible protein 4); [*ADARB1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=226) (EC 3.5.‐.‐, , also known as dsRNA adenosine deaminase) and [*ADARB2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=227) (EC 3.5.‐.‐, also known as dsRNA adenosine deaminase B2, RNA‐dependent adenosine deaminase 3) act on double‐stranded RNA. Particular polymorphisms of the ADA gene result in loss‐of‐function and severe combined immunodeficiency syndrome. Adenosine deaminase is able to complex with dipeptidyl peptidase IV ([EC 3.4.14.5](http://www.genome.jp/dbget-bin/www_bget?ec:3.4.14.5), [*DPP4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3009), also known as T‐cell activation antigen CD26, TP103, adenosine deaminase complexing protein 2) to form a cell‐surface activity \[[248](http://www.ncbi.nlm.nih.gov/pubmed/8101391?dopt=AbstractPlus)\].

Further Reading {#bph13354-sec-0057}
---------------
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[Amino acid hydroxylases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=249) {#bph13354-sec-0058}
====================================================================================================

Overview {#bph13354-sec-0059}
--------

The amino acid hydroxylases (monooxygenases), EC.1.14.16.‐, are iron‐containing enzymes which utilise molecular oxygen and [sapropterin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5276) as co‐substrate and co‐factor, respectively. In humans, as well as in other mammals, there are two distinct L‐Tryptophan hydroxylase 2 genes. In humans, these genes are located on chromosomes 11 and 12 and encode two different homologous enzymes, TPH1 and TPH2.

Nomenclature[L‐Phenylalanine hydroxylase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1240)[L‐Tyrosine hydroxylase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1243)[L‐Tryptophan hydroxylase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1241)[L‐Tryptophan hydroxylase 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1242)HGNC, UniProt[*PAH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8582), [P00439](http://www.uniprot.org/uniprot/P00439)[*TH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11782), [P07101](http://www.uniprot.org/uniprot/P07101)[*TPH1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12008), [P17752](http://www.uniprot.org/uniprot/P17752)[*TPH2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20692), [Q8IWU9](http://www.uniprot.org/uniprot/Q8IWU9)EC number[1.14.16.1](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.16.1): [L‐phenylalanine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313) + O~2~ ‐\>[L‐tyrosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791)[1.14.16.2](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.16.2): [L‐tyrosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791) + O~2~ ‐\>[levodopa](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639)[1.14.16.4](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.16.4)[1.14.16.4](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.16.4)Endogenous activatorsProtein kinase A‐mediated phosphorylation (Rat) \[[1](http://www.ncbi.nlm.nih.gov/pubmed/182695?dopt=AbstractPlus)\]Protein kinase A‐mediated phosphorylation \[[239](http://www.ncbi.nlm.nih.gov/pubmed/33381?dopt=AbstractPlus)\]Protein kinase A‐mediated phosphorylation \[[240](http://www.ncbi.nlm.nih.gov/pubmed/8592157?dopt=AbstractPlus)\]Protein kinase A‐mediated phosphorylation \[[240](http://www.ncbi.nlm.nih.gov/pubmed/8592157?dopt=AbstractPlus)\]Endogenous substrates[L‐phenylalanine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313)[L‐tyrosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791)[L‐tryptophan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717)[L‐tryptophan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717)Products[L‐tyrosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791)[levodopa](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639)[5‐hydroxy‐L‐tryptophan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4671)[5‐hydroxy‐L‐tryptophan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4671)Cofactors[sapropterin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5276)[sapropterin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5276), Fe^2+^----Selective activators[sapropterin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5276) (p*K* ~i~ 5.4) \[[481](http://www.ncbi.nlm.nih.gov/pubmed/15537351?dopt=AbstractPlus)\]------Inhibitors--[methyltyrosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5094)----Selective inhibitors[*α*‐methylphenylalanine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5093) \[[180](http://www.ncbi.nlm.nih.gov/pubmed/944951?dopt=AbstractPlus)\] -- Rat, [fenclonine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5240)[*α*‐propyldopacetamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5095), [3‐chlorotyrosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5114), [3‐iodotyrosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5117), [alpha‐methyltyrosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6956)[*α*‐propyldopacetamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5095), [6‐fluorotryptophan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5126) \[[352](http://www.ncbi.nlm.nih.gov/pubmed/6457252?dopt=AbstractPlus)\], [fenclonine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5240), [fenfluramine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4613)[*α*‐propyldopacetamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5095), [6‐fluorotryptophan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5126) \[[352](http://www.ncbi.nlm.nih.gov/pubmed/6457252?dopt=AbstractPlus)\], [fenclonine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5240), [fenfluramine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4613)CommentsPAH is an iron bound homodimer or ‐tetramer from the same structural family as tyrosine 3‐monooxygenase and the tryptophan hydroxylases. Deficiency or loss‐of‐function of PAH is associated with [phenylketonuria](http://omim.org/entry/612349)TH is a homotetramer, which is inhibited by dopamine and other catecholamines in a physiological negative feedback pathway \[[102](http://www.ncbi.nlm.nih.gov/pubmed/21176768?dopt=AbstractPlus)\].----

Further Reading {#bph13354-sec-0060}
---------------
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[L‐Arginine turnover](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=239) {#bph13354-sec-0061}
================================================================================================

Overview {#bph13354-sec-0062}
--------

[L‐arginine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721) is a basic amino acid with a guanidino sidechain. As an amino acid, metabolism of L‐arginine to form [L‐ornithine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=725), catalysed by arginase, forms the last step of the [urea](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4539) production cycle. L‐Ornithine may be utilised as a precursor of polyamines (see [Carboxylases and Decarboxylases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=240)) or recycled via [L‐argininosuccinic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5324) to L‐arginine. L‐Arginine [may itself be decarboxylated](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=240#Decarboxylases) to form [agmatine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4127), although the prominence of this pathway in human tissues is uncertain. L‐Arginine may be used as a precursor for [guanidoacetic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5325) formation in the [creatine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4496) synthesis pathway under the influence of arginine:glycine amidinotransferase with L‐ornithine as a byproduct. Nitric oxide synthase uses L‐arginine to generate nitric oxide, with [L‐citrulline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=722) also as a byproduct.

L‐Arginine in proteins may be subject to post‐translational modification through methylation, catalysed by protein arginine methyltransferases. Subsequent proteolysis can liberate asymmetric [N^G^,N^G^‐dimethyl‐L‐arginine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5229)(ADMA), which is an endogenous inhibitor of nitric oxide synthase activities. ADMA is hydrolysed by dimethylarginine dimethylhydrolase activities to generate [L‐citrulline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=722) and [dimethylamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5177).

Further Reading {#bph13354-sec-0063}
---------------
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[Arginase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=250) {#bph13354-sec-0064}
=====================================================================================

Overview {#bph13354-sec-0065}
--------

Arginase ([EC 3.5.3.1](http://www.genome.jp/kegg-bin/search_brite?option=-a&search_string=3.5.3.1)) are manganese‐containing isoforms, which appear to show differential distribution, where the ARG1 isoform predominates in the liver and erythrocytes, while ARG2 is associated more with the kidney.

Comments {#bph13354-sec-0066}
--------

[N^*ω*^‐hydroxyarginine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5227), an intermediate in NOS metabolism of L‐arginine acts as a weak inhibitor and may function as a physiological regulator of arginase activity. Although isoform‐selective inhibitors of arginase are not available, examples of inhibitors selective for arginase compared to NOS are [N^*ω*^‐hydroxy‐nor‐L‐arginine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5091)\[[483](http://www.ncbi.nlm.nih.gov/pubmed/10637120?dopt=AbstractPlus)\], [S‐(2‐boronoethyl)‐L‐cysteine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5264)\[[90](http://www.ncbi.nlm.nih.gov/pubmed/11478904?dopt=AbstractPlus), [256](http://www.ncbi.nlm.nih.gov/pubmed/11258879?dopt=AbstractPlus)\] and [2(S)‐amino‐6‐boronohexanoic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5107) \[[22](http://www.ncbi.nlm.nih.gov/pubmed/10454520?dopt=AbstractPlus), [90](http://www.ncbi.nlm.nih.gov/pubmed/11478904?dopt=AbstractPlus)\].

[Arginine:glycine amidinotransferase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=251) {#bph13354-sec-0067}
================================================================================================================

Nomenclature[Arginine:glycine amidinotransferase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1246)Common abreviationAGATHGNC, UniProt[*GATM*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4175), [P50440](http://www.uniprot.org/uniprot/P50440)EC number[2.1.4.1](http://www.genome.jp/dbget-bin/www_bget?ec:2.1.4.1)

[Dimethylarginine dimethylaminohydrolases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=252) {#bph13354-sec-0068}
=====================================================================================================================

Overview {#bph13354-sec-0069}
--------

Dimethylarginine dimethylaminohydrolases (DDAH, [EC 3.5.3.18](http://www.genome.jp/kegg-bin/search_brite?option=-a&search_string=3.5.3.18)) are cytoplasmic enzymes which hydrolyse [N^G^,N^G^‐dimethyl‐L‐arginine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5229) to form [dimethylamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5177) and [L‐citrulline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=722).

Nomenclature[*N*^G^,*N*^G^‐Dimethylarginine dimethylaminohydrolase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1247)[*N*^G^,*N*^G^‐Dimethylarginine dimethylaminohydrolase 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1248)Common abreviationDDAH1DDAH2HGNC, UniProt[*DDAH1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2715), [O94760](http://www.uniprot.org/uniprot/O94760)[*DDAH2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2716), [O95865](http://www.uniprot.org/uniprot/O95865)EC number[3.5.3.18](http://www.genome.jp/dbget-bin/www_bget?ec:3.5.3.18)[3.5.3.18](http://www.genome.jp/dbget-bin/www_bget?ec:3.5.3.18)Cofactors[Zn^2+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566)--

[Nitric oxide synthases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=253) {#bph13354-sec-0070}
===================================================================================================

Overview {#bph13354-sec-0071}
--------

Nitric oxide synthases (NOS, [E.C. 1.14.13.39](http://www.genome.jp/kegg-bin/search_brite?option=-a&search_string=1.14.13.39)) utilise [L‐arginine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721)(not D‐arginine) and molecular oxygen to generate nitric oxide and [L‐citrulline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=722). The nomenclature suggested by **NC‐IUPHAR**of NOS I, II and III \[[340](http://www.ncbi.nlm.nih.gov/pubmed/9228663?dopt=AbstractPlus)\] has not gained wide acceptance. eNOS and nNOS isoforms are activated at concentrations of calcium greater than 100 nM, while iNOS shows higher affinity for Ca^2+^/[calmodulin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351)([*CALM1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1442) [*CALM2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1445) [*CALM3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1449), [P62158](http://www.uniprot.org/uniprot/P62158)) and thus appears to be constitutively active. All the three isoforms are homodimers and require [sapropterin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5276), [flavin adenine dinucleotide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5184), [flavin mononucleotide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5185) and [NADPH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041) for catalytic activity. [L‐NAME](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5213) is an inhibitor of all three isoforms, with an IC~50~ value in the micromolar range.

Nomenclature[Endothelial NOS](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1249)[Inducible NOS](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1250)[Neuronal NOS](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1251)Common abreviationeNOSiNOSnNOSHGNC, UniProt[*NOS3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7876), [P29474](http://www.uniprot.org/uniprot/P29474)[*NOS2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7873), [P35228](http://www.uniprot.org/uniprot/P35228)[*NOS1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7872), [P29475](http://www.uniprot.org/uniprot/P29475)EC number[1.14.13.39](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.13.39)[1.14.13.39](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.13.39)[1.14.13.39](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.13.39)Inhibitors----[N^*ω*^propyl‐L‐arginine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6525) (p*K* ~i~ 7.2) \[[548](http://www.ncbi.nlm.nih.gov/pubmed/9397167?dopt=AbstractPlus)\] -- RatSelective inhibitors--[1400W](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5102) (pIC~50~ 8.2) \[[168](http://www.ncbi.nlm.nih.gov/pubmed/9030556?dopt=AbstractPlus)\], [2‐amino‐4‐methylpyridine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5111) (pIC~50~ 7.4) \[[131](http://www.ncbi.nlm.nih.gov/pubmed/8937711?dopt=AbstractPlus)\], [PIBTU](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5246) (pIC~50~ 7.3) \[[169](http://www.ncbi.nlm.nih.gov/pubmed/7523409?dopt=AbstractPlus)\], [NIL](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5231) (pIC~50~ 5.5) \[[341](http://www.ncbi.nlm.nih.gov/pubmed/7525961?dopt=AbstractPlus)\], [aminoguanidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5135) \[[92](http://www.ncbi.nlm.nih.gov/pubmed/1378415?dopt=AbstractPlus)\][3‐bromo‐7NI](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5113) (pIC~50~ 6.1--6.5) \[[40](http://www.ncbi.nlm.nih.gov/pubmed/7544863?dopt=AbstractPlus)\], [7NI](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5127) (pIC~50~ 5.3) \[[19](http://www.ncbi.nlm.nih.gov/pubmed/7693279?dopt=AbstractPlus)\]

Comments {#bph13354-sec-0072}
--------

The reductase domain of NOS catalyses the reduction of cytochrome c and other redox‐active dyes \[[322](http://www.ncbi.nlm.nih.gov/pubmed/9433128?dopt=AbstractPlus)\]. NADPH:O~2~ oxidoreductase catalyses the formation of superoxide anion/[H~2~O~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2448) in the absence of [L‐arginine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721) and [sapropterin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5276).

[Carboxylases and decarboxylases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=240) {#bph13354-sec-0073}
============================================================================================================

[Carboxylases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=255) {#bph13354-sec-0074}
=========================================================================================

Overview {#bph13354-sec-0075}
--------

The carboxylases allow the production of new carbon‐carbon bonds by introducing HCO~3~ ^−^ or CO~2~ into target molecules. Two groups of carboxylase activities, some of which are bidirectional, can be defined on the basis of the cofactor requirement, making use of [biotin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4787) (EC 6.4.1.‐) or [vitamin K hydroquinone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5286) (EC 4.1.1.‐).

Nomenclature[Pyruvate carboxylase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1262)[Acetyl‐CoA carboxylase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1263)[Acetyl‐CoA carboxylase 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1264)Common abreviationPCACC1ACC2HGNC, UniProt[*PC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8636), [P11498](http://www.uniprot.org/uniprot/P11498)[*ACACA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=84), [Q13085](http://www.uniprot.org/uniprot/Q13085)[*ACACB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=85), [O00763](http://www.uniprot.org/uniprot/O00763)EC number[6.4.1.1](http://www.genome.jp/dbget-bin/www_bget?ec:6.4.1.1)[6.4.1.2](http://www.genome.jp/dbget-bin/www_bget?ec:6.4.1.2)[6.4.1.2](http://www.genome.jp/dbget-bin/www_bget?ec:6.4.1.2)Endogenous substrates[ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713), [pyruvic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809)[ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713), [acetyl CoA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038)[acetyl CoA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038), [ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713)ProductsP~i~, [adenosine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712), [oxalacetic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5236)P~i~, [adenosine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712), [malonyl‐CoA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5219)P~i~, [adenosine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712), [malonyl‐CoA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5219)Cofactors[biotin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4787)[biotin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4787)[biotin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4787)Selective inhibitors--[TOFA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5280) \[[294](http://www.ncbi.nlm.nih.gov/pubmed/10875926?dopt=AbstractPlus)\][TOFA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5280) \[[294](http://www.ncbi.nlm.nih.gov/pubmed/10875926?dopt=AbstractPlus)\]Comments--Citrate and other dicarboxylic acids are allosteric activators of acetyl‐CoA carboxylase.Citrate and other dicarboxylic acids are allosteric activators of acetyl‐CoA carboxylase.

Nomenclature[Propionyl‐CoA carboxylase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1265)[*γ*‐Glutamyl carboxylase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1268)Common abreviationPCCA, PCCBGGCXHGNC, UniProt[*PCCA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8653), [P05165](http://www.uniprot.org/uniprot/P05165)[*GGCX*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4247), [P38435](http://www.uniprot.org/uniprot/P38435)[*PCCB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8654), [P05166](http://www.uniprot.org/uniprot/P05166)Subunits[Propionyl‐CoA carboxylase *α* subunit](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1266)[Propionyl‐CoA carboxylase *β* subunit](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1266)--EC number[6.4.1.3](http://www.genome.jp/dbget-bin/www_bget?ec:6.4.1.3)[4.1.1.90](http://www.genome.jp/dbget-bin/www_bget?ec:4.1.1.90)Endogenous substrates[propionyl‐CoA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5248), [ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713)glutamyl peptidesProducts[adenosine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712), [methylmalonyl‐CoA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5223), P~i~carboxyglutamyl peptidesCofactors[biotin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4787)[vitamin K hydroquinone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5286), [NADPH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041)Inhibitors--[anisindione](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6960)CommentsPropionyl‐CoA carboxylase is able to function in both forward and reverse activity modes, as a ligase (carboxylase) or lyase (decarboxylase), respectively.Loss‐of‐function mutations in *γ*‐glutamyl carboxylase are associated with [clotting disorders](http://omim.org/entry/277450).

Comments {#bph13354-sec-0076}
--------

Dicarboxylic acids including [citric acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2478) are able to activate ACC1/ACC2 activity allosterically. PCC is able to function in forward and reverse modes as a ligase (carboxylase) or lyase (decarboxylase) activity, respectively. Loss‐of‐function mutations in GGCX are associated with clotting disorders.

[Decarboxylases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=256) {#bph13354-sec-0077}
===========================================================================================

Overview {#bph13354-sec-0078}
--------

The decarboxylases generate CO~2~ and the indicated products from acidic substrates, requiring [pyridoxal phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249) or [pyruvic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809) as a co‐factor.

Nomenclature[S‐Adenosylmethionine](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1269)[L‐Arginine](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1272)[L‐Aromatic amino‐acid](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1270)[Glutamic acid](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1273)[Glutamic acid](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1271)[decarboxylase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)[decarboxylase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)[decarboxylase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)[decarboxylase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)[decarboxylase 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)Common abreviationSAMDCADCAADCGAD1GAD2HGNC, UniProt[*AMD1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=457), [P17707](http://www.uniprot.org/uniprot/P17707)[*AZIN2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=29957), [Q96A70](http://www.uniprot.org/uniprot/Q96A70)[*DDC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2719), [P20711](http://www.uniprot.org/uniprot/P20711)[*GAD1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4092), [Q99259](http://www.uniprot.org/uniprot/Q99259)[*GAD2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4093), [Q05329](http://www.uniprot.org/uniprot/Q05329)EC number[4.1.1.50](http://www.genome.jp/dbget-bin/www_bget?ec:4.1.1.50)[4.1.1.19](http://www.genome.jp/dbget-bin/www_bget?ec:4.1.1.19)[4.1.1.28](http://www.genome.jp/dbget-bin/www_bget?ec:4.1.1.28): [levodopa](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639) ‐\>[dopamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940) + CO~2~ [5‐hydroxy‐L‐tryptophan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4671) ‐\>[5‐hydroxytryptamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5) + CO~2~ This enzyme also catalyses the following reaction:: [L‐tryptophan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717) ‐\>[tryptamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=125) + CO~2~[4.1.1.15](http://www.genome.jp/dbget-bin/www_bget?ec:4.1.1.15): [L‐glutamic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369) + H^+^ ‐\>[GABA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067) + CO~2~[4.1.1.15](http://www.genome.jp/dbget-bin/www_bget?ec:4.1.1.15): [L‐glutamic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369) + H^+^ ‐\>[GABA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067) + CO~2~Substrates----[Deuterium‐substituted](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8611)----[L‐DOPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8611) \[[312](http://www.ncbi.nlm.nih.gov/pubmed/24906468?dopt=AbstractPlus)\]Endogenous substrates[S‐adenosyl methionine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4786)[L‐arginine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=721)[levodopa](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639), [5‐hydroxy‐L‐tryptophan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4671), [L‐tryptophan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717)[L‐glutamic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369), [L‐aspartic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309)[L‐glutamic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369), [L‐aspartic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309)Products[S‐adenosyl‐L‐](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5121)[agmatine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4127) \[[552](http://www.ncbi.nlm.nih.gov/pubmed/14738999?dopt=AbstractPlus)\][5‐hydroxytryptamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5),[GABA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067)[GABA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067)[methioninamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5121)[dopamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940)Cofactors[pyruvic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809)[pyridoxal phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249)[pyridoxal phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249)[pyridoxal phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249)[pyridoxal phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249)Selective inhibitors[sardomozide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5268) (pIC~50~ 8) \[[455](http://www.ncbi.nlm.nih.gov/pubmed/8340919?dopt=AbstractPlus)\]--[3‐hydroxybenzylhydrazine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5116), [L‐*α*‐methyldopa](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5217), [benserazide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5150) \[[101](http://www.ncbi.nlm.nih.gov/pubmed/22384042?dopt=AbstractPlus)\], [carbidopa](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5159)[s‐allylglycine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5267)[s‐allylglycine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5267)Comments[s‐allylglycine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5267) is also an inhibitor of SAMDC \[[368](http://www.ncbi.nlm.nih.gov/pubmed/438812?dopt=AbstractPlus)\].The presence of a functional ADC activity in human tissues has been questioned \[[89](http://www.ncbi.nlm.nih.gov/pubmed/14763899?dopt=AbstractPlus)\].AADC is a homodimer.[L‐aspartic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309) is a less rapidly metabolised substrate of mouse brain glutamic acid decarboxylase generating *β*‐alanine \[[530](http://www.ncbi.nlm.nih.gov/pubmed/4700449?dopt=AbstractPlus)\]. Autoantibodies against GAD1 and GAD2 are elevated in type 1 diabetes mellitus and neurological disorders (see Further reading).[L‐aspartic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309) is a less rapidly metabolised substrate of mouse brain glutamic acid decarboxylase generating *β*‐alanine \[[530](http://www.ncbi.nlm.nih.gov/pubmed/4700449?dopt=AbstractPlus)\]. Autoantibodies against GAD1 and GAD2 are elevated in type 1 diabetes mellitus and neurological disorders (see Further reading).

Nomenclature[Histidine decarboxylase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1274)[Malonyl‐CoA decarboxylase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1275)[Ornithine decarboxylase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1276)[Phosphatidylserine decarboxylase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1277)Common abreviationHDCMLYCDODCPSDCHGNC, UniProt[*HDC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4855), [P19113](http://www.uniprot.org/uniprot/P19113)[*MLYCD*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7150), [O95822](http://www.uniprot.org/uniprot/O95822)[*ODC1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8109), [P11926](http://www.uniprot.org/uniprot/P11926)[*PISD*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8999), [Q9UG56](http://www.uniprot.org/uniprot/Q9UG56)EC number[4.1.1.22](http://www.genome.jp/dbget-bin/www_bget?ec:4.1.1.22)[4.1.1.9](http://www.genome.jp/dbget-bin/www_bget?ec:4.1.1.9)[4.1.1.17](http://www.genome.jp/dbget-bin/www_bget?ec:4.1.1.17)[4.1.1.65](http://www.genome.jp/dbget-bin/www_bget?ec:4.1.1.65)Endogenous substrates[L‐histidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3310)[malonyl‐CoA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5219)[L‐ornithine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=725)[phosphatidylserine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3638)Products[histamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1204)[acetyl CoA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038)[putrescine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2388)[phosphatidylethanolamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2796)Cofactors[pyridoxal phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249)[pyridoxal phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249)[pyridoxal phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249)[pyruvic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809)Selective inhibitors[AMA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5134), [FMH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5189) \[[164](http://www.ncbi.nlm.nih.gov/pubmed/7452304?dopt=AbstractPlus)\]--[APA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5139) (pIC~50~ 7.5) \[[456](http://www.ncbi.nlm.nih.gov/pubmed/1573631?dopt=AbstractPlus)\], [eflornithine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5176) (p*K* ~d~ 4.9) \[[394](http://www.ncbi.nlm.nih.gov/pubmed/12859253?dopt=AbstractPlus)\]--Comments--Inhibited by AMP‐activated protein kinase‐evoked phosphorylation \[[415](http://www.ncbi.nlm.nih.gov/pubmed/10854420?dopt=AbstractPlus)\]The activity of ODC is regulated by the presence of an antizyme ([ENSG00000104904](http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000104904;r=19:2269520-2273487;t=ENST00000322297)) and an ODC antizyme inhibitor ([ENSG00000155096](http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000155096;r=8:103838585-103906092)).S‐allylglycine is also an inhibitor of SAMDC \[[368](http://www.ncbi.nlm.nih.gov/pubmed/438812?dopt=AbstractPlus)\].

Further Reading {#bph13354-sec-0079}
---------------

Bale S *et al*. (2010) Structural biology of S‐adenosylmethionine decarboxylase. *Amino Acids* **38**: 451‐60 [\[PMID:19997761\]](http://www.ncbi.nlm.nih.gov/pubmed/19997761?dopt=AbstractPlus)

Jitrapakdee S *et al*. (2008) Structure, mechanism and regulation of pyruvate carboxylase. *Biochem. J.* **413**: 369‐87 [\[PMID:18613815\]](http://www.ncbi.nlm.nih.gov/pubmed/18613815?dopt=AbstractPlus)

Lietzan AD *et al*. (2014) Functionally diverse biotin‐dependent enzymes with oxaloacetate decarboxylase activity. *Arch. Biochem. Biophys.* **544**: 75‐86 [\[PMID:24184447\]](http://www.ncbi.nlm.nih.gov/pubmed/24184447?dopt=AbstractPlus)

Moya‐García AA *et al*. (2009) Structural features of mammalian histidine decarboxylase reveal the basis for specific inhibition. *Br. J. Pharmacol.* **157**: 4‐13 [\[PMID:19413567\]](http://www.ncbi.nlm.nih.gov/pubmed/19413567?dopt=AbstractPlus)

Tong L. (2013) Structure and function of biotin‐dependent carboxylases. *Cell. Mol. Life Sci.* **70**: 863‐91 [\[PMID:22869039\]](http://www.ncbi.nlm.nih.gov/pubmed/22869039?dopt=AbstractPlus)

Vance JE *et al*. (2013) Formation and function of phosphatidylserine and phosphatidylethanolamine in mammalian cells. *Biochim. Biophys. Acta* **1831**: 543‐54 [\[PMID:22960354\]](http://www.ncbi.nlm.nih.gov/pubmed/22960354?dopt=AbstractPlus)

[Catecholamine turnover](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=766) {#bph13354-sec-0080}
===================================================================================================

Overview {#bph13354-sec-0081}
--------

Catecholamines are defined by the presence of two adjacent hydroxyls on a benzene ring with a sidechain containing an amine. The predominant catacholamines in mammalian biology are the neurotransmitter/hormones [dopamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940), [(‐)‐noradrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505) (norepinephrine) and [(‐)‐adrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479)(epinephrine). These hormone/transmitters are synthesized by sequential metabolism from [L‐phenylalanine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313) via [L‐tyrosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791). Hydroxylation of [L‐tyrosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791) generates [levodopa](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639), which is decarboxylated to form [dopamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940). Hydroxylation of the ethylamine sidechain generates [(‐)‐noradrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505) (norepinephrine), which can be methylated to form [(‐)‐adrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479)(epinephrine). In particular neuronal and adrenal chromaffin cells, the catecholamines [dopamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940), [(‐)‐noradrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505) and [(‐)‐adrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479) are accumulated into vesicles under the influence of the [vesicular monoamine transporters](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=193) (VMAT1/SLC18A1 and VMAT2/SLC18A2). After release into the synapse or the bloodstream, catecholamines are accumulated through the action cell‐surface transporters, primarily the dopamine ([DAT/SLC6A3](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=144#Monoaminetransportersubfamily)) and norepinephrine transporter ([NET/SLC6A2](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=144#Monoaminetransportersubfamily)). The primary routes of metabolism of these catecholamines are oxidation via monoamine oxidase activities of methylation via catechol O‐methyltransferase.

Nomenclature[L‐Phenylalanine hydroxylase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1240)[Tyrosine aminotransferase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2527)[L‐Aromatic amino‐acid decarboxylase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1271)Common abreviation--TATAADCHGNC, UniProt[*PAH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8582), [P00439](http://www.uniprot.org/uniprot/P00439)[*TAT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11573), [P17735](http://www.uniprot.org/uniprot/P17735)[*DDC*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2719), [P20711](http://www.uniprot.org/uniprot/P20711)EC number[1.14.16.1](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.16.1): [L‐phenylalanine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313) + O~2~ ‐\>[L‐tyrosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791)[2.6.1.5](http://www.genome.jp/dbget-bin/www_bget?ec:2.6.1.5): [L‐tyrosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791) + [*α*‐ketoglutaric acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3636) ‐\>[4‐hydroxyphenylpyruvic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6629) + [L‐glutamic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369)[4.1.1.28](http://www.genome.jp/dbget-bin/www_bget?ec:4.1.1.28): [levodopa](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639) ‐\>[dopamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940) + CO~2~ [5‐hydroxy‐L‐tryptophan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4671) ‐\>[5‐hydroxytryptamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5) + CO~2~ This enzyme also catalyses the following reaction:: [L‐tryptophan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717) ‐\>[tryptamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=125) + CO~2~Endogenous activatorsProtein kinase A‐mediated phosphorylation (Rat) \[[1](http://www.ncbi.nlm.nih.gov/pubmed/182695?dopt=AbstractPlus)\]----Substrates----[Deuterium‐substituted L‐DOPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8611) \[[312](http://www.ncbi.nlm.nih.gov/pubmed/24906468?dopt=AbstractPlus)\]Endogenous substrates[L‐phenylalanine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3313)--[levodopa](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639), [5‐hydroxy‐L‐tryptophan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4671), [L‐tryptophan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=717)Products[L‐tyrosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791)--[5‐hydroxytryptamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5), [dopamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940)Cofactors[sapropterin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5276)[pyridoxal phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249)[pyridoxal phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249)Selective activators[sapropterin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5276) (p*K* ~i~ 5.4) \[[481](http://www.ncbi.nlm.nih.gov/pubmed/15537351?dopt=AbstractPlus)\]----Selective inhibitors[*α*‐methylphenylalanine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5093) \[[180](http://www.ncbi.nlm.nih.gov/pubmed/944951?dopt=AbstractPlus)\] -- Rat, [fenclonine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5240)--[3‐hydroxybenzylhydrazine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5116), [L‐*α*‐methyldopa](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5217), [benserazide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5150) \[[101](http://www.ncbi.nlm.nih.gov/pubmed/22384042?dopt=AbstractPlus)\], [carbidopa](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5159)CommentsPAH is an iron bound homodimer or ‐tetramer from the same structural family as tyrosine 3‐monooxygenase and the tryptophan hydroxylases. Deficiency or loss‐of‐function of PAH is associated with [phenylketonuria](http://omim.org/entry/612349)Tyrosine may also be metabolized in the liver by tyrosine transaminase to generate [4‐hydroxyphenylpyruvic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6629), which can be further metabolized to homogentisic acid. TAT is a homodimer, where loss‐of‐function mutations are associated with [type II tyrosinemia](http://omim.org/entry/276600).AADC is a homodimer.

Nomenclature[L‐Tyrosine hydroxylase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1243)[Dopamine beta‐hydroxylase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2486)[Phenylethanolamine N‐methyltransferase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2496)[(dopamine beta‐monooxygenase)](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2486)Common abreviation--DBHPNMTHGNC, UniProt[*TH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11782), [P07101](http://www.uniprot.org/uniprot/P07101)[*DBH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2689), [P09172](http://www.uniprot.org/uniprot/P09172)[*PNMT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9160), [P11086](http://www.uniprot.org/uniprot/P11086)EC number[1.14.16.2](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.16.2): [L‐tyrosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791) + O~2~ ‐\>[levodopa](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639)[1.14.17.1](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.17.1): [dopamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940) + O~2~ = [(‐)‐noradrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505) + H~2~O[2.1.1.28](http://www.genome.jp/dbget-bin/www_bget?ec:2.1.1.28): [(‐)‐noradrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505) ‐\>[(‐)‐adrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479)Endogenous activatorsProtein kinase A‐mediated phosphorylation \[[239](http://www.ncbi.nlm.nih.gov/pubmed/33381?dopt=AbstractPlus)\]----Endogenous substrates[L‐tyrosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791)----Products[levodopa](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639)----Cofactors[sapropterin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5276), Fe^2+^[Cu^2+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4164), [L‐ascorbic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4781)[S‐adenosyl methionine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4786)Inhibitors[methyltyrosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5094)[nepicastat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6630) (pIC~50~ 8) \[[458](http://www.ncbi.nlm.nih.gov/pubmed/9283721?dopt=AbstractPlus)\][LY134046](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6631) (p*K* ~i~ 7.6) \[[154](http://www.ncbi.nlm.nih.gov/pubmed/6268095?dopt=AbstractPlus)\]Selective inhibitors[*α*‐propyldopacetamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5095), [3‐chlorotyrosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5114), [3‐iodotyrosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5117), [alpha‐methyltyrosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6956)----CommentsTH is a homotetramer, which is inhibited by dopamine and other catecholamines in a physiological negative feedback pathway \[[102](http://www.ncbi.nlm.nih.gov/pubmed/21176768?dopt=AbstractPlus)\].DBH is a homotetramer. A protein structurally‐related to DBH ([*MOXD1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=21063), [Q6UVY6](http://www.uniprot.org/uniprot/Q6UVY6)) has been described and for which a function has yet to be identified \[[71](http://www.ncbi.nlm.nih.gov/pubmed/9751809?dopt=AbstractPlus)\].--

Nomenclature[Monoamine oxidase A](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2489)[Monoamine oxidase B](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2490)[Catechol‐O‐methyltransferase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2472)Common abreviationMAO‐AMAO‐BCOMTHGNC, UniProt[*MAOA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6833), [P21397](http://www.uniprot.org/uniprot/P21397)[*MAOB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6834), [P27338](http://www.uniprot.org/uniprot/P27338)[*COMT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2228), [P21964](http://www.uniprot.org/uniprot/P21964)EC number[1.4.3.4](http://www.genome.jp/dbget-bin/www_bget?ec:1.4.3.4) [(‐)‐adrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479) ‐\>[3,4‐dihydroxymandelic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6633) + NH~3~ [(‐)‐noradrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505) ‐\>[3,4‐dihydroxymandelic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6633) + NH~3~ [tyramine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2150) ‐\>[4‐hydroxyphenyl acetaldehyde](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6635) + NH~3~ [dopamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940) ‐\>[3,4‐dihydroxyphenylacetaldehyde](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6632) + NH~3~ [5‐hydroxytryptamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5) ‐\>[5‐hydroxyindole acetaldehyde](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6634) + NH~3~[1.4.3.4](http://www.genome.jp/dbget-bin/www_bget?ec:1.4.3.4)[2.1.1.6](http://www.genome.jp/dbget-bin/www_bget?ec:2.1.1.6): S‐adenosyl‐L‐methionine + a catechol = S‐adenosyl‐L‐homocysteine + a guaiacol [(‐)‐noradrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=505) ‐\>[normetanephrine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6643) [dopamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=940) ‐\>[3‐methoxytyramine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6642) [3,4‐dihydroxymandelic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6633) ‐\>[vanillylmandelic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6645) [(‐)‐adrenaline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=479) ‐\>[metanephrine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6644)Cofactors[flavin adenine dinucleotide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5184)[flavin adenine dinucleotide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5184)[S‐adenosyl methionine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4786)Inhibitors[moclobemide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7428) (p*K* ~i~ 8.3) \[[234](http://www.ncbi.nlm.nih.gov/pubmed/21680183?dopt=AbstractPlus)\], [phenelzine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7266) (Irreversible inhibition) (p*K* ~i~ 7.3) \[[36](http://www.ncbi.nlm.nih.gov/pubmed/18426226?dopt=AbstractPlus)\], [tranylcypromine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5281) (pIC~50~ 4.7) \[[538](http://www.ncbi.nlm.nih.gov/pubmed/15110846?dopt=AbstractPlus)\], [selegiline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6639) (p*K* ~i~ 4.2) \[[333](http://www.ncbi.nlm.nih.gov/pubmed/21377879?dopt=AbstractPlus)\], [befloxatone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6637) \[[100](http://www.ncbi.nlm.nih.gov/pubmed/10333983?dopt=AbstractPlus)\], [clorgiline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6636), [pirlindole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6638) \[[327](http://www.ncbi.nlm.nih.gov/pubmed/9564636?dopt=AbstractPlus)\][rasagiline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6641) (pIC~50~ 7.8) \[[542](http://www.ncbi.nlm.nih.gov/pubmed/11159700?dopt=AbstractPlus)\], [phenelzine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7266) (Irreversible inhibition) (p*K* ~i~ 7.8) \[[36](http://www.ncbi.nlm.nih.gov/pubmed/18426226?dopt=AbstractPlus)\], [lazabemide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6640) (p*K* ~i~ 7.1) \[[188](http://www.ncbi.nlm.nih.gov/pubmed/2122653?dopt=AbstractPlus), [489](http://www.ncbi.nlm.nih.gov/pubmed/16137882?dopt=AbstractPlus)\], [selegiline](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6639) (p*K* ~i~ 5.7--6) \[[113](http://www.ncbi.nlm.nih.gov/pubmed/15974574?dopt=AbstractPlus), [333](http://www.ncbi.nlm.nih.gov/pubmed/21377879?dopt=AbstractPlus)\], [tranylcypromine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5281) (pIC~50~ 4.7) \[[538](http://www.ncbi.nlm.nih.gov/pubmed/15110846?dopt=AbstractPlus)\][tolcapone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6646) (soluble enzyme) (p*K* ~i~ 9.6) \[[299](http://www.ncbi.nlm.nih.gov/pubmed/7703232?dopt=AbstractPlus)\], [tolcapone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6646) (membrane‐bound enzyme) (p*K* ~i~ 9.5) \[[299](http://www.ncbi.nlm.nih.gov/pubmed/7703232?dopt=AbstractPlus)\], [entacapone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6647) (soluble enzyme) (p*K* ~i~ 9.5) \[[299](http://www.ncbi.nlm.nih.gov/pubmed/7703232?dopt=AbstractPlus)\], [entacapone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6647) (membrane‐bound enzyme) (p*K* ~i~ 8.7) \[[299](http://www.ncbi.nlm.nih.gov/pubmed/7703232?dopt=AbstractPlus)\]Selective inhibitors--[safinamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8291) (p*K* ~i~ 6.3) \[[35](http://www.ncbi.nlm.nih.gov/pubmed/15027868?dopt=AbstractPlus)\]--Comments----COMT appears to exist in both membrane‐bound and soluble forms. COMT has also been described to methylate steroids, particularly hydroxyestradiols
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[Ceramide turnover](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=767) {#bph13354-sec-0083}
==============================================================================================

Overview {#bph13354-sec-0084}
--------

Ceramides are a family of sphingophospholipids synthesized in the endoplasmic reticulum, which mediate cell stress responses, including apoptosis, autophagy and senescence, Serine palmitoyltransferase generates [3‐ketosphinganine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6654), which is reduced to [sphinganine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453)(dihydrosphingosine). N‐Acylation allows the formation of dihydroceramides, which are subsequently reduced to form ceramides. Once synthesized, ceramides are trafficked from the ER to the Golgi bound to the ceramide transfer protein, CERT ([*COL4A3BP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2205), [Q9Y5P4](http://www.uniprot.org/uniprot/Q9Y5P4)). Ceramide can be metabolized via multiple routes, ensuring tight regulation of its cellular levels. Addition of phosphocholine generates sphingomyelin while carbohydrate is added to form glucosyl‐ or galactosylceramides. Ceramidase re‐forms sphingosine or sphinganine from ceramide or dihydroceramide. Phosphorylation of ceramide generates ceramide phosphate. The determination of accurate kinetic parameters for many of the enzymes in the sphingolipid metabolic pathway is complicated by the lipophilic nature of the substrates.

[Serine palmitoyltransferase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=788) {#bph13354-sec-0085}
========================================================================================================

Overview {#bph13354-sec-0086}
--------

The functional enzyme is a heterodimer of SPT1 (LCB1) with either SPT2 (LCB2) or SPT3 (LCB2B); the small subunits of SPT (ssSPTa or ssSPTb) bind to the heterodimer to enhance enzymatic activity. The complexes of SPT1/SPT2/ssSPTa and SPT1/SPT2/ssSPTb were most active with palmitoylCoA as substrate, with the latter complex also showing some activity with stearoylCoA \[[190](http://www.ncbi.nlm.nih.gov/pubmed/19416851?dopt=AbstractPlus)\]. Complexes involving SPT3 appeared more broad in substrate selectivity, with incorporation of myristoylCoA prominent for SPT1/SPT3/ssSPTa complexes, while SP1/SPT3/ssSPTb complexes had similar activity with C16, C18 and C20 acylCoAs \[[190](http://www.ncbi.nlm.nih.gov/pubmed/19416851?dopt=AbstractPlus)\].

Nomenclature[serine palmitoyltransferase,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2509)[serine palmitoyltransferase,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2510)[serine palmitoyltransferase,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2511)[serine palmitoyltransferase,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2512)[serine palmitoyltransferase,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2513)[long chain base subunit 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2509)[long chain base subunit 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2509)[long chain base subunit 3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2509)[small subunit A](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2509)[small subunit B](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2509)Common abreviationSPT1SPT2SPT3SPTSSASPTSSBHGNC, UniProt[*SPTLC1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11277), [O15269](http://www.uniprot.org/uniprot/O15269)[*SPTLC2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11278), [O15270](http://www.uniprot.org/uniprot/O15270)[*SPTLC3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16253), [Q9NUV7](http://www.uniprot.org/uniprot/Q9NUV7)[*SPTSSA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20361), [Q969W0](http://www.uniprot.org/uniprot/Q969W0)[*SPTSSB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=24045), [Q8NFR3](http://www.uniprot.org/uniprot/Q8NFR3)EC number[2.3.1.50](http://www.genome.jp/dbget-bin/www_bget?ec:2.3.1.50): [L‐serine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=726) +[2.3.1.50](http://www.genome.jp/dbget-bin/www_bget?ec:2.3.1.50): [L‐serine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=726) +[2.3.1.50](http://www.genome.jp/dbget-bin/www_bget?ec:2.3.1.50): [L‐serine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=726) +----[palmitoyl‐CoA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6765) ‐\>[palmitoyl‐CoA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6765) ‐\>[palmitoyl‐CoA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6765) ‐\>[3‐ketosphinganine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6654) +[3‐ketosphinganine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6654) +[3‐ketosphinganine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6654) +[coenzyme A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044) + CO~2~[coenzyme A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044) CO~2~ +[coenzyme A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044) CO~2~ +Cofactors[pyridoxal phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249)[pyridoxal phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249)[pyridoxal phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249)----Selective inhibitors[myriocin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6664) \[[334](http://www.ncbi.nlm.nih.gov/pubmed/7794249?dopt=AbstractPlus)\][myriocin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6664) \[[334](http://www.ncbi.nlm.nih.gov/pubmed/7794249?dopt=AbstractPlus)\][myriocin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6664) \[[334](http://www.ncbi.nlm.nih.gov/pubmed/7794249?dopt=AbstractPlus)\]----

[Ceramide synthase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=789) {#bph13354-sec-0087}
==============================================================================================

Overview {#bph13354-sec-0088}
--------

This family of enzymes, also known as sphingosine *N*‐acyltransferase, is located in the ER facing the cytosol with an as‐yet undefined topology and stoichiometry. Ceramide synthase *in vitro* is sensitive to inhibition by the fungal derived toxin, fumonisin B1.

Nomenclature[ceramide synthase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2474)[ceramide synthase 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2475)[ceramide synthase 3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2476)Common abreviationCERS1CERS2CERS3HGNC, UniProt[*CERS1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14253), [P27544](http://www.uniprot.org/uniprot/P27544)[*CERS2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14076), [Q96G23](http://www.uniprot.org/uniprot/Q96G23)[*CERS3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23752), [Q8IU89](http://www.uniprot.org/uniprot/Q8IU89)EC number[2.3.1.24](http://www.genome.jp/dbget-bin/www_bget?ec:2.3.1.24): acylCoA + [sphinganine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453) ‐\> dihydroceramide + [coenzyme A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044) [sphingosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452) + acylCoA ‐\> ceramide + [coenzyme A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044)[2.3.1.24](http://www.genome.jp/dbget-bin/www_bget?ec:2.3.1.24): acylCoA + [sphinganine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453) ‐\> dihydroceramide + [coenzyme A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044) [sphingosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452) + acylCoA ‐\> ceramide + [coenzyme A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044)[2.3.1.24](http://www.genome.jp/dbget-bin/www_bget?ec:2.3.1.24): acylCoA + [sphinganine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453) ‐\> dihydroceramide + [coenzyme A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044) [sphingosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452) + acylCoA ‐\> ceramide + [coenzyme A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044)SubstratesC18‐CoA \[[499](http://www.ncbi.nlm.nih.gov/pubmed/12105227?dopt=AbstractPlus)\]C24‐ and C26‐CoA \[[278](http://www.ncbi.nlm.nih.gov/pubmed/18165233?dopt=AbstractPlus)\]C26‐CoA and longer \[[337](http://www.ncbi.nlm.nih.gov/pubmed/14511335?dopt=AbstractPlus), [396](http://www.ncbi.nlm.nih.gov/pubmed/18308723?dopt=AbstractPlus)\]

Nomenclature[ceramide synthase 4](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2477)[ceramide synthase 5](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2478)[ceramide synthase 6](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2479)Common abreviationCERS4CERS5CERS6HGNC, UniProt[*CERS4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23747), [Q9HA82](http://www.uniprot.org/uniprot/Q9HA82)[*CERS5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23749), [Q8N5B7](http://www.uniprot.org/uniprot/Q8N5B7)[*CERS6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23826), [Q6ZMG9](http://www.uniprot.org/uniprot/Q6ZMG9)EC number[2.3.1.24](http://www.genome.jp/dbget-bin/www_bget?ec:2.3.1.24): acylCoA + [sphinganine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453) ‐\> dihydroceramide + [coenzyme A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044) [sphingosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452) + acylCoA ‐\> ceramide + [coenzyme A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044)[2.3.1.24](http://www.genome.jp/dbget-bin/www_bget?ec:2.3.1.24): acylCoA + [sphinganine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453) ‐\> dihydroceramide + [coenzyme A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044) [sphingosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452) + acylCoA ‐\> ceramide + [coenzyme A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044)[2.3.1.24](http://www.genome.jp/dbget-bin/www_bget?ec:2.3.1.24): acylCoA + [sphinganine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453) ‐\> dihydroceramide + [coenzyme A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044) [sphingosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452) + acylCoA ‐\> ceramide + [coenzyme A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044)SubstratesC18‐, C20‐ and C22‐CoA \[[405](http://www.ncbi.nlm.nih.gov/pubmed/12912983?dopt=AbstractPlus)\]C16‐CoA \[[274](http://www.ncbi.nlm.nih.gov/pubmed/16100120?dopt=AbstractPlus), [405](http://www.ncbi.nlm.nih.gov/pubmed/12912983?dopt=AbstractPlus)\]C14‐ and C16‐CoA \[[336](http://www.ncbi.nlm.nih.gov/pubmed/15823095?dopt=AbstractPlus)\]

[Sphingolipid Δ^4^‐desaturase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=790) {#bph13354-sec-0089}
=========================================================================================================

Overview {#bph13354-sec-0090}
--------

DEGS1 and DEGS2 are 4TM proteins.

Nomenclature[delta(4)‐desaturase, sphingolipid 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2484)[delta(4)‐desaturase, sphingolipid 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2485)HGNC, UniProt[*DEGS1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13709), [O15121](http://www.uniprot.org/uniprot/O15121)[*DEGS2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20113), [Q6QHC5](http://www.uniprot.org/uniprot/Q6QHC5)EC number[1.14.‐.‐](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.-.-)[1.14.‐.‐](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.-.-)Cofactors[NAD](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451)[NAD](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451)CommentsMyristoylation of DEGS1 enhances its activity and targets it to the mitochondria \[[26](http://www.ncbi.nlm.nih.gov/pubmed/19647031?dopt=AbstractPlus)\].--

Comments {#bph13354-sec-0091}
--------

DEGS1 activity is inhibited by a number of natural products, including [curcumin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7000) and [Δ^9^‐tetrahydrocannabinol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2424)\[[130](http://www.ncbi.nlm.nih.gov/pubmed/22200621?dopt=AbstractPlus)\].

[Sphingomyelin synthase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=774) {#bph13354-sec-0092}
===================================================================================================

Overview {#bph13354-sec-0093}
--------

Following translocation from the ER to the Golgi under the influence of the ceramide transfer protein, sphingomyelin synthases allow the formation of sphingomyelin by the transfer of phosphocholine from the phospholipid phosphatidylcholine.

Sphingomyelin synthase‐related protein 1 is structurally related but lacks sphingomyelin synthase activity.

Nomenclature[sphingomyelin synthase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2520)[sphingomyelin synthase 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2521)[sterile alpha motif domain containing 8](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2525)HGNC, UniProt[*SGMS1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=29799), [Q86VZ5](http://www.uniprot.org/uniprot/Q86VZ5)[*SGMS2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=28395), [Q8NHU3](http://www.uniprot.org/uniprot/Q8NHU3)[*SAMD8*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=26320), [Q96LT4](http://www.uniprot.org/uniprot/Q96LT4)EC number[2.7.8.27](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.8.27): ceramide + phosphatidylcholine ‐\> sphingomyelin + diacylglycerol[2.7.8.27](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.8.27): ceramide + phosphatidylcholine ‐\> sphingomyelin + diacylglycerol[2.7.8.‐](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.8.-): ceramide + [phosphatidylethanolamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2796) ‐\> ceramide phosphoethanolamineComments--Palmitoylation of sphingomyelin synthase 2 may allow targeting to the plasma membrane \[[476](http://www.ncbi.nlm.nih.gov/pubmed/19233134?dopt=AbstractPlus)\].--

[Sphingomyelin phosphodiesterase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=773) {#bph13354-sec-0094}
============================================================================================================

Overview {#bph13354-sec-0095}
--------

Also known as sphingomyelinase.

Nomenclature[sphingomyelin phosphodiesterase 1,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2514)[sphingomyelin phosphodiesterase 2,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2515)[sphingomyelin phosphodiesterase 3,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2516)[acid lysosomal](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2514)[neutral membrane (neutral sphingomyelinase)](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2515)[neutral membrane (neutral sphingomyelinase II)](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2516)HGNC, UniProt[*SMPD1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11120), [P17405](http://www.uniprot.org/uniprot/P17405)[*SMPD2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11121), [O60906](http://www.uniprot.org/uniprot/O60906)[*SMPD3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14240), [Q9NY59](http://www.uniprot.org/uniprot/Q9NY59)EC number[3.1.4.12](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.12): sphingomyelin ‐\> ceramide + phosphocholine[3.1.4.12](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.12): sphingomyelin ‐\> ceramide + phosphocholine[3.1.4.12](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.12): sphingomyelin ‐\> ceramide + phosphocholine

Nomenclature[sphingomyelin phosphodiesterase 4, neutral](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2517)[sphingomyelin phosphodiesterase, acid‐like 3A](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2518)[sphingomyelin phosphodiesterase, acid‐like 3B](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2519)[membrane (neutral sphingomyelinase‐3)](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2517)HGNC, UniProt[*SMPD4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=32949), [Q9NXE4](http://www.uniprot.org/uniprot/Q9NXE4)[*SMPDL3A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17389), [Q92484](http://www.uniprot.org/uniprot/Q92484)[*SMPDL3B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=21416), [Q92485](http://www.uniprot.org/uniprot/Q92485)EC number[3.1.4.12](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.12): sphingomyelin ‐\> ceramide + phosphocholine[3.1.4.‐](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.-): sphingomyelin ‐\> ceramide + phosphocholine[3.1.4.‐](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.-): sphingomyelin ‐\> ceramide + phosphocholine

[Neutral sphingomyelinase coupling factors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=772) {#bph13354-sec-0096}
======================================================================================================================

Overview {#bph13354-sec-0097}
--------

Protein FAN \[[2](http://www.ncbi.nlm.nih.gov/pubmed/8808629?dopt=AbstractPlus)\] and polycomb protein EED \[[383](http://www.ncbi.nlm.nih.gov/pubmed/20080539?dopt=AbstractPlus)\] allow coupling between TNF receptors and neutral sphingomyelinase phosphodiesterases.

Nomenclature[embryonic ectoderm development](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2487)[neutral sphingomyelinase (N‐SMase) activation associated factor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2495)HGNC, UniProt[*EED*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3188), [O75530](http://www.uniprot.org/uniprot/O75530)[*NSMAF*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8017), [Q92636](http://www.uniprot.org/uniprot/Q92636)

[Ceramide glucosyltransferase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=775) {#bph13354-sec-0098}
=========================================================================================================

Nomenclature[UDP‐glucose ceramide glucosyltransferase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2528)HGNC, UniProt[*UGCG*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12524), [Q16739](http://www.uniprot.org/uniprot/Q16739)EC number[2.4.1.80](http://www.genome.jp/dbget-bin/www_bget?ec:2.4.1.80): [UDP‐glucose](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1783) + ceramide = [uridine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1749) + glucosylceramideInhibitors[miglustat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4841) (p*K* ~i~ 5.1) \[[53](#bph13354-bib-0053){ref-type="ref"}\]CommentsGlycoceramides are an extended family of sphingolipids, differing in the content and organization of the sugar moieties, as well as the acyl sidechains.

[Acid ceramidase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=769) {#bph13354-sec-0099}
============================================================================================

Overview {#bph13354-sec-0100}
--------

The six human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.

Nomenclature[N‐acylsphingosine amidohydrolase (acid ceramidase) 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2491)HGNC, UniProt[*ASAH1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=735), [Q13510](http://www.uniprot.org/uniprot/Q13510)EC number[3.5.1.23](http://www.genome.jp/dbget-bin/www_bget?ec:3.5.1.23): ceramide ‐\>[sphingosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452) + a fatty acidCommentsThis lysosomal enzyme is proteolysed to form the mature protein made up of two chains from the same gene product \[[261](http://www.ncbi.nlm.nih.gov/pubmed/8955159?dopt=AbstractPlus)\].

[Neutral ceramidases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=770) {#bph13354-sec-0101}
================================================================================================

Overview {#bph13354-sec-0102}
--------

The six human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.

Nomenclature[N‐acylsphingosine amidohydrolase (non‐lysosomal ceramidase) 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2492)[N‐acylsphingosine amidohydrolase (non‐lysosomal ceramidase) 2B](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2493)HGNC, UniProt[*ASAH2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18860), [Q9NR71](http://www.uniprot.org/uniprot/Q9NR71)[*ASAH2B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23456), [P0C7U1](http://www.uniprot.org/uniprot/P0C7U1)EC number[3.5.1.23](http://www.genome.jp/dbget-bin/www_bget?ec:3.5.1.23): ceramide ‐\>[sphingosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452) + a fatty acid--CommentsThe enzyme is associated with the plasma membrane \[[475](http://www.ncbi.nlm.nih.gov/pubmed/12499379?dopt=AbstractPlus)\].--

Comments {#bph13354-sec-0103}
--------

ASAH2B appears to be an enzymatically inactive protein, which may result from gene duplication and truncation.

[Alkaline ceramidases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=768) {#bph13354-sec-0104}
=================================================================================================

Overview {#bph13354-sec-0105}
--------

The six human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.

Nomenclature[alkaline ceramidase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2468)[alkaline ceramidase 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2469)[alkaline ceramidase 3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2470)HGNC, UniProt[*ACER1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18356), [Q8TDN7](http://www.uniprot.org/uniprot/Q8TDN7)[*ACER2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23675), [Q5QJU3](http://www.uniprot.org/uniprot/Q5QJU3)[*ACER3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16066), [Q9NUN7](http://www.uniprot.org/uniprot/Q9NUN7)EC number[3.5.1.23](http://www.genome.jp/dbget-bin/www_bget?ec:3.5.1.23): ceramide ‐\>[sphingosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452) + a fatty acid[3.5.1.23](http://www.genome.jp/dbget-bin/www_bget?ec:3.5.1.23): ceramide ‐\>[sphingosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452) + a fatty acid[3.5.1.‐](http://www.genome.jp/dbget-bin/www_bget?ec:3.5.1.-)CommentsACER1 is associated with the ER \[[466](http://www.ncbi.nlm.nih.gov/pubmed/17713573?dopt=AbstractPlus)\].ACER2 is associated with the Golgi apparatus \[[534](http://www.ncbi.nlm.nih.gov/pubmed/16940153?dopt=AbstractPlus)\].ACER3 is associated with the ER and Golgi apparatus \[[314](http://www.ncbi.nlm.nih.gov/pubmed/11356846?dopt=AbstractPlus)\].

[Ceramide kinase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=771) {#bph13354-sec-0106}
============================================================================================

Nomenclature[ceramide kinase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2473)HGNC, UniProt[*CERK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19256), [Q8TCT0](http://www.uniprot.org/uniprot/Q8TCT0)EC number[2.7.1.138](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.1.138): ceramide + [ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713) ‐\> ceramide 1‐phosphate + [adenosine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712)Inhibitors[NVP 231](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6668) (pIC~50~ 7.9) \[[178](http://www.ncbi.nlm.nih.gov/pubmed/18612076?dopt=AbstractPlus)\]

Comments {#bph13354-sec-0107}
--------

A ceramide kinase‐like protein has been identified in the human genome ([*CERKL*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=21699), [Q49MI3](http://www.uniprot.org/uniprot/Q49MI3)).

Further Reading {#bph13354-sec-0108}
---------------

Castro BM *et al*. (2014) Ceramide: a simple sphingolipid with unique biophysical properties. *Prog. Lipid Res.* **54**: 53‐67 [\[PMID:24513486\]](http://www.ncbi.nlm.nih.gov/pubmed/24513486?dopt=AbstractPlus)

Halmer R *et al*. (2014) Sphingolipids: important players in multiple sclerosis. *Cell. Physiol. Biochem.* **34**: 111‐8 [\[PMID:24977485\]](http://www.ncbi.nlm.nih.gov/pubmed/24977485?dopt=AbstractPlus)

Ito M *et al*. (2014) New insight into the structure, reaction mechanism, and biological functions of neutral ceramidase. *Biochim. Biophys. Acta* **1841**: 682‐91 [\[PMID:24064302\]](http://www.ncbi.nlm.nih.gov/pubmed/24064302?dopt=AbstractPlus)

Khavandgar Z *et al*. (2015) Sphingolipid metabolism and its role in the skeletal tissues. *Cell. Mol. Life Sci.* **72**: 959‐69 [\[PMID:25424644\]](http://www.ncbi.nlm.nih.gov/pubmed/25424644?dopt=AbstractPlus)

Lowther J *et al*. (2012) Structural, mechanistic and regulatory studies of serine palmitoyltransferase. *Biochem. Soc. Trans.* **40**: 547‐54 [\[PMID:22616865\]](http://www.ncbi.nlm.nih.gov/pubmed/22616865?dopt=AbstractPlus)

Saied EM *et al*. (2014) Small molecule inhibitors of ceramidases. *Cell. Physiol. Biochem.* **34**: 197‐212 [\[PMID:24977492\]](http://www.ncbi.nlm.nih.gov/pubmed/24977492?dopt=AbstractPlus)

[Chromatin modifying enzymes](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=865) {#bph13354-sec-0109}
========================================================================================================

Overview {#bph13354-sec-0110}
--------

Chromatin modifying enzymes, and other chromatin‐modifying proteins, fall into three broad categories: **writers**, **readers** and **erasers**. The function of these proteins is to dynamically maintain cell identity and regulate processes such as differentiation, development, proliferation and genome integrity *via* recognition of specific \'marks\' (covalent post‐translational modifications) on histone proteins and DNA \[[267](http://www.ncbi.nlm.nih.gov/pubmed/17320507?dopt=AbstractPlus)\]. In normal cells, tissues and organs, precise co‐ordination of these proteins ensures expression of only those genes required to specify phenotype or which are required at specific times, for specific functions. Chromatin modifications allow DNA modifications not coded by the DNA sequence to be passed on through the genome and underlies heritable phenomena such as X chromosome inactivation, aging, heterochromatin formation, reprogramming, and gene silencing (epigenetic control).

To date at least eight distinct types of modifications are found on histones. These include small covalent modifications such as acetylation, methylation, and phosphorylation, the attachment of larger modifiers such as ubiquitination or sumoylation, and ADP ribosylation, proline isomerization and deimination. Chromatin modifications and the functions they regulate in cells are reviewed by Kouzarides (2007) \[[267](http://www.ncbi.nlm.nih.gov/pubmed/17320507?dopt=AbstractPlus)\].

**Writer** proteins include the histone methyltransferases, histone acetyltransferases, some kinases and ubiquitin ligases.

**Readers** include proteins which contain methyl‐lysine‐recognition motifs such as bromodomains, chromodomains, tudor domains, PHD zinc fingers, PWWP domains and MBT domains.

**Erasers** include the histone demethylases and histone deacetylases (HDACs and sirtuins).

Dysregulated epigenetic control can be associated with human diseases such as cancer \[[129](http://www.ncbi.nlm.nih.gov/pubmed/18337604?dopt=AbstractPlus)\], where a wide variety of cellular and protein abberations are known to perturb chromatin structure, gene transcription and ultimately cellular pathways \[[24](http://www.ncbi.nlm.nih.gov/pubmed/21941284?dopt=AbstractPlus), [439](http://www.ncbi.nlm.nih.gov/pubmed/24104525?dopt=AbstractPlus)\]. Due to the reversible nature of epigenetic modifications, chromatin regulators are very tractable targets for drug discovery and the development of novel therapeutics. Indeed, small molecule inhibitors of writers (*e.g.* [azacitidine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6796) and [decitabine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6805) target the DNA methyltransferases DNMT1 and DNMT3 for the treatment of myelodysplastic syndromes \[[165](http://www.ncbi.nlm.nih.gov/pubmed/21220589?dopt=AbstractPlus), [520](http://www.ncbi.nlm.nih.gov/pubmed/24523604?dopt=AbstractPlus)\]) and erasers (*e.g.* the HDAC inhibitors [vorinostat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6852), [romidepsin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7006) and [belinostat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7496) for the treatment of T‐cell lymphomas \[[144](http://www.ncbi.nlm.nih.gov/pubmed/21493798?dopt=AbstractPlus), [254](http://www.ncbi.nlm.nih.gov/pubmed/22124371?dopt=AbstractPlus)\]) are already being used in the clinic. The search for the next generation of compounds with improved specificity against chromatin‐associated proteins is an area of intense basic and clinical research \[[56](http://www.ncbi.nlm.nih.gov/pubmed/25974248?dopt=AbstractPlus)\]. Current progress in this field is reviewed by Simó‐Riudalbas and Esteller (2015) \[[440](http://www.ncbi.nlm.nih.gov/pubmed/25039449?dopt=AbstractPlus)\].

[2.1.1.‐ Protein arginine N‐methyltransferases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=254) {#bph13354-sec-0111}
==========================================================================================================================

Overview {#bph13354-sec-0112}
--------

Protein arginine N‐methyltransferases (PRMT, EC 2.1.1.‐) encompass histone arginine *N*‐methyltransferases (PRMT4, PRMT7, [EC 2.1.1.125](http://www.genome.jp/kegg-bin/search_brite?option=-a&search_string=2.1.1.125)) and myelin basic protein *N*‐methyltransferases (PRMT7, [EC 2.1.1.126](http://www.genome.jp/kegg-bin/search_brite?option=-a&search_string=2.1.1.126)). They are dimeric or tetrameric enzymes which use [S‐adenosyl methionine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4786) as a methyl donor, generating [S‐adenosylhomocysteine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5265) as a by‐product. They generate both mono‐methylated and di‐methylated products; these may be symmetric ([SDMA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5271)) or asymmetric ([N^G^,N^G^‐dimethyl‐L‐arginine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5229)) versions, where both guanidine nitrogens are monomethylated or one of the two is dimethylated, respectively.

[3.5.1.‐ Histone deacetylases (HDACs)](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=848) {#bph13354-sec-0113}
=================================================================================================================

Overview {#bph13354-sec-0114}
--------

Histone deacetylases act as erasers of epigenetic acetylation marks on lysine residues in histones. Removal of the acetyl groups facilitates tighter packing of chromatin (heterochromatin formation) leading to transcriptional repression.

The histone deacetylase family has been classified in to five subfamilies based on phylogenetic comparison with yeast homologues:

Class I contains HDACs 1, 2, 3 and 8

Class IIa contains HDACs 4, 5, 7 and 9

Class IIb contains HDACs 6 and 10

Class III contains the sirtuins (SIRT1‐7)

Class IV contains only HDAC11.

Classes I, II and IV use Zn^+^ as a co‐factor, whereas catalysis by Class III enzymes requires NAD^+^ as a co‐factor, and members of this subfamily have ADP‐ribosylase activity in addition to protein deacetylase function \[[420](http://www.ncbi.nlm.nih.gov/pubmed/20132909?dopt=AbstractPlus)\].

HDACs have more general protein deacetylase activity, being able to deacetylate lysine residues in non‐histone proteins \[[82](http://www.ncbi.nlm.nih.gov/pubmed/19608861?dopt=AbstractPlus)\] such as microtubules \[[221](http://www.ncbi.nlm.nih.gov/pubmed/12024216?dopt=AbstractPlus)\], the hsp90 chaperone \[[268](http://www.ncbi.nlm.nih.gov/pubmed/15916966?dopt=AbstractPlus)\] and the tumour suppressor p53 \[[302](http://www.ncbi.nlm.nih.gov/pubmed/11099047?dopt=AbstractPlus)\].

Dysregulated HDAC activity has been identified in cancer cells and tumour tissues \[[288](http://www.ncbi.nlm.nih.gov/pubmed/11704848?dopt=AbstractPlus), [410](http://www.ncbi.nlm.nih.gov/pubmed/19383284?dopt=AbstractPlus)\], making HDACs attractive molecular targets in the search for novel mechanisms to treat cancer \[[522](http://www.ncbi.nlm.nih.gov/pubmed/24382387?dopt=AbstractPlus)\]. Several small molecule HDAC inhibitors are already approved for clinical use: [romidepsin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7006), [belinostat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7496), [vorinostat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6852), [panobinostat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7489), [belinostat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7496), [valproic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7009) and [chidamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8305). HDACs and HDAC inhibitors currently in development as potential anti‐cancer therapeutics are reviewed by Simó‐Riudalbas and Esteller (2015) \[[440](http://www.ncbi.nlm.nih.gov/pubmed/25039449?dopt=AbstractPlus)\].

[Cyclic nucleotide turnover](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=241) {#bph13354-sec-0115}
=======================================================================================================

Overview {#bph13354-sec-0116}
--------

Cyclic nucleotides are second messengers generated by cyclase enzymes from precursor triphosphates and hydrolysed by phosphodiesterases. The cellular actions of these cyclic nucleotides are mediated through activation of protein kinases ([cAMP](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=284)‐ and [cGMP](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=287)‐dependent protein kinases), ion channels ([cyclic nucleotide‐gated, CNG](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=71), and [hyperpolarization and cyclic nucleotide‐gated, HCN](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=71)) and guanine nucleotide exchange factors (GEFs, [Epac](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=259)).

[Adenylyl cyclases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=257) {#bph13354-sec-0117}
==============================================================================================

Overview {#bph13354-sec-0118}
--------

Adenylyl cyclase, [E.C. 4.6.1.1](http://www.genome.jp/kegg-bin/search_brite?option=-a&search_string=4.6.1.1), converts [ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713) to [cyclic AMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352) and pyrophosphate. Mammalian membrane‐bound adenylyl cyclases are typically made up of two clusters of six TM domains separating two intracellular, overlapping catalytic domains that are the target for the nonselective activators [forskolin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5190), [NKH477](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5232)(except AC9, \[[392](http://www.ncbi.nlm.nih.gov/pubmed/8662814?dopt=AbstractPlus)\]) and G*α* ~s~(the stimulatory G protein *α* subunit). [Adenosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2844) and its derivatives (*e.g.* [2\',5\'‐dideoxyadenosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5108)), acting through the P‐site, appear to be physiological inhibitors of adenylyl cyclase activity \[[485](http://www.ncbi.nlm.nih.gov/pubmed/11087399?dopt=AbstractPlus)\]. Three families of adenylyl cyclase are distinguishable: [calmodulin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351)([*CALM1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1442) [*CALM2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1445) [*CALM3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1449), [P62158](http://www.uniprot.org/uniprot/P62158))‐stimulated (AC1, AC3 and AC8), Ca^2+^‐inhibitable (AC5, AC6 and AC9) and Ca^2+^‐insensitive (AC2, AC4 and AC7) forms.

Nomenclature[AC1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1278)[AC2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1279)[AC3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1280)[AC4](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1281)[AC5](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1282)HGNC, UniProt[*ADCY1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=232), [Q08828](http://www.uniprot.org/uniprot/Q08828)[*ADCY2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=233), [Q08462](http://www.uniprot.org/uniprot/Q08462)[*ADCY3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=234), [O60266](http://www.uniprot.org/uniprot/O60266)[*ADCY4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=235), [Q8NFM4](http://www.uniprot.org/uniprot/Q8NFM4)[*ADCY5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=236), [O95622](http://www.uniprot.org/uniprot/O95622)EC number[4.6.1.1](http://www.genome.jp/dbget-bin/www_bget?ec:4.6.1.1)[4.6.1.1](http://www.genome.jp/dbget-bin/www_bget?ec:4.6.1.1)[4.6.1.1](http://www.genome.jp/dbget-bin/www_bget?ec:4.6.1.1)[4.6.1.1](http://www.genome.jp/dbget-bin/www_bget?ec:4.6.1.1)[4.6.1.1](http://www.genome.jp/dbget-bin/www_bget?ec:4.6.1.1)Endogenous activators[calmodulin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351) ([*CALM1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1442) [*CALM2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1445) [*CALM3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1449), [P62158](http://www.uniprot.org/uniprot/P62158)), PKC‐evoked phosphorylation \[[233](http://www.ncbi.nlm.nih.gov/pubmed/8440678?dopt=AbstractPlus), [474](http://www.ncbi.nlm.nih.gov/pubmed/2022671?dopt=AbstractPlus)\]G*β* *γ*, PKC‐evoked phosphorylation \[[73](http://www.ncbi.nlm.nih.gov/pubmed/8389756?dopt=AbstractPlus), [306](http://www.ncbi.nlm.nih.gov/pubmed/8390980?dopt=AbstractPlus), [478](http://www.ncbi.nlm.nih.gov/pubmed/8416978?dopt=AbstractPlus)\][calmodulin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351) ([*CALM1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1442) [*CALM2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1445) [*CALM3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1449), [P62158](http://www.uniprot.org/uniprot/P62158)), PKC‐evoked phosphorylation \[[81](http://www.ncbi.nlm.nih.gov/pubmed/1633161?dopt=AbstractPlus), [233](http://www.ncbi.nlm.nih.gov/pubmed/8440678?dopt=AbstractPlus)\]G*β* *γ* \[[163](http://www.ncbi.nlm.nih.gov/pubmed/1946437?dopt=AbstractPlus)\]PKC‐evoked phophorylation \[[250](http://www.ncbi.nlm.nih.gov/pubmed/8206971?dopt=AbstractPlus)\]Endogenous inhibitorsG*α* ~i~, G*α* ~o~, G*β* *γ* \[[478](http://www.ncbi.nlm.nih.gov/pubmed/8416978?dopt=AbstractPlus), [479](http://www.ncbi.nlm.nih.gov/pubmed/8119955?dopt=AbstractPlus)\]--G*α* ~i~, [RGS2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2808), CaM kinase II‐evoked phosphorylation \[[441](http://www.ncbi.nlm.nih.gov/pubmed/11234015?dopt=AbstractPlus), [479](http://www.ncbi.nlm.nih.gov/pubmed/8119955?dopt=AbstractPlus), [517](http://www.ncbi.nlm.nih.gov/pubmed/7665559?dopt=AbstractPlus)\]PKC‐evoked phophorylation \[[554](http://www.ncbi.nlm.nih.gov/pubmed/8900209?dopt=AbstractPlus)\]G*α* ~i~, [Ca^2+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707), PKA‐evoked phosphorylation \[[227](http://www.ncbi.nlm.nih.gov/pubmed/1618857?dopt=AbstractPlus), [230](http://www.ncbi.nlm.nih.gov/pubmed/7759492?dopt=AbstractPlus), [479](http://www.ncbi.nlm.nih.gov/pubmed/8119955?dopt=AbstractPlus)\]Selective inhibitors--------[NKY80](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5233) \[[364](http://www.ncbi.nlm.nih.gov/pubmed/11602596?dopt=AbstractPlus)\]

Nomenclature[AC6](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1283)[AC7](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1284)[AC8](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1285)[AC9](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1286)HGNC, UniProt[*ADCY6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=237), [O43306](http://www.uniprot.org/uniprot/O43306)[*ADCY7*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=238), [P51828](http://www.uniprot.org/uniprot/P51828)[*ADCY8*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=239), [P40145](http://www.uniprot.org/uniprot/P40145)[*ADCY9*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=240), [O60503](http://www.uniprot.org/uniprot/O60503)EC number[4.6.1.1](http://www.genome.jp/dbget-bin/www_bget?ec:4.6.1.1)[4.6.1.1](http://www.genome.jp/dbget-bin/www_bget?ec:4.6.1.1)[4.6.1.1](http://www.genome.jp/dbget-bin/www_bget?ec:4.6.1.1)[4.6.1.1](http://www.genome.jp/dbget-bin/www_bget?ec:4.6.1.1)Endogenous activators--PKC‐evoked phosphorylation \[[516](http://www.ncbi.nlm.nih.gov/pubmed/7961850?dopt=AbstractPlus)\][Ca^2+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707) \[[57](http://www.ncbi.nlm.nih.gov/pubmed/8163524?dopt=AbstractPlus)\]--Endogenous inhibitorsG*α* ~i~, [Ca^2+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707), PKA‐evoked phosphorylation, PKC‐evoked phosphorylation \[[76](http://www.ncbi.nlm.nih.gov/pubmed/9391159?dopt=AbstractPlus), [275](http://www.ncbi.nlm.nih.gov/pubmed/10462552?dopt=AbstractPlus), [479](http://www.ncbi.nlm.nih.gov/pubmed/8119955?dopt=AbstractPlus), [541](http://www.ncbi.nlm.nih.gov/pubmed/1379717?dopt=AbstractPlus)\]----Ca^2+^/calcineurin \[[376](http://www.ncbi.nlm.nih.gov/pubmed/10987815?dopt=AbstractPlus)\]

Comments {#bph13354-sec-0119}
--------

Nitric oxide has been proposed to inhibit AC5 and AC6 selectively \[[210](http://www.ncbi.nlm.nih.gov/pubmed/10781930?dopt=AbstractPlus)\], although it is unclear whether this phenomenon is of physiological significance. A soluble adenylyl cyclase has been described ([*ADCY10*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=21285), [Q96PN6](http://www.uniprot.org/uniprot/Q96PN6) \[[48](http://www.ncbi.nlm.nih.gov/pubmed/9874775?dopt=AbstractPlus)\]), unaffected by either G*α* or G*β* *γ* subunits, which has been suggested to be a cytoplasmic bicarbonate (pH‐insensitive) sensor \[[75](http://www.ncbi.nlm.nih.gov/pubmed/10915626?dopt=AbstractPlus)\]. It can be inhibited selectively by KH7 (pIC~50~ 5.0‐5.5) \[[208](http://www.ncbi.nlm.nih.gov/pubmed/16054031?dopt=AbstractPlus)\].

[Soluble guanylyl cyclase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=258) {#bph13354-sec-0120}
=====================================================================================================

Overview {#bph13354-sec-0121}
--------

Soluble guanylyl cyclase (GTP diphosphate‐lyase (cyclising)), [E.C. 4.6.1.2](http://www.genome.jp/kegg-bin/search_brite?option=-a&search_string=4.6.1.2), is a heterodimer comprising *α* and *β* chains, both of which have two subtypes in man (predominantly *α*1*β*1; \[[544](http://www.ncbi.nlm.nih.gov/pubmed/9742212?dopt=AbstractPlus)\]). A haem group is associated with the *β* chain and is the target for the endogenous ligand nitric oxide (NO∙), and, potentially, carbon monoxide \[[150](http://www.ncbi.nlm.nih.gov/pubmed/9003762?dopt=AbstractPlus)\]. The enzyme converts [guanosine‐5\'‐triphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1742) to the intracellular second messenger 3\',5\'‐guanosine monophosphate ([cyclic GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347)).

Nomenclature[Soluble guanylyl cyclase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1287)Common abreviationsGCSubunits[Soluble guanylyl cyclase *β* 1 subunit](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1290), [Soluble guanylyl cyclase *α* 1 subunit](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1288)EC number[4.6.1.2](http://www.genome.jp/dbget-bin/www_bget?ec:4.6.1.2)Activators[isosorbide dinitrate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7051), [isosorbide mononitrate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7052), [nitroglycerin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7053)Selective activators[BAY412272](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5146) \[[460](http://www.ncbi.nlm.nih.gov/pubmed/11242081?dopt=AbstractPlus)\], [NO](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2509), [YC1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5291) \[[150](http://www.ncbi.nlm.nih.gov/pubmed/9003762?dopt=AbstractPlus)\], [ataciguat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5141) \[[421](http://www.ncbi.nlm.nih.gov/pubmed/16332991?dopt=AbstractPlus)\], [cinaciguat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5168) \[[461](http://www.ncbi.nlm.nih.gov/pubmed/12086987?dopt=AbstractPlus)\], [riociguat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5257) \[[461](http://www.ncbi.nlm.nih.gov/pubmed/12086987?dopt=AbstractPlus)\]Inhibitors[NS 2028](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6554) (pIC~50~ 8.1) \[[363](http://www.ncbi.nlm.nih.gov/pubmed/9489619?dopt=AbstractPlus)\] -- BovineSelective inhibitors[ODQ](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5234) (pIC~50~ 7.5) \[[167](http://www.ncbi.nlm.nih.gov/pubmed/7544433?dopt=AbstractPlus)\]

Subunits {#bph13354-sec-0122}
--------

Nomenclature[*α* 1 subunit](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1287)[*α* 2 subunit](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1287)[*β* 1 subunit](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1287)[*β* 2 subunit](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1287)HGNC, UniProt[*GUCY1A3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4685), [Q02108](http://www.uniprot.org/uniprot/Q02108)[*GUCY1A2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4684), [P33402](http://www.uniprot.org/uniprot/P33402)[*GUCY1B3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4687), [Q02153](http://www.uniprot.org/uniprot/Q02153)[*GUCY1B2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4686), [O75343](http://www.uniprot.org/uniprot/O75343)

Comments {#bph13354-sec-0123}
--------

[ODQ](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5234) also shows activity at other haem‐containing proteins \[[134](http://www.ncbi.nlm.nih.gov/pubmed/10419542?dopt=AbstractPlus)\], while [YC1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5291) may also inhibit cGMP‐hydrolysing phosphodiesterases \[[149](http://www.ncbi.nlm.nih.gov/pubmed/9855623?dopt=AbstractPlus), [159](http://www.ncbi.nlm.nih.gov/pubmed/10369473?dopt=AbstractPlus)\].

[Exchange protein activated by cyclic AMP (Epac)](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=259) {#bph13354-sec-0124}
============================================================================================================================

Overview {#bph13354-sec-0125}
--------

Epacs are members of a family of guanine nucleotide exchange factors ([ENSFM00250000000899](http://www.ensembl.org/Homo_sapiens/Gene/Family/Genes?family=ENSFM00250000000899)), which also includes [*RapGEF5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16862)(GFR, KIAA0277, MR‐GEF, [Q92565](http://www.uniprot.org/uniprot/Q92565)) and [*RapGEFL1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17428) (Link‐GEFII, [Q9UHV5](http://www.uniprot.org/uniprot/Q9UHV5)). They are activated endogenously by [cyclic AMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352) and with some pharmacological selectivity by [8‐pCPT‐2\'‐O‐Me‐cAMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5172)\[[126](http://www.ncbi.nlm.nih.gov/pubmed/12402047?dopt=AbstractPlus)\]. Once activated, Epacs induce an enhanced activity of the monomeric G proteins, Rap1 and Rap2 by facilitating binding of [guanosine‐5\'‐triphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1742) in place of [guanosine 5\'‐diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2410), leading to activation of [phospholipase C](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=244) \[[423](http://www.ncbi.nlm.nih.gov/pubmed/11715024?dopt=AbstractPlus)\].

Nomenclature[Epac1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1292)[Epac2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1293)HGNC, UniProt[*RAPGEF3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16629), [O95398](http://www.uniprot.org/uniprot/O95398)[*RAPGEF4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16626), [Q8WZA2](http://www.uniprot.org/uniprot/Q8WZA2)Inhibitors--[HJC 0350](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6556) (pIC~50~ 6.5) \[[72](http://www.ncbi.nlm.nih.gov/pubmed/23286832?dopt=AbstractPlus)\], [ESI‐09](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7917) (pIC~50~ 4.4) \[[11](http://www.ncbi.nlm.nih.gov/pubmed/23066090?dopt=AbstractPlus)\]

[Phosphodiesterases, 3\',5\'‐cyclic nucleotide](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=260) {#bph13354-sec-0126}
==========================================================================================================================

Overview {#bph13354-sec-0127}
--------

3\',5\'‐Cyclic nucleotide phosphodiesterases (PDEs, 3\',5\'‐cyclic‐nucleotide 5\'‐nucleotidohydrolase), [E.C. 3.1.4.17](http://www.genome.jp/kegg-bin/search_brite?option=-a&search_string=3.1.4.17), catalyse the hydrolysis of a 3\',5\'‐cyclic nucleotide (usually [cyclic AMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352) or [cyclic GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347)). [Isobutylmethylxanthine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=388) is a nonselective inhibitor with an IC~50~ value in the millimolar range for all isoforms except PDE 8A, 8B and 9A. A 2\',3\'‐cyclic nucleotide 3\'‐phosphodiesterase ([E.C. 3.1.4.37](http://www.genome.jp/kegg-bin/search_brite?option=-a&search_string=3.1.4.37) CNPase) activity is associated with myelin formation in the development of the CNS.

Nomenclature[PDE1A](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1294)[PDE1B](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1295)[PDE1C](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1296)HGNC, UniProt[*PDE1A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8774), [P54750](http://www.uniprot.org/uniprot/P54750)[*PDE1B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8775), [Q01064](http://www.uniprot.org/uniprot/Q01064)[*PDE1C*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8776), [Q14123](http://www.uniprot.org/uniprot/Q14123)EC number[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)Rank order of affinity[cyclic GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347)\>[cyclic AMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352)[cyclic GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347)\>[cyclic AMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352)[cyclic GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347) = [cyclic AMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352)Endogenous activators[calmodulin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351) ([*CALM1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1442) [*CALM2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1445) [*CALM3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1449), [P62158](http://www.uniprot.org/uniprot/P62158))[calmodulin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351) ([*CALM1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1442) [*CALM2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1445) [*CALM3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1449), [P62158](http://www.uniprot.org/uniprot/P62158))[calmodulin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351) ([*CALM1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1442) [*CALM2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1445) [*CALM3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1449), [P62158](http://www.uniprot.org/uniprot/P62158))Selective inhibitors[SCH51866](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5270) (pIC~50~ 7.2) \[[498](http://www.ncbi.nlm.nih.gov/pubmed/8961086?dopt=AbstractPlus)\], [vinpocetine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5285) (pIC~50~ 5.1) \[[300](http://www.ncbi.nlm.nih.gov/pubmed/8557689?dopt=AbstractPlus)\][SCH51866](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5270) (pIC~50~ 7.2) \[[498](http://www.ncbi.nlm.nih.gov/pubmed/8961086?dopt=AbstractPlus)\][SCH51866](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5270) (pIC~50~ 7.2) \[[498](http://www.ncbi.nlm.nih.gov/pubmed/8961086?dopt=AbstractPlus)\], [vinpocetine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5285) (pIC~50~ 4.3) \[[300](http://www.ncbi.nlm.nih.gov/pubmed/8557689?dopt=AbstractPlus)\]Comments------

Nomenclature[PDE2A](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1297)[PDE3A](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1298)[PDE3B](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1299)HGNC, UniProt[*PDE2A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8777), [O00408](http://www.uniprot.org/uniprot/O00408)[*PDE3A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8778), [Q14432](http://www.uniprot.org/uniprot/Q14432)[*PDE3B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8779), [Q13370](http://www.uniprot.org/uniprot/Q13370)EC number[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)Rank order of affinity[cyclic AMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352)≫[cyclic GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347)----Endogenous activators[cyclic GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347)----Endogenous inhibitors--[cyclic GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347) (Selective)[cyclic GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347) (Selective)Inhibitors[milrinone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5225) (pIC~50~\<6.5) \[[465](http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus)\][cilostazol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7148) (pIC~50~ 6.7) \[[465](http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus)\], [inamrinone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7202) (pIC~50~ 4.8) \[[442](http://www.ncbi.nlm.nih.gov/pubmed/2536438?dopt=AbstractPlus)\]--Selective inhibitors[BAY607550](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5147) (pIC~50~ 8.3--8.8) \[[44](http://www.ncbi.nlm.nih.gov/pubmed/15555642?dopt=AbstractPlus)\], [EHNA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5179) (pIC~50~ 5.3) \[[332](http://www.ncbi.nlm.nih.gov/pubmed/8730511?dopt=AbstractPlus)\][cilostamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5167) (pIC~50~ 7.5) \[[465](http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus)\], [anagrelide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7114) (pIC~50~ 7.1--7.3) \[[245](http://www.ncbi.nlm.nih.gov/pubmed/3027338?dopt=AbstractPlus), [319](http://www.ncbi.nlm.nih.gov/pubmed/1311763?dopt=AbstractPlus), [326](http://www.ncbi.nlm.nih.gov/pubmed/1321910?dopt=AbstractPlus)\], [milrinone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5225) (pIC~50~ 6.3--6.4) \[[123](http://www.ncbi.nlm.nih.gov/pubmed/14592490?dopt=AbstractPlus), [465](http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus)\][cilostamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5167) (pIC~50~ 7.3) \[[465](http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus)\], [cilostazol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7148) (pIC~50~ 6.4) \[[465](http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus)\], [milrinone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5225) (pIC~50~ 6) \[[465](http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus)\], [inamrinone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7202) (pIC~50~ 4.5) \[[465](http://www.ncbi.nlm.nih.gov/pubmed/10644042?dopt=AbstractPlus)\]Comments[EHNA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5179) is also an inhibitor of [adenosine deaminase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=248#show_object_1230) ([E.C. 3.5.4.4](http://www.genome.jp/kegg-bin/search_brite?option=-a&search_string=3.5.4.4)).----

Nomenclature[PDE4A](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300)[PDE4B](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301)[PDE4C](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1302)[PDE4D](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303)[PDE5A](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1304)HGNC, UniProt[*PDE4A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8780), [P27815](http://www.uniprot.org/uniprot/P27815)[*PDE4B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8781), [Q07343](http://www.uniprot.org/uniprot/Q07343)[*PDE4C*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8782), [Q08493](http://www.uniprot.org/uniprot/Q08493)[*PDE4D*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8783), [Q08499](http://www.uniprot.org/uniprot/Q08499)[*PDE5A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8784), [O76074](http://www.uniprot.org/uniprot/O76074)EC number[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)Activator------PKA‐mediated phosphorylation \[[217](http://www.ncbi.nlm.nih.gov/pubmed/12444918?dopt=AbstractPlus)\]Protein kinase A, protein kinase G \[[93](http://www.ncbi.nlm.nih.gov/pubmed/10785399?dopt=AbstractPlus)\]Rank order of affinity[cyclic AMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352)≫[cyclic GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347)[cyclic AMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352)≫[cyclic GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347)[cyclic AMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352)≫[cyclic GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347)[cyclic AMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352)≫[cyclic GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347)[cyclic GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347)\>[cyclic AMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352)Inhibitors[ibudilast](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7399) (pIC~50~ 7.3) \[[262](http://www.ncbi.nlm.nih.gov/pubmed/18686943?dopt=AbstractPlus)\], [RS‐25344](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6557) (pIC~50~ 7.2) \[[417](http://www.ncbi.nlm.nih.gov/pubmed/9720765?dopt=AbstractPlus)\][roflumilast](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6962) (pIC~50~ 9.4) \[[301](http://www.ncbi.nlm.nih.gov/pubmed/19195882?dopt=AbstractPlus)\], [ibudilast](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7399) (pIC~50~ 7.2) \[[262](http://www.ncbi.nlm.nih.gov/pubmed/18686943?dopt=AbstractPlus)\], [RS‐25344](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6557) (pIC~50~ 6.5) \[[417](http://www.ncbi.nlm.nih.gov/pubmed/9720765?dopt=AbstractPlus)\][RS‐25344](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6557) (pIC~50~ 8.1) \[[417](http://www.ncbi.nlm.nih.gov/pubmed/9720765?dopt=AbstractPlus)\], [ibudilast](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7399) (pIC~50~ 6.6) \[[262](http://www.ncbi.nlm.nih.gov/pubmed/18686943?dopt=AbstractPlus)\][RS‐25344](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6557) (pIC~50~ 8.4) \[[417](http://www.ncbi.nlm.nih.gov/pubmed/9720765?dopt=AbstractPlus)\][gisadenafil](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6558) (pIC~50~ 8.9) \[[402](http://www.ncbi.nlm.nih.gov/pubmed/22100260?dopt=AbstractPlus)\], [milrinone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5225) (pIC~50~ 7.3)(Sub)family‐selective inhibitors[rolipram](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5260) (pIC~50~ 9) \[[508](http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus)\], [Ro20‐1724](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5258) (pIC~50~ 6.5) \[[508](http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus)\][rolipram](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5260) (pIC~50~ 9) \[[508](http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus)\], [Ro20‐1724](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5258) (pIC~50~ 6.4) \[[508](http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus)\][rolipram](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5260) (pIC~50~ 6.5) \[[508](http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus)\], [Ro20‐1724](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5258) (pIC~50~ 5.4) \[[508](http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus)\][rolipram](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5260) (pIC~50~ 7.2) \[[508](http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus)\], [Ro20‐1724](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5258) (pIC~50~ 6.2) \[[508](http://www.ncbi.nlm.nih.gov/pubmed/9177268?dopt=AbstractPlus)\]--Selective inhibitors[YM976](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5292) (pIC~50~ 8.3) \[[13](http://www.ncbi.nlm.nih.gov/pubmed/10991987?dopt=AbstractPlus)\]------[vardenafil](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7320) (pIC~50~ 9.7) \[[47](http://www.ncbi.nlm.nih.gov/pubmed/15837326?dopt=AbstractPlus)\], [T0156](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5275) (pIC~50~ 9.5) \[[338](http://www.ncbi.nlm.nih.gov/pubmed/12450574?dopt=AbstractPlus)\], [sildenafil](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4743) (pIC~50~ 9) \[[494](http://www.ncbi.nlm.nih.gov/pubmed/10385692?dopt=AbstractPlus)\], [tadalafil](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7299) (pIC~50~ 8.5) \[[339](http://www.ncbi.nlm.nih.gov/pubmed/21189023?dopt=AbstractPlus)\], [SCH51866](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5270) (pIC~50~ 7.2) \[[498](http://www.ncbi.nlm.nih.gov/pubmed/8961086?dopt=AbstractPlus)\], [zaprinast](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2919) (pIC~50~ 6.8) \[[494](http://www.ncbi.nlm.nih.gov/pubmed/10385692?dopt=AbstractPlus)\]

Nomenclature[PDE6A](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1312)[PDE6B](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1313)[PDE6C](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1314)[PDE6D](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1315)[PDE6G](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1316)[PDE6H](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1317)HGNC, UniProt[*PDE6A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8785), [P16499](http://www.uniprot.org/uniprot/P16499)[*PDE6B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8786), [P35913](http://www.uniprot.org/uniprot/P35913)[*PDE6C*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8787), [P51160](http://www.uniprot.org/uniprot/P51160)[*PDE6D*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8788), [O43924](http://www.uniprot.org/uniprot/O43924)[*PDE6G*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8789), [P18545](http://www.uniprot.org/uniprot/P18545)[*PDE6H*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8790), [Q13956](http://www.uniprot.org/uniprot/Q13956)EC number[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)Activators------------Rank order of affinity------------Inhibitors------------Selective inhibitors------------

Nomenclature[PDE7A](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1305)[PDE7B](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1306)[PDE8A](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1307)[PDE8B](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1308)HGNC, UniProt[*PDE7A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8791), [Q13946](http://www.uniprot.org/uniprot/Q13946)[*PDE7B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8792), [Q9NP56](http://www.uniprot.org/uniprot/Q9NP56)[*PDE8A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8793), [O60658](http://www.uniprot.org/uniprot/O60658)[*PDE8B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8794), [O95263](http://www.uniprot.org/uniprot/O95263)EC number[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)Rank order of affinity[cyclic AMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352)≫[cyclic GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347) \[[330](http://www.ncbi.nlm.nih.gov/pubmed/8389765?dopt=AbstractPlus)\][cyclic AMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352)≫[cyclic GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347) \[[166](http://www.ncbi.nlm.nih.gov/pubmed/10872825?dopt=AbstractPlus)\][cyclic AMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352)≫[cyclic GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347) \[[138](http://www.ncbi.nlm.nih.gov/pubmed/9618252?dopt=AbstractPlus)\][cyclic AMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352)≫[cyclic GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347) \[[201](http://www.ncbi.nlm.nih.gov/pubmed/9784418?dopt=AbstractPlus)\]Inhibitors--[BRL50481](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5154) (pIC~50~ 4.9) \[[7](http://www.ncbi.nlm.nih.gov/pubmed/20228279?dopt=AbstractPlus)\]----Selective inhibitors[BRL50481](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5154) (pIC~50~ 6.7--6.8) \[[7](http://www.ncbi.nlm.nih.gov/pubmed/20228279?dopt=AbstractPlus), [448](http://www.ncbi.nlm.nih.gov/pubmed/15371556?dopt=AbstractPlus)\][dipyridamole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4807) (pIC~50~ 5.7--6) \[[166](http://www.ncbi.nlm.nih.gov/pubmed/10872825?dopt=AbstractPlus), [419](http://www.ncbi.nlm.nih.gov/pubmed/10814504?dopt=AbstractPlus)\], [SCH51866](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5270) (pIC~50~ 5.8) \[[419](http://www.ncbi.nlm.nih.gov/pubmed/10814504?dopt=AbstractPlus)\][dipyridamole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4807) (pIC~50~ 5.1) \[[138](http://www.ncbi.nlm.nih.gov/pubmed/9618252?dopt=AbstractPlus)\][dipyridamole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4807) (pIC~50~ 4.3) \[[201](http://www.ncbi.nlm.nih.gov/pubmed/9784418?dopt=AbstractPlus)\]Comments----PDE7A appears to be membrane‐bound or soluble for PDE7A1 and 7A2 splice variants, respectively--

Nomenclature[PDE9A](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1309)[PDE10A](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1310)[PDE11A](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1311)HGNC, UniProt[*PDE9A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8795), [O76083](http://www.uniprot.org/uniprot/O76083)[*PDE10A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8772), [Q9Y233](http://www.uniprot.org/uniprot/Q9Y233)[*PDE11A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8773), [Q9HCR9](http://www.uniprot.org/uniprot/Q9HCR9)EC number[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)[3.1.4.17](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.4.17)Rank order of affinity[cyclic GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347)≫[cyclic AMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352) \[[137](http://www.ncbi.nlm.nih.gov/pubmed/9624146?dopt=AbstractPlus)\][cyclic AMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352), [cyclic GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347) \[[152](http://www.ncbi.nlm.nih.gov/pubmed/10373451?dopt=AbstractPlus)\][cyclic AMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352), [cyclic GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347) \[[133](http://www.ncbi.nlm.nih.gov/pubmed/10725373?dopt=AbstractPlus)\]Inhibitors----[tadalafil](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7299) (pIC~50~ 6.5) \[[339](http://www.ncbi.nlm.nih.gov/pubmed/21189023?dopt=AbstractPlus)\], [BC11‐38](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6559) (pIC~50~ 6.5) \[[68](http://www.ncbi.nlm.nih.gov/pubmed/22284362?dopt=AbstractPlus)\]Selective inhibitors[SCH51866](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5270) (pIC~50~ 5.8) \[[137](http://www.ncbi.nlm.nih.gov/pubmed/9624146?dopt=AbstractPlus)\], [zaprinast](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2919) (pIC~50~ 4.5) \[[137](http://www.ncbi.nlm.nih.gov/pubmed/9624146?dopt=AbstractPlus)\]----Comments--

Comments {#bph13354-sec-0128}
--------

PDE1A, 1B and 1C appear to act as soluble homodimers, while PDE2A is a membrane‐bound homodimer. PDE3A and PDE3B are membrane‐bound.

PDE4 isoforms are essentially [cyclic AMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2352) specific. The potency of [YM976](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5292) at other members of the PDE4 family has not been reported. PDE4B‐D long forms are inhibited by extracellular signal‐regulated kinase (ERK)‐mediated phosphorylation \[[212](http://www.ncbi.nlm.nih.gov/pubmed/10022832?dopt=AbstractPlus), [213](http://www.ncbi.nlm.nih.gov/pubmed/9639573?dopt=AbstractPlus)\]. PDE4A‐D splice variants can be membrane‐bound or cytosolic \[[217](http://www.ncbi.nlm.nih.gov/pubmed/12444918?dopt=AbstractPlus)\]. PDE4 isoforms may be labelled with [\[^3^H\]rolipram](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5313).

PDE6 is a membrane‐bound tetramer composed of two catalytic chains (PDE6A or PDE6C and PDE6B), an inhibitory chain (PDE6G or PDE6H) and the PDE6D chain. The enzyme is essentially [cyclic GMP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2347) specific and is activated by the *α*‐subunit of transducin (G*α* ~t~) and inhibited by [sildenafil](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4743), [zaprinast](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2919) and [dipyridamole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4807) with potencies lower than those observed for PDE5A. Defects in PDE6B are a cause of retinitis pigmentosa and congenital stationary night blindness.
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[Cytochrome P450](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=242) {#bph13354-sec-0130}
============================================================================================

Overview {#bph13354-sec-0131}
--------

The cytochrome P450 enzyme family (CYP450), E.C. 1.14.‐.‐, were originally defined by their strong absorbance at 450 nm due to the reduced carbon monoxide‐complexed haem component of the cytochromes. They are an extensive family of haem‐containing monooxygenases with a huge range of both endogenous and exogenous substrates. Listed below are the human enzymes; their relationship with rodent CYP450 enzyme activities is obscure in that the species orthologue may not mediate metabolism of the same substrates. Although the majority of CYP450 enzyme activities are concentrated in the liver, the extrahepatic enzyme activities also contribute to patho/physiological processes. Genetic variation of CYP450 isoforms is widespread and likely underlies a significant proportion of the individual variation to drug administration. Further family members are included on the online database at [www.GuidetoPHARMACOLOGY.org](http://www.GuidetoPHARMACOLOGY.org)

[CYP1 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=261) {#bph13354-sec-0132}
========================================================================================

Nomenclature[CYP1A1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1318)[CYP1A2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1319)[CYP1B1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1320)HGNC, UniProt[*CYP1A1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2595), [P04798](http://www.uniprot.org/uniprot/P04798)[*CYP1A2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2596), [P05177](http://www.uniprot.org/uniprot/P05177)[*CYP1B1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2597), [Q16678](http://www.uniprot.org/uniprot/Q16678)EC number[1.14.1.1](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.1.1)[1.14.1.1](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.1.1)[1.14.1.1](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.1.1)Comments----Mutations have been associated with primary congenitial glucoma \[[464](http://www.ncbi.nlm.nih.gov/pubmed/9097971?dopt=AbstractPlus)\]

[CYP2 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=262) {#bph13354-sec-0133}
========================================================================================

Nomenclature[CYP2A6](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1321)[CYP2A7](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1322)[CYP2C8](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1325)HGNC, UniProt[*CYP2A6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2610), [P11509](http://www.uniprot.org/uniprot/P11509)[*CYP2A7*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2611), [P20853](http://www.uniprot.org/uniprot/P20853)[*CYP2C8*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2622), [P10632](http://www.uniprot.org/uniprot/P10632)EC number[1.14.14.1](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.14.1)[1.14.14.1](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.14.1)[1.14.14.1](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.14.1)CommentsMetabolises [nicotine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2585)CYP2A7 does not incorporate haem and is functionally inactive \[[153](http://www.ncbi.nlm.nih.gov/pubmed/16636685?dopt=AbstractPlus)\]Converts [arachidonic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391) to 11(R)‐12(S)‐epoxyeicosatrienoic acid or 14(R)‐15(S)‐epoxyeicosatrienoic acid \[[547](http://www.ncbi.nlm.nih.gov/pubmed/7574697?dopt=AbstractPlus)\].

Nomenclature[CYP2J2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1332)[CYP2R1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1333)HGNC, UniProt[*CYP2J2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2634), [P51589](http://www.uniprot.org/uniprot/P51589)[*CYP2R1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20580), [Q6VVX0](http://www.uniprot.org/uniprot/Q6VVX0)EC number[1.14.14.1](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.14.1)[1.14.13.15](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.13.15)CommentsConverts [arachidonic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391) to 14(R)‐15(S)‐epoxyeicosatrienoic acid \[[531](http://www.ncbi.nlm.nih.gov/pubmed/8631948?dopt=AbstractPlus)\].Converts [vitamin D3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2747) to [25‐hydroxyvitamin D~3~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6921) \[[78](http://www.ncbi.nlm.nih.gov/pubmed/12867411?dopt=AbstractPlus)\].

[CYP3 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=263) {#bph13354-sec-0134}
========================================================================================

Nomenclature[CYP3A4](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1337)HGNC, UniProt[*CYP3A4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2637), [P08684](http://www.uniprot.org/uniprot/P08684)EC number[1.14.13.32](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.13.32): Albendazole + [NADPH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041) + O~2~ = albendazole S‐oxide + [NADP^+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045) + H~2~ [1.14.13.157](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.13.157): 1,8‐cineole + [NADPH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041) + O~2~ = 2‐exo‐hydroxy‐1,8‐cineole + [NADP^+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045) + H~2~O [1.14.13.97](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.13.97): Taurochenodeoxycholate + [NADPH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041) + O~2~ = taurohyocholate + [NADP^+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045) + H~2~O Lithocholate + [NADPH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041) + O~2~ = hyodeoxycholate + [NADP^+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045) + H~2~O [1.14.13.67](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.13.67): [quinine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2510) + [NADPH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041) + O~2~ = 3‐hydroxyquinine + [NADP^+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045) + [H~2~O~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2448)Substrates[atorvastatin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2949) \[[140](#bph13354-bib-0140){ref-type="ref"}\], [codeine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1673) \[[140](#bph13354-bib-0140){ref-type="ref"}\], [diazepam](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3364) \[[140](#bph13354-bib-0140){ref-type="ref"}\], [tamoxifen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1016) \[[140](#bph13354-bib-0140){ref-type="ref"}\], [erlotinib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4920) \[[140](#bph13354-bib-0140){ref-type="ref"}\]Products4‐hydroxy‐tamoxifen quinone methide \[[432](http://www.ncbi.nlm.nih.gov/pubmed/22677141?dopt=AbstractPlus)\], 4‐hydroxy‐tamoxifen \[[432](http://www.ncbi.nlm.nih.gov/pubmed/22677141?dopt=AbstractPlus)\]CommentsMetabolises a vast range of xenobiotics, including antidepressants, benzodiazepines, calcium channel blockers, and chemotherapeutic agents. CYP3A4 catalyses the 25‐hydroxylation of [trihydroxycholestane](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2767) in liver microsomes \[[157](http://www.ncbi.nlm.nih.gov/pubmed/9931427?dopt=AbstractPlus)\].

[CYP4 family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=264) {#bph13354-sec-0135}
========================================================================================

Nomenclature[CYP4A11](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1341)[CYP4F2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1344)[CYP4F3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1345)[CYP4F8](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1346)[CYP4F12](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1348)HGNC, UniProt[*CYP4A11*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2642), [Q02928](http://www.uniprot.org/uniprot/Q02928)[*CYP4F2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2645), [P78329](http://www.uniprot.org/uniprot/P78329)[*CYP4F3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2646), [Q08477](http://www.uniprot.org/uniprot/Q08477)[*CYP4F8*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2648), [P98187](http://www.uniprot.org/uniprot/P98187)[*CYP4F12*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18857), [Q9HCS2](http://www.uniprot.org/uniprot/Q9HCS2)EC number[1.14.15.3](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.15.3)[1.14.13.30](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.13.30)[1.14.13.30](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.13.30)[1.14.14.1](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.14.1)[1.14.14.1](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.14.1)CommentsConverts [lauric acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5534) to [12‐hydroxylauric acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6922).Responsible for *ω*‐hydroxylation of [LTB~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2487), [LXB~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5216) \[[335](http://www.ncbi.nlm.nih.gov/pubmed/8389204?dopt=AbstractPlus)\], and tocopherols, including vitamin E \[[453](http://www.ncbi.nlm.nih.gov/pubmed/11997390?dopt=AbstractPlus)\]Responsible for *ω*‐hydroxylation of [LTB~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2487), [LXB~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5216) \[[335](http://www.ncbi.nlm.nih.gov/pubmed/8389204?dopt=AbstractPlus)\], and polyunsaturated fatty acids \[[135](http://www.ncbi.nlm.nih.gov/pubmed/18577768?dopt=AbstractPlus), [194](http://www.ncbi.nlm.nih.gov/pubmed/16820285?dopt=AbstractPlus)\]Converts [PGH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483) to 19‐hydroxyPGH~2~ \[[54](http://www.ncbi.nlm.nih.gov/pubmed/10791960?dopt=AbstractPlus)\] and 8,9‐EET or 11,12‐EET to 18‐hydroxy‐8,9‐EET or 18‐hydroxy‐11,12‐EET \[[353](http://www.ncbi.nlm.nih.gov/pubmed/19919823?dopt=AbstractPlus)\].AC004597.1 ([ENSG00000225607](http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000225607;r=19:15880826-15890774;t=ENST00000412610)) is described as being highly similar to CYP4F12

Nomenclature[CYP4F22](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1349)[CYP4V2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1350)[CYP4X1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1351)[CYP4Z1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1352)HGNC, UniProt[*CYP4F22*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=26820), [Q6NT55](http://www.uniprot.org/uniprot/Q6NT55)[*CYP4V2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23198), [Q6ZWL3](http://www.uniprot.org/uniprot/Q6ZWL3)[*CYP4X1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20244), [Q8N118](http://www.uniprot.org/uniprot/Q8N118)[*CYP4Z1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20583), [Q86W10](http://www.uniprot.org/uniprot/Q86W10)EC number[1.14.14.‐](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.14.-)[1.14.‐.‐](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.-.-)[1.14.14.1](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.14.1)[1.14.14.1](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.14.1)CommentsConverts [arachidonic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391) to [16‐HETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6923) and [18‐HETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6924) \[[353](http://www.ncbi.nlm.nih.gov/pubmed/19919823?dopt=AbstractPlus)\].Converts [myristic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2806) to 14‐hydroxymyristic acid \[[348](http://www.ncbi.nlm.nih.gov/pubmed/19661213?dopt=AbstractPlus)\].Converts [anandamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364) to 14,15‐epoxyeicosatrienoic ethanolamide \[[459](http://www.ncbi.nlm.nih.gov/pubmed/18549450?dopt=AbstractPlus)\].Converts lauric acid to 12‐hydroxylauric acid

[CYP5, CYP7 and CYP8 families](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=265) {#bph13354-sec-0136}
=========================================================================================================

Nomenclature[CYP5A1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1353)[CYP8A1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1356)[CYP7A1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1354)[CYP7B1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1355)[CYP8B1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1357)Common name--Prostacyclin synthase------HGNC, UniProt[*TBXAS1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11609), [P24557](http://www.uniprot.org/uniprot/P24557)[*PTGIS*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9603), [Q16647](http://www.uniprot.org/uniprot/Q16647)[*CYP7A1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2651), [P22680](http://www.uniprot.org/uniprot/P22680)[*CYP7B1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2652), [O75881](http://www.uniprot.org/uniprot/O75881)[*CYP8B1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2653), [Q9UNU6](http://www.uniprot.org/uniprot/Q9UNU6)EC number[5.3.99.5](http://www.genome.jp/dbget-bin/www_bget?ec:5.3.99.5): [PGH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483) = [thromboxane A~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482)[5.3.99.4](http://www.genome.jp/dbget-bin/www_bget?ec:5.3.99.4)[1.14.13.17](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.13.17)[1.14.13.100](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.13.100)[1.14.13.95](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.13.95)CommentsInhibited by [dazoxiben](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5175) \[[398](http://www.ncbi.nlm.nih.gov/pubmed/6795753?dopt=AbstractPlus)\] and [camonagrel](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5157) \[[182](http://www.ncbi.nlm.nih.gov/pubmed/7778318?dopt=AbstractPlus)\].Converts [PGH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483) to [PGI~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915) \[[196](http://www.ncbi.nlm.nih.gov/pubmed/8766713?dopt=AbstractPlus)\]. Inhibited by [tranylcypromine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5281) \[[181](http://www.ncbi.nlm.nih.gov/pubmed/824685?dopt=AbstractPlus)\]Converts [cholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2718) to [7*α*‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4351) \[[354](http://www.ncbi.nlm.nih.gov/pubmed/2384150?dopt=AbstractPlus)\].Converts [dehydroepiandrosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2370) to 7*α*‐DHEA \[[411](http://www.ncbi.nlm.nih.gov/pubmed/9144166?dopt=AbstractPlus)\].Converts 7*α*‐hydroxycholest‐4‐en‐3‐one to 7‐alpha,12*α*‐dihydroxycholest‐4‐en‐3‐one (in rabbit) \[[226](http://www.ncbi.nlm.nih.gov/pubmed/1400444?dopt=AbstractPlus)\] in the biosynthesis of bile acids.

[CYP11, CYP17, CYP19, CYP20 and CYP21 families](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=266) {#bph13354-sec-0137}
==========================================================================================================================

Nomenclature[CYP11A1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1358)[CYP11B1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1359)[CYP11B2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1360)[CYP17A1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1361)Common name----Aldosterone synthase--HGNC, UniProt[*CYP11A1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2590), [P05108](http://www.uniprot.org/uniprot/P05108)[*CYP11B1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2591), [P15538](http://www.uniprot.org/uniprot/P15538)[*CYP11B2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2592), [P19099](http://www.uniprot.org/uniprot/P19099)[*CYP17A1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2593), [P05093](http://www.uniprot.org/uniprot/P05093)EC number[1.14.15.6](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.15.6)[1.14.15.4](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.15.4)[1.14.15.4](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.15.4)[1.14.99.9](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.99.9)[1.14.15.5](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.15.5)Inhibitors[mitotane](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6957)[metyrapone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5224) (pIC~50~ 7.8) \[[553](http://www.ncbi.nlm.nih.gov/pubmed/21129965?dopt=AbstractPlus)\], [mitotane](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6957)[osilodrostat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8310) (pIC~50~ 9.7) \[[537](http://www.ncbi.nlm.nih.gov/pubmed/24899257?dopt=AbstractPlus)\][abiraterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6745) (pIC~50~ 7.1--8.4) \[[386](http://www.ncbi.nlm.nih.gov/pubmed/18672868?dopt=AbstractPlus), [390](http://www.ncbi.nlm.nih.gov/pubmed/7608911?dopt=AbstractPlus)\]Selective inhibitors------[galeterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8638) (pIC~50~ 6.5) \[[192](http://www.ncbi.nlm.nih.gov/pubmed/15828836?dopt=AbstractPlus)\]CommentsConverts [cholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2718) to [pregnenolone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2376) plus 4‐methylpentanal.Converts [deoxycortisone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3450) and [11‐deoxycortisol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5100) to [cortisone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5171) and [cortisol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2868), respectively. Loss‐of‐function mutations are associated with familial adrenal hyperplasia and hypertension. Inhibited by [metyrapone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5224) \[[513](http://www.ncbi.nlm.nih.gov/pubmed/412519?dopt=AbstractPlus)\]Converts [corticosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2869) to [aldosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2872)Converts [pregnenolone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2376) and [progesterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377) to [17*α*‐hydroxypregnenolone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5103) and [17*α*‐hydroxyprogesterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5104), respectively. Converts [17*α*‐hydroxypregnenolone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5103) and [17*α*‐hydroxyprogesterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5104) to [dehydroepiandrosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2370) and [androstenedione](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2860), respectively. Converts [corticosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2869) to [cortisol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2868).

Nomenclature[CYP19A1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1362)[CYP20A1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1363)[CYP21A2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1364)Common nameAromatase----HGNC, UniProt[*CYP19A1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2594), [P11511](http://www.uniprot.org/uniprot/P11511)[*CYP20A1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20576), [Q6UW02](http://www.uniprot.org/uniprot/Q6UW02)[*CYP21A2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2600), [P08686](http://www.uniprot.org/uniprot/P08686)EC number[1.14.14.1](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.14.1)[1.14.‐.‐](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.-.-)[1.14.99.10](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.99.10)Inhibitors[anastrozole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5137) (pIC~50~ 7.8) \[[343](http://www.ncbi.nlm.nih.gov/pubmed/20413308?dopt=AbstractPlus)\], [aminoglutethimide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7054) \[[379](http://www.ncbi.nlm.nih.gov/pubmed/19470632?dopt=AbstractPlus)\]----Selective inhibitors[letrozole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5209) (p*K* ~i~ 10.7) \[[323](http://www.ncbi.nlm.nih.gov/pubmed/22386564?dopt=AbstractPlus)\], [exemestane](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7073) (pIC~50~ 7.3) \[[85](http://www.ncbi.nlm.nih.gov/pubmed/2951074?dopt=AbstractPlus)\], [testolactone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7303) (p*K* ~i~ 4.5) \[[95](http://www.ncbi.nlm.nih.gov/pubmed/7083195?dopt=AbstractPlus)\]----CommentsConverts [androstenedione](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2860) and [testosterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2858) to [estrone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2818) and [17*β*‐estradiol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1013), respectively. Inhibited by [anastrozole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5137) \[[388](http://www.ncbi.nlm.nih.gov/pubmed/7949201?dopt=AbstractPlus)\], and [letrozole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5209) \[[33](http://www.ncbi.nlm.nih.gov/pubmed/2149502?dopt=AbstractPlus)\]--Converts [progesterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2377) and [17*α*‐hydroxyprogesterone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5104) to [deoxycortisone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3450) and [11‐deoxycortisol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5100), respectively

[CYP24, CYP26 and CYP27 families](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=267) {#bph13354-sec-0138}
============================================================================================================

Nomenclature[CYP24A1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1365)[CYP26A1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1366)[CYP26B1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1367)[CYP27A1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1369)[CYP27B1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1370)Common abreviation------Sterol 27‐hydroxylase--HGNC, UniProt[*CYP24A1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2602), [Q07973](http://www.uniprot.org/uniprot/Q07973)[*CYP26A1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2603), [O43174](http://www.uniprot.org/uniprot/O43174)[*CYP26B1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=20581), [Q9NR63](http://www.uniprot.org/uniprot/Q9NR63)[*CYP27A1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2605), [Q02318](http://www.uniprot.org/uniprot/Q02318)[*CYP27B1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2606), [O15528](http://www.uniprot.org/uniprot/O15528)EC number[1.14.13.126](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.13.126)[1.14.‐.‐](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.-.-)[1.14.‐.‐](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.-.-)[1.14.13.15](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.13.15)[1.14.13.13](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.13.13)CommentsConverts [1,25‐dihydroxyvitamin D3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2779) (calcitriol) to 1*α*,24R,25‐trihydroxyvitamin D~3~.Converts retinoic acid to 4‐hydroxyretinoic acid. Inhibited by [liarozole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5210)Converts retinoic acid to 4‐hydroxyretinoic acid.Converts [cholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2718) to [27‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2752).Converts 25‐hydroxyvitamin D~3~ to [1,25‐dihydroxyvitamin D3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2779) (calcitriol)

[CYP39, CYP46 and CYP51 families](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=268) {#bph13354-sec-0139}
============================================================================================================

Nomenclature[CYP39A1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1372)[CYP46A1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1373)[CYP51A1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1374)Common abreviation--Cholesterol 24‐hydroxylaseLanosterol 14‐*α*‐demethylaseHGNC, UniProt[*CYP39A1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17449), [Q9NYL5](http://www.uniprot.org/uniprot/Q9NYL5)[*CYP46A1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2641), [Q9Y6A2](http://www.uniprot.org/uniprot/Q9Y6A2)[*CYP51A1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2649), [Q16850](http://www.uniprot.org/uniprot/Q16850)EC number[1.14.13.99](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.13.99)[1.14.13.98](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.13.98)--CommentsConverts 24‐hydroxycholesterol to 7*α*,24‐dihydroxycholesterol \[[286](http://www.ncbi.nlm.nih.gov/pubmed/10748047?dopt=AbstractPlus)\].Converts [cholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2718) to [24(S)‐hydroxycholesterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2750).Converts [lanosterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2746) to 4,4‐dimethylcholesta‐8.14.24‐trienol.

Further Reading {#bph13354-sec-0140}
---------------
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Lorbek G *et al*. (2012) Cytochrome P450s in the synthesis of cholesterol and bile acids--from mouse models to human diseases. *FEBS J.* **279**: 1516‐33 [\[PMID:22111624\]](http://www.ncbi.nlm.nih.gov/pubmed/22111624?dopt=AbstractPlus)
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Shahabi P *et al*. (2014) Human cytochrome P450 epoxygenases: variability in expression and role in inflammation‐related disorders. *Pharmacol. Ther.* **144**: 134‐61 [\[PMID:24882266\]](http://www.ncbi.nlm.nih.gov/pubmed/24882266?dopt=AbstractPlus)

Werk AN *et al*. (2014) Functional gene variants of CYP3A4. *Clin. Pharmacol. Ther.* **96**: 340‐8 [\[PMID:24926778\]](http://www.ncbi.nlm.nih.gov/pubmed/24926778?dopt=AbstractPlus)

[Endocannabinoid turnover](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=273) {#bph13354-sec-0141}
=====================================================================================================

Overview {#bph13354-sec-0142}
--------

The principle endocannabinoids are [2‐arachidonoylglycerol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=729)(2AG) and [anandamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364)(N‐arachidonoylethanolamine, AEA), thought to be generated on demand rather than stored, although this may not always be the case \[[10](http://www.ncbi.nlm.nih.gov/pubmed/21507493?dopt=AbstractPlus)\]. Mechanisms for release and re‐uptake of endocannabinoids (and related entities) are unclear, although candidates for intracellular transport have been suggested. For the generation of [2‐arachidonoylglycerol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=729), the key enzyme involved is diacylglycerol lipase (DGL), whilst several routes for [anandamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364) synthesis have been described, the best characterized of which involves *N*‐acylphosphatidylethanolamine‐phospholipase D (NAPE‐PLD, \[[438](http://www.ncbi.nlm.nih.gov/pubmed/20393650?dopt=AbstractPlus)\]). Inactivation of these endocannabinoids appears to occur predominantly through monoacylglycerol lipase (MGL) and fatty acid amide hydrolase (FAAH) for [2‐arachidonoylglycerol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=729) and [anandamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364), respectively. Note that these enzymes also contribute to the turnover of many endogenous ligands inactive at CB~1~ and CB~2~ cannabinoid receptors, such as [N‐oleoylethanolamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661), [N‐palmitoylethanolamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3622) and [2‐oleoyl glycerol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5112). *In vitro* experiments indicate that the endocannabinoids are also substrates for oxidative metabolism *via* cyclooxygenase, lipoxygenase and cytochrome P450 enzyme activities \[[9](http://www.ncbi.nlm.nih.gov/pubmed/17876303?dopt=AbstractPlus), [145](http://www.ncbi.nlm.nih.gov/pubmed/17618306?dopt=AbstractPlus), [450](http://www.ncbi.nlm.nih.gov/pubmed/20133390?dopt=AbstractPlus)\].

Nomenclature[Diacylglycerol lipase *α*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1396)[Diacylglycerol lipase *β*](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1397)[*N*‐Acylphosphatidylethanolamine‐phospholipase D](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1398)Common abreviationDGL*α*DGL*β*NAPE‐PLDHGNC, UniProt[*DAGLA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1165), [Q9Y4D2](http://www.uniprot.org/uniprot/Q9Y4D2)[*DAGLB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=28923), [Q8NCG7](http://www.uniprot.org/uniprot/Q8NCG7)[*NAPEPLD*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=21683), [Q6IQ20](http://www.uniprot.org/uniprot/Q6IQ20)EC number[3.1.1.‐](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.1.-)[3.1.1.‐](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.1.-)--Selective inhibitors[orlistat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5277) (pIC~50~ 7.2) \[[37](http://www.ncbi.nlm.nih.gov/pubmed/14610053?dopt=AbstractPlus)\], [RHC80267](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5255) (pIC~50~ 4.2) \[[243](http://www.ncbi.nlm.nih.gov/pubmed/22738638?dopt=AbstractPlus)\][orlistat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5277) (pIC~50~ 7) \[[37](http://www.ncbi.nlm.nih.gov/pubmed/14610053?dopt=AbstractPlus)\], [RHC80267](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5255)--Comments----NAPE‐PLD activity appears to be enhanced by polyamines in the physiological range \[[292](http://www.ncbi.nlm.nih.gov/pubmed/12047899?dopt=AbstractPlus)\], but fails to transphosphatidylate with alcohols \[[381](http://www.ncbi.nlm.nih.gov/pubmed/10428468?dopt=AbstractPlus)\] unlike phosphatidylcholine‐specific phospholipase D.

Nomenclature[Monoacylglycerol lipase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1399)[Fatty acid amide hydrolase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1400)[Fatty acid amide hydrolase‐2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1401)[*N*‐Acylethanolamine acid amidase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1402)Common abreviationMGLFAAHFAAH2NAAAHGNC, UniProt[*MGLL*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17038), [Q99685](http://www.uniprot.org/uniprot/Q99685)[*FAAH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3553), [O00519](http://www.uniprot.org/uniprot/O00519)[*FAAH2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=26440), [Q6GMR7](http://www.uniprot.org/uniprot/Q6GMR7)[*NAAA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=736), [Q02083](http://www.uniprot.org/uniprot/Q02083)EC number[3.1.1.23](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.1.23)[3.5.1.‐](http://www.genome.jp/dbget-bin/www_bget?ec:3.5.1.-)[3.5.1.‐](http://www.genome.jp/dbget-bin/www_bget?ec:3.5.1.-)[3.5.1.‐](http://www.genome.jp/dbget-bin/www_bget?ec:3.5.1.-)Rank order of affinity[2‐oleoyl glycerol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5112) = [2‐arachidonoylglycerol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=729)≫[anandamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364) \[[171](http://www.ncbi.nlm.nih.gov/pubmed/15492019?dopt=AbstractPlus)\][anandamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364)\>[oleamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=284)\>[N‐oleoylethanolamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661)\>[N‐palmitoylethanolamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3622) \[[518](http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus)\][oleamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=284)\>[N‐oleoylethanolamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661)\>[anandamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364)\>[N‐palmitoylethanolamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3622) \[[518](http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus)\][N‐palmitoylethanolamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3622)\>[MEA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5221)\>[SEA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3621)≥[N‐oleoylethanolamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2661)\>[anandamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364) \[[495](http://www.ncbi.nlm.nih.gov/pubmed/11463796?dopt=AbstractPlus)\]Selective inhibitors[JZL184](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5207) (pIC~50~ 8.1) \[[295](http://www.ncbi.nlm.nih.gov/pubmed/19029917?dopt=AbstractPlus)\][JNJ1661010](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5206) (pIC~50~ 7.8) \[[253](http://www.ncbi.nlm.nih.gov/pubmed/18693015?dopt=AbstractPlus)\], [PF750](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5244) (pIC~50~ 6.3--7.8) \[[4](http://www.ncbi.nlm.nih.gov/pubmed/17949010?dopt=AbstractPlus)\], [OL135](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5235) (pIC~50~ 7.4) \[[518](http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus)\], [URB597](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4339) (pIC~50~ 6.3--7) \[[518](http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus)\], [PF3845](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5243) (pIC~50~ 6.6) \[[5](http://www.ncbi.nlm.nih.gov/pubmed/19389627?dopt=AbstractPlus)\][URB597](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4339) (pIC~50~ 7.5--8.3) \[[518](http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus)\], [OL135](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5235) (pIC~50~ 7.9) \[[518](http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus)\][*S*‐OOPP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6493) (pIC~50~ 6.4) \[[451](http://www.ncbi.nlm.nih.gov/pubmed/19926854?dopt=AbstractPlus)\] -- Rat, [CCP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5161) (pIC~50~ 5.3) \[[492](http://www.ncbi.nlm.nih.gov/pubmed/14686878?dopt=AbstractPlus)\]

Comments {#bph13354-sec-0143}
--------

Many of the compounds described as inhibitors are irreversible and so potency estimates will vary with incubation time. FAAH2 is not found in rodents \[[518](http://www.ncbi.nlm.nih.gov/pubmed/17015445?dopt=AbstractPlus)\] and few of the inhibitors described have been assessed at this enzyme activity. [2‐arachidonoylglycerol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=729) has been reported to be hydrolysed by multiple enzyme activities from neural preparations, including [*ABHD6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=21398)([Q9BV23](http://www.uniprot.org/uniprot/Q9BV23)) \[[41](http://www.ncbi.nlm.nih.gov/pubmed/18096503?dopt=AbstractPlus)\], [*ABHD12*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=15868) ([8N2K0](http://www.uniprot.org/uniprot/8N2K0)) \[[41](http://www.ncbi.nlm.nih.gov/pubmed/18096503?dopt=AbstractPlus)\], neuropathy target esterase ([*PNPLA6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16268), [Q8IY17](http://www.uniprot.org/uniprot/Q8IY17)\[[316](http://www.ncbi.nlm.nih.gov/pubmed/20657592?dopt=AbstractPlus)\]) and carboxylesterase 1 ([*CES1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1863), [P23141](http://www.uniprot.org/uniprot/P23141)\[[533](http://www.ncbi.nlm.nih.gov/pubmed/21049984?dopt=AbstractPlus)\]). Although these have been incompletely defined, [WWL70](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5289) has been described to inhibit ABHD6 selectively with a pIC~50~ value of 7.2 \[[284](http://www.ncbi.nlm.nih.gov/pubmed/17629278?dopt=AbstractPlus)\]. Other selective inhibitors of NAAA (with respect to FAAH) have been described, but these are not yet commercially available.
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---------------
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[Eicosanoid turnover](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=243) {#bph13354-sec-0145}
================================================================================================

Overview {#bph13354-sec-0146}
--------

Eicosanoids are 20‐carbon fatty acids, where the usual focus is the polyunsaturated analogue [arachidonic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391) and its metabolites. Arachidonic acid is thought primarily to derive from [phospholipase A2](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=244#PhospholipaseA2) action on membrane phosphatidylcholine, and may be re‐cycled to form phospholipid through conjugation with [coenzyme A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044) and subsequently glycerol derivatives. Oxidative metabolism of arachidonic acid is conducted through three major enzymatic routes: cyclooxygenases; lipoxygenases and cytochrome P450‐like epoxygenases, particularly [CYP2J2](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=242#show_object_1332). Isoprostanes are structural analogues of the prostanoids (hence the nomenclature D‐, E‐, F‐isoprostanes and isothromboxanes), which are produced in the presence of elevated free radicals in a non‐enzymatic manner, leading to suggestions for their use as biomarkers of oxidative stress. Molecular targets for their action have yet to be defined.

[Cyclooxygenase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=269) {#bph13354-sec-0147}
===========================================================================================

Overview {#bph13354-sec-0148}
--------

Prostaglandin (PG) G/H synthase, most commonly referred to as cyclooxygenase (COX, (5Z,8Z,11Z,14Z)‐icosa‐5,8,11,14‐tetraenoate,hydrogen‐donor : oxygen oxidoreductase) activity, catalyses the formation of [PGG~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5245) from [arachidonic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391). Hydroperoxidase activity inherent in the enzyme catalyses the formation of [PGH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483) from [PGG~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5245). COX‐1 and ‐2 can be nonselectively inhibited by [ibuprofen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2713), [ketoprofen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4795), [naproxen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5230), [indomethacin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1909) and [paracetamol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5239) (acetaminophen). PGH~2~ may then be metabolised to prostaglandins and thromboxanes by various prostaglandin synthases in an apparently tissue‐dependent manner.

Nomenclature[COX‐1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1375)[COX‐2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1376)HGNC, UniProt[*PTGS1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9604), [P23219](http://www.uniprot.org/uniprot/P23219)[*PTGS2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9605), [P35354](http://www.uniprot.org/uniprot/P35354)EC number[1.14.99.1](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.99.1): Hydrogen donor + [arachidonic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391) + 2O~2~ = hydrogen acceptor + H~2~O + [PGH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483) [arachidonic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391) =\>[PGG~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5245) =\>[PGH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483) This enzyme is also associated with the following reaction:: [docosahexaenoic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1051) =\> PGH~3~[1.14.99.1](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.99.1): Hydrogen donor + [arachidonic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391) + 2O~2~ = hydrogen acceptor + H~2~O + [PGH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483) [arachidonic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391) =\>[PGG~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5245) =\>[PGH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483) This enzyme is also associated with the following reaction:: [docosahexaenoic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1051) =\> PGH~3~Inhibitors[bromfenac](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7131) (pIC~50~ 8.1) \[[17](#bph13354-bib-0017){ref-type="ref"}\], [diclofenac](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2714) (pIC~50~ 7.9) \[[556](http://www.ncbi.nlm.nih.gov/pubmed/16252917?dopt=AbstractPlus)\], [meclofenamic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7219) (pIC~50~ 7.3) \[[247](http://www.ncbi.nlm.nih.gov/pubmed/11844663?dopt=AbstractPlus)\], [flurbiprofen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4194) (pIC~50~ 7.1) \[[512](http://www.ncbi.nlm.nih.gov/pubmed/10377455?dopt=AbstractPlus)\], [fenoprofen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4820) (pIC~50~ 6.8) \[[17](#bph13354-bib-0017){ref-type="ref"}\], [ketoprofen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4795) (pIC~50~ 6.5) \[[55](http://www.ncbi.nlm.nih.gov/pubmed/18667313?dopt=AbstractPlus)\], [suprofen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7298) (pIC~50~ 6.2) \[[55](http://www.ncbi.nlm.nih.gov/pubmed/18667313?dopt=AbstractPlus)\],[benzquinamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7124) (pIC~50~ 8.3) \[[17](#bph13354-bib-0017){ref-type="ref"}\], [flurbiprofen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4194) (pIC~50~ 8) \[[25](http://www.ncbi.nlm.nih.gov/pubmed/10091674?dopt=AbstractPlus)\], [meclofenamic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7219) (pIC~50~ 7.4) \[[247](http://www.ncbi.nlm.nih.gov/pubmed/11844663?dopt=AbstractPlus)\], [carprofen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7141) (pIC~50~ 7) \[[209](http://www.ncbi.nlm.nih.gov/pubmed/21873070?dopt=AbstractPlus)\], [ketorolac](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6661) (pIC~50~ 6.9) \[[503](http://www.ncbi.nlm.nih.gov/pubmed/22091869?dopt=AbstractPlus)\], [nimesulide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7401) (pIC~50~ 6.2) \[[366](http://www.ncbi.nlm.nih.gov/pubmed/15993594?dopt=AbstractPlus)\], [ketoprofen](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4795) (pIC~50~ 6.2) \[[55](http://www.ncbi.nlm.nih.gov/pubmed/18667313?dopt=AbstractPlus)\],Selective inhibitors[ketorolac](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6661) (pIC~50~ 9.7) \[[512](http://www.ncbi.nlm.nih.gov/pubmed/10377455?dopt=AbstractPlus)\], [FR122047](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5191) (pIC~50~ 7.5) \[[357](http://www.ncbi.nlm.nih.gov/pubmed/10720634?dopt=AbstractPlus)\][celecoxib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2892) (pIC~50~ 8.7) \[[38](http://www.ncbi.nlm.nih.gov/pubmed/12643942?dopt=AbstractPlus)\], [valdecoxib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2894) (pIC~50~ 8.3) \[[473](http://www.ncbi.nlm.nih.gov/pubmed/10715145?dopt=AbstractPlus)\], [diclofenac](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2714) (pIC~50~ 7.7) \[[42](http://www.ncbi.nlm.nih.gov/pubmed/17341061?dopt=AbstractPlus)\], [rofecoxib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2893) (pIC~50~ 6.1--6.5) \[[512](http://www.ncbi.nlm.nih.gov/pubmed/10377455?dopt=AbstractPlus)\], [lumiracoxib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2897) (p*K* ~i~ 6.5) \[[43](http://www.ncbi.nlm.nih.gov/pubmed/17434872?dopt=AbstractPlus)\], [meloxicam](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7220) (pIC~50~ 6.3) \[[280](http://www.ncbi.nlm.nih.gov/pubmed/9083488?dopt=AbstractPlus)\], [etoricoxib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2896) (pIC~50~ 6) \[[406](http://www.ncbi.nlm.nih.gov/pubmed/11160644?dopt=AbstractPlus)\]

[Prostaglandin synthases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=270) {#bph13354-sec-0149}
====================================================================================================

Overview {#bph13354-sec-0150}
--------

Subsequent to the formation of [PGH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483), the [cytochrome P450 activities](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=242) thromboxane synthase (CYP5A1, [*TBXAS1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11609), [P24557](http://www.uniprot.org/uniprot/P24557), [EC 5.3.99.5](http://www.genome.jp/kegg-bin/search_brite?option=-a&search_string=5.3.99.5)) and prostacyclin synthase (CYP8A1, [*PTGIS*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9603), [Q16647](http://www.uniprot.org/uniprot/Q16647), [EC 5.3.99.4](http://www.genome.jp/kegg-bin/search_brite?option=-a&search_string=5.3.99.4)) generate [thromboxane A~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482) and prostacyclin ([PGI~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915)), respectively. Additionally, multiple enzyme activities are able to generate prostaglandin E~2~([PGE~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883)), prostaglandin D~2~([PGD~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881)) and prostaglandin F~2*α*~([PGF~2*α*~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884)). PGD~2~ can be metabolised to 9*α*,11*β*‐prostacyclin F~2*α*~ through the multifunctional enzyme activity of AKR1C3. PGE~2~ can be metabolised to [9*α*,11*β*‐prostaglandin F~2*α*~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5129) through the 9‐ketoreductase activity of CBR1. Conversion of the 15‐hydroxyecosanoids, including prostaglandins, lipoxins and leukotrienes to their keto derivatives by the NAD‐dependent enzyme HPGD leads to a reduction in their biological activity.

Nomenclature[CYP5A1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1353)[CYP8A1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1356)[mPGES1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1377)[mPGES2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1378)[cPGES](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1379)Common name--Prostacyclin synthase------HGNC, UniProt[*TBXAS1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11609), [P24557](http://www.uniprot.org/uniprot/P24557)[*PTGIS*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9603), [Q16647](http://www.uniprot.org/uniprot/Q16647)[*PTGES*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9599), [O14684](http://www.uniprot.org/uniprot/O14684)[*PTGES2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17822), [Q9H7Z7](http://www.uniprot.org/uniprot/Q9H7Z7)[*PTGES3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=16049), [Q15185](http://www.uniprot.org/uniprot/Q15185)EC number[5.3.99.5](http://www.genome.jp/dbget-bin/www_bget?ec:5.3.99.5): [PGH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483) = [thromboxane A~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4482)[5.3.99.4](http://www.genome.jp/dbget-bin/www_bget?ec:5.3.99.4)[5.3.99.3](http://www.genome.jp/dbget-bin/www_bget?ec:5.3.99.3): [PGH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483) = [PGE~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883)[5.3.99.3](http://www.genome.jp/dbget-bin/www_bget?ec:5.3.99.3): [PGH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483) = [PGE~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883)[5.3.99.3](http://www.genome.jp/dbget-bin/www_bget?ec:5.3.99.3): [PGH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483) = [PGE~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883)Cofactors----[glutathione](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6737)[dihydrolipoic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6738)--CommentsInhibited by [dazoxiben](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5175) \[[398](http://www.ncbi.nlm.nih.gov/pubmed/6795753?dopt=AbstractPlus)\] and [camonagrel](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5157) \[[182](http://www.ncbi.nlm.nih.gov/pubmed/7778318?dopt=AbstractPlus)\].Converts [PGH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483) to [PGI~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1915) \[[196](http://www.ncbi.nlm.nih.gov/pubmed/8766713?dopt=AbstractPlus)\]. Inhibited by [tranylcypromine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5281) \[[181](http://www.ncbi.nlm.nih.gov/pubmed/824685?dopt=AbstractPlus)\]----Phosphorylated and activated by casein kinase 2 ([CK2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?familyId=565&objectId=1548&familyType=ENZYME)) \[[260](http://www.ncbi.nlm.nih.gov/pubmed/15040786?dopt=AbstractPlus)\]. Appears to regulate steroid hormone function by interaction with dimeric hsp90 \[[69](http://www.ncbi.nlm.nih.gov/pubmed/11050175?dopt=AbstractPlus), [241](http://www.ncbi.nlm.nih.gov/pubmed/8603045?dopt=AbstractPlus)\].

Nomenclature[L‐PGDS](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1380)[H‐PGDS](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1381)[AKR1C3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1382)[CBR1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1383)[HPGD](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1384)HGNC, UniProt[*PTGDS*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9592), [P41222](http://www.uniprot.org/uniprot/P41222)[*HPGDS*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17890), [O60760](http://www.uniprot.org/uniprot/O60760)[*AKR1C3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=386), [P42330](http://www.uniprot.org/uniprot/P42330)[*CBR1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1548), [P16152](http://www.uniprot.org/uniprot/P16152)[*HPGD*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5154), [P15428](http://www.uniprot.org/uniprot/P15428)EC number[5.3.99.2](http://www.genome.jp/dbget-bin/www_bget?ec:5.3.99.2): [PGH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483) = [PGD~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881)[5.3.99.2](http://www.genome.jp/dbget-bin/www_bget?ec:5.3.99.2): [PGH~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4483) = [PGD~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881)[1.3.1.20](http://www.genome.jp/dbget-bin/www_bget?ec:1.3.1.20) [1.1.1.188](http://www.genome.jp/dbget-bin/www_bget?ec:1.1.1.188): [PGD~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1881) + [NADP^+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045) = [PGF~2*α*~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884) + [NADPH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041) + H^+^ [1.1.1.64](http://www.genome.jp/dbget-bin/www_bget?ec:1.1.1.64) [1.1.1.239](http://www.genome.jp/dbget-bin/www_bget?ec:1.1.1.239) [1.1.1.213](http://www.genome.jp/dbget-bin/www_bget?ec:1.1.1.213)[1.1.1.184](http://www.genome.jp/dbget-bin/www_bget?ec:1.1.1.184) [1.1.1.189](http://www.genome.jp/dbget-bin/www_bget?ec:1.1.1.189): [PGE~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1883) + [NADP^+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045) = [PGF~2*α*~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1884) + [NADPH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041) + H^+^ [1.1.1.197](http://www.genome.jp/dbget-bin/www_bget?ec:1.1.1.197)[1.1.1.141](http://www.genome.jp/dbget-bin/www_bget?ec:1.1.1.141) 15‐hydroxyprostaglandins =\> 15‐ketoprostaglandins [LXA~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1034) =\> 15‐keto‐lipoxin A~4~Inhibitors----[flufenamic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2447), [indomethacin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1909), flavonoids \[[321](http://www.ncbi.nlm.nih.gov/pubmed/9792917?dopt=AbstractPlus), [446](http://www.ncbi.nlm.nih.gov/pubmed/19007764?dopt=AbstractPlus)\]----Cofactors----[NADP^+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045)[NADP^+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045)--Inhibitors--[HQL‐79](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6662) (pIC~50~ 5.3--5.5) \[[15](http://www.ncbi.nlm.nih.gov/pubmed/16547010?dopt=AbstractPlus)\]--[wedelolactone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5551) (pIC~50~ 5.4) \[[555](http://www.ncbi.nlm.nih.gov/pubmed/19097799?dopt=AbstractPlus)\]--Comments----Also acts as a hydroxysteroid dehydrogenase activity.----

Comments {#bph13354-sec-0151}
--------

[YS121](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5293) has been reported to inhibit mPGES1 and 5‐LOX with a *p*IC~50~value of 5.5 \[[263](http://www.ncbi.nlm.nih.gov/pubmed/19053751?dopt=AbstractPlus)\].

[Lipoxygenases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=271) {#bph13354-sec-0152}
==========================================================================================

Overview {#bph13354-sec-0153}
--------

The lipoxygenases (LOXs) are a structurally related family of non‐heme iron dioxygenases that function in the production, and in some cases metabolism, of fatty acid hydroperoxides. For [arachidonic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391) as substrate, these products are hydroperoxyeicosatetraenoic acids (HPETEs). In humans there are five lipoxygenases, the 5S‐(arachidonate : oxygen 5‐oxidoreductase), 12R‐(arachidonate 12‐lipoxygenase, 12R‐type), 12S‐(arachidonate : oxygen 12‐oxidoreductase), and two distinct 15S‐(arachidonate : oxygen 15‐oxidoreductase) LOXs that oxygenate arachidonic acid in different positions along the carbon chain and form the corresponding 5S‐, 12S‐, 12R‐, or 15S‐hydroperoxides, respectively.

Nomenclature[5‐LOX](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1385)[12R‐LOX](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1386)[12S‐LOX](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1387)[15‐LOX‐1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1388)[15‐LOX‐2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1389)[E‐LOX](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1390)HGNC, UniProt[*ALOX5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=435), [P09917](http://www.uniprot.org/uniprot/P09917)[*ALOX12B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=430), [O75342](http://www.uniprot.org/uniprot/O75342)[*ALOX12*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=429), [P18054](http://www.uniprot.org/uniprot/P18054)[*ALOX15*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=433), [P16050](http://www.uniprot.org/uniprot/P16050)[*ALOX15B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=434), [O15296](http://www.uniprot.org/uniprot/O15296)[*ALOXE3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13743), [Q9BYJ1](http://www.uniprot.org/uniprot/Q9BYJ1)EC number[1.13.11.34](http://www.genome.jp/dbget-bin/www_bget?ec:1.13.11.34): [arachidonic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391) + O~2~ = [LTA~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5214) + H~2~O[1.13.11.31](http://www.genome.jp/dbget-bin/www_bget?ec:1.13.11.31) [arachidonic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391) + O~2~ =\>[12R‐HPETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5101)[1.13.11.31](http://www.genome.jp/dbget-bin/www_bget?ec:1.13.11.31) [arachidonic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391) + O~2~ =\>[12S‐HPETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2481)[1.13.11.33](http://www.genome.jp/dbget-bin/www_bget?ec:1.13.11.33): [arachidonic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391) + O~2~ = [15S‐HPETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2482) [linoleic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1052) + O~2~ =\> 13S‐HPODE[1.13.11.33](http://www.genome.jp/dbget-bin/www_bget?ec:1.13.11.33): [arachidonic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391) + O~2~ = [15S‐HPETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2482)[1.13.11.‐](http://www.genome.jp/dbget-bin/www_bget?ec:1.13.11.-)Endogenous inhibitorProtein kinase A‐mediated phosphorylation \[[304](http://www.ncbi.nlm.nih.gov/pubmed/15280375?dopt=AbstractPlus)\]----------Substrates--[methyl arachidonate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5222)--------Endogenous substrates[arachidonic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391)--------[12R‐HPETE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5101)Endogenous activators[5‐LOX activating protein](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5183) ([*ALOX5AP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=436), [P20292](http://www.uniprot.org/uniprot/P20292))----------Selective inhibitors[CJ13610](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5169) (pIC~50~ 7.2) \[[136](http://www.ncbi.nlm.nih.gov/pubmed/15197110?dopt=AbstractPlus)\], [zileuton](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5297)----------CommentsFLAP activity can be inhibited by [MK‐886](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2655) \[[116](http://www.ncbi.nlm.nih.gov/pubmed/2300173?dopt=AbstractPlus)\] and [BAY‐X1005](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5148) \[[197](http://www.ncbi.nlm.nih.gov/pubmed/8381000?dopt=AbstractPlus)\] leading to a selective inhibition of 5‐LOX activity--------E‐LOX metabolises the product from the 12R‐lipoxygenase (12R‐HPETE) to a specific epoxyalcohol compound \[[543](http://www.ncbi.nlm.nih.gov/pubmed/12881489?dopt=AbstractPlus)\].

Comments {#bph13354-sec-0154}
--------

An 8‐LOX ([EC 1.13.11.40](http://www.genome.jp/kegg-bin/search_brite?option=-a&search_string=1.13.11.40), arachidonate:oxygen 8‐oxidoreductase) may be the mouse orthologue of 15‐LOX‐2 \[[158](http://www.ncbi.nlm.nih.gov/pubmed/12432921?dopt=AbstractPlus)\]. Some general LOX inhibitors are [nordihydroguiaretic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4265) and [esculetin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5180). [Zileuton](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5297) and [caffeic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5155) are used as 5‐lipoxygenase inhibitors, while [baicalein](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5144) and [CDC](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5162) are 12‐lipoxygenase inhibitors. The specificity of these inhibitors has not been rigorously assessed with all LOX forms: [baicalein](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5144), along with other flavonoids, such as [fisetin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5182) and [luteolin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5215), also inhibits 15‐LOX‐1 \[[414](http://www.ncbi.nlm.nih.gov/pubmed/12628491?dopt=AbstractPlus)\].

1. [Leukotriene and lipoxin metabolism](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=272) {#bph13354-sec-0155}
==================================================================================================================

Overview {#bph13354-sec-0156}
--------

Leukotriene A~4~([LTA~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5214)), produced by 5‐LOX activity, and lipoxins may be subject to further oxidative metabolism; *ω*‐hydroxylation is mediated by [CYP4F2](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=242#show_object_1344) and [CYP4F3](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=242#show_object_1345), while *β*‐oxidation in mitochondria and peroxisomes proceeds in a manner dependent on coenzyme A conjugation. Conjugation of [LTA~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5214) at the 6 position with reduced glutathione to generate [LTC~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354) occurs under the influence of leukotriene C~4~ synthase, with the subsequent formation of [LTD~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353) and [LTE~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3352), all three of which are agonists at [CysLT receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=35). [LTD~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353) formation is catalysed by *γ*‐glutamyltransferase, and subsequently dipeptidase 2 removes the terminal [glycine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727) from [LTD~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353) to generate [LTE~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3352). Leukotriene A~4~ hydrolase converts the 5,6‐epoxide LTA~4~ to the 5‐hydroxylated LTB~4~, an agonist for [BLT receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=35). [LTA~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5214) is also acted upon by 12S‐LOX to produce the trihydroxyeicosatetraenoic acids lipoxins [LXA~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1034) and [LXB~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5216). Treatment with a LTA~4~ hydrolase inhibitor in a murine model of allergic airway inflammation increased LXA~4~ levels, in addition to reducing [LTB~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2487), in lung lavage fluid \[[400](http://www.ncbi.nlm.nih.gov/pubmed/20110560?dopt=AbstractPlus)\].

LTA~4~ hydrolase is also involved in biosynthesis of [resolvin Es](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=134). [Aspirin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4139) has been reported to increase endogenous formation of 18S‐hydroxyeicosapentaenoate ([18S‐HEPE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5105)) compared with [18R‐HEPE](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3400), a resolvin precursor. Both enantiomers may be metabolised by human recombinant 5‐LOX; recombinant LTA~4~hydrolase converted chiral 5S(6)‐epoxide‐containing intermediates to [resolvin E1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3333) and [18S‐resolvin E1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5106) \[[358](http://www.ncbi.nlm.nih.gov/pubmed/21206090?dopt=AbstractPlus)\].

Nomenclature[Leukotriene C4 synthase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1391)[*γ*‐Glutamyltransferase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1392)[Dipeptidase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1393)[Dipeptidase 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1394)HGNC, UniProt[*LTC4S*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6719), [Q16873](http://www.uniprot.org/uniprot/Q16873)[*GGCT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=21705), [O75223](http://www.uniprot.org/uniprot/O75223)[*DPEP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3002), [P16444](http://www.uniprot.org/uniprot/P16444)[*DPEP2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23028), [Q9H4A9](http://www.uniprot.org/uniprot/Q9H4A9)EC number[4.4.1.20](http://www.genome.jp/dbget-bin/www_bget?ec:4.4.1.20): [LTC~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354) = [glutathione](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6737) + [LTA~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5214)[2.3.2.2](http://www.genome.jp/dbget-bin/www_bget?ec:2.3.2.2): (5‐L‐glutamyl)‐peptide + an amino acid = a peptide + a 5‐L‐glutamyl amino acid [LTC~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3354) + H~2~O =\>[LTD~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353) + L‐glutamate[3.4.13.19](http://www.genome.jp/dbget-bin/www_bget?ec:3.4.13.19): [LTD~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353) + H~2~O = [LTE~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3352) + [glycine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727)[3.4.13.19](http://www.genome.jp/dbget-bin/www_bget?ec:3.4.13.19): [LTD~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353) + H~2~O = [LTE~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3352) + [glycine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=727)Inhibitors----[cilastatin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5166) (p*K* ~i~ 6) \[[179](http://www.ncbi.nlm.nih.gov/pubmed/3495664?dopt=AbstractPlus)\] -- Unknown--

Comments {#bph13354-sec-0157}
--------

LTA4H is a member of a family of arginyl aminopeptidases ([ENSFM00250000001675](http://www.ensembl.org/Homo_sapiens/Gene/Family/Genes?family=ENSFM00250000001675)), which also includes aminopeptidase B ([*RNPEP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10078), [9H4A4](http://www.uniprot.org/uniprot/9H4A4)) and aminopeptidase B‐like 1 ([*RNPEPL1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10079), [Q9HAU8](http://www.uniprot.org/uniprot/Q9HAU8)). Dipeptidase 1 and 2 are members of a family of membrane dipeptidases, which also includes ([*DPEP3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23029), [Q9H4B8](http://www.uniprot.org/uniprot/Q9H4B8)) for which [LTD~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3353) appears not to be a substrate.

Further Reading {#bph13354-sec-0158}
---------------
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Smith WL *et al*. (2011) Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. *Chem. Rev.* **111**: 5821‐65 [\[PMID:21942677\]](http://www.ncbi.nlm.nih.gov/pubmed/21942677?dopt=AbstractPlus)
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2. [GABA turnover](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=764) {#bph13354-sec-0159}
=============================================================================================

Overview {#bph13354-sec-0160}
--------

The inhibitory neurotransmitter *γ*‐aminobutyrate (GABA, 4‐aminobutyrate) is generated in neurones by glutamic acid decarboxylase. GAD1 and GAD2 are differentially expressed during development, where GAD2 is thought to subserve a trophic role in early life and is distributed throughout the cytoplasm. GAD1 is expressed in later life and is more associated with nerve terminals \[[128](http://www.ncbi.nlm.nih.gov/pubmed/8126575?dopt=AbstractPlus)\] where GABA is principally accumulated in vesicles through the action of the vesicular inhibitory amino acid transporter [SLC32A1](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=219). The role of *γ*‐aminobutyraldehyde dehydrogenase (ALDH9A1) in neurotransmitter GABA synthesis is less clear. Following release from neurons, GABA may interact with either GABA~A~ or GABA~B~ receptors and may be accumulated in neurones and glia through the action of members of the [SLC6 family of transporters](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=144). Successive metabolism through GABA transaminase and succinate semialdehyde dehydrogenase generates succinic acid, which may be further metabolized in the mitochondria in the tricarboxylic acid cycle.

Nomenclature[Glutamic acid](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1272)[aldehyde dehydrogenase 9](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2467)[4‐aminobutyrate](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2464)[aldehyde dehydrogenase 5](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2466)[decarboxylase 1,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1272)[family, member A1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2467)[aminotransferase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2464)[family, member A1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2466)[decarboxylase 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1272)Common abreviationGAD1, GAD2--GABA‐TSSADHHGNC, UniProt[*GAD1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4092), [Q99259](http://www.uniprot.org/uniprot/Q99259),[*ALDH9A1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=412), [P49189](http://www.uniprot.org/uniprot/P49189)[*ABAT*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23), [P80404](http://www.uniprot.org/uniprot/P80404)[*ALDH5A1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=408), [P51649](http://www.uniprot.org/uniprot/P51649)[*GAD2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4093), [Q05329](http://www.uniprot.org/uniprot/Q05329)EC number[4.1.1.15](http://www.genome.jp/dbget-bin/www_bget?ec:4.1.1.15): [L‐glutamic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369) + H^+^ ‐\>[GABA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067) + CO~2~[1.2.1.19](http://www.genome.jp/dbget-bin/www_bget?ec:1.2.1.19): [4‐aminobutanal](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6606) + [NAD](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451) + H~2~O = [GABA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067) + [NADH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4487) + H^+^ [1.2.1.47](http://www.genome.jp/dbget-bin/www_bget?ec:1.2.1.47): [4‐trimethylammoniobutanal](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6604) + [NAD](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451) + H~2~O = [4‐trimethylammoniobutanoate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6605) + [NADPH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041) + 2H^+^ [1.2.1.3](http://www.genome.jp/dbget-bin/www_bget?ec:1.2.1.3): an aldehyde + H~2~O + [NAD](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451) = a carboxylate + 2H^+^ + [NADH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4487)[2.6.1.19](http://www.genome.jp/dbget-bin/www_bget?ec:2.6.1.19): [GABA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067) + [*α*‐ketoglutaric acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3636) = [L‐glutamic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369) + [4‐oxobutanoate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6608) [2.6.1.22](http://www.genome.jp/dbget-bin/www_bget?ec:2.6.1.22): [(S)‐3‐amino‐2‐methylpropanoate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6610) + [*α*‐ketoglutaric acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3636) = [2‐methyl‐3‐oxopropanoate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6611) + [L‐glutamic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369)[1.2.1.24](http://www.genome.jp/dbget-bin/www_bget?ec:1.2.1.24): [4‐oxobutanoate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6608) + [NAD](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451) + H~2~O = [succinic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3637) + [NADH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4487) + 2H^+^ 4‐hydroxy‐trans‐2‐nonenal + [NAD](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451) + H~2~O = 4‐hydroxy‐trans‐2‐nonenoate + [NADH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4487) + 2H^+^Endogenous substrates[L‐glutamic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1369), [L‐aspartic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309)------Products[GABA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1067)------Cofactors[pyridoxal phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249)[NAD](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451)[pyridoxal phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249)[NAD](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2451) \[[432](http://www.ncbi.nlm.nih.gov/pubmed/22677141?dopt=AbstractPlus)\]Inhibitors----[vigabatrin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4821) (Irreversible inhibition) (p*K* ~i~ 3.1) \[[289](http://www.ncbi.nlm.nih.gov/pubmed/856582?dopt=AbstractPlus), [437](http://www.ncbi.nlm.nih.gov/pubmed/22168767?dopt=AbstractPlus)\]--Selective inhibitors[s‐allylglycine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5267)------Comments[L‐aspartic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3309) is a less rapidly metabolised substrate of mouse brain glutamic acid decarboxylase generating *β*‐alanine \[[530](http://www.ncbi.nlm.nih.gov/pubmed/4700449?dopt=AbstractPlus)\]. Autoantibodies against GAD1 and GAD2 are elevated in type 1 diabetes mellitus and neurological disorders (see Further reading).------

Further Reading {#bph13354-sec-0161}
---------------
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3. [Glycerophospholipid turnover](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=244) {#bph13354-sec-0162}
============================================================================================================

Overview {#bph13354-sec-0163}
--------

Phospholipids are the basic barrier components of membranes in eukaryotic cells divided into glycerophospholipids (phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, phosphatidylinositol and its phosphorylated derivatives) and sphingolipids (ceramide phosphorylcholine and ceramide phosphorylethanolamine).

4. [Phosphatidylinositol kinases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=781) {#bph13354-sec-0164}
============================================================================================================

Overview {#bph13354-sec-0165}
--------

Phosphatidylinositol may be phosphorylated at either 3‐ or 4‐ positions on the inositol ring by PI 3‐kinases or PI 4‐kinases, respectively.

**Phosphatidylinositol 3‐kinases**Phosphatidylinositol 3‐kinases (PI3K, provisional nomenclature) catalyse the introduction of a phosphate into the 3‐position of phosphatidylinositol (PI), phosphatidylinositol 4‐phosphate (PIP) or phosphatidylinositol 4,5‐bisphosphate (PIP~2~). There is evidence that PI3K can also phosphorylate serine/threonine residues on proteins. In addition to the classes described below, further serine/threonine protein kinases, including [ATM](http://www.genenames.org/data/hgnc_data.php?hgnc_id=795) ([Q13315](http://www.uniprot.org/uniprot/Q13315)) and [mTOR](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3942)([P42345](http://www.uniprot.org/uniprot/P42345)), have been described to phosphorylate phosphatidylinositol and have been termed PI3K‐related kinases. Structurally, PI3K have common motifs of at least one C2, calcium‐binding domain and helical domains, alongside structurally‐conserved catalytic domains. [Wortmannin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6060) and LY294002 are widely‐used inhibitors of PI3K activities. [Wortmannin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6060) is irreversible and shows modest selectivity between Class I and Class II PI3K, while LY294002 is reversible and selective for Class I compared to Class II PI3K.

**Class I PI3Ks** (EC 2.7.1.153) phosphorylate phosphatidylinositol 4,5‐bisphosphate to generate phosphatidylinositol 3,4,5‐trisphosphate and are heterodimeric, matching catalytic and regulatory subunits. Class IA PI3Ks include p110*α*, p110*β* and p110*δ* catalytic subunits, with predominantly p85 and p55 regulatory subunits. The single catalytic subunit that forms Class IB PI3K is p110*γ*. Class IA PI3Ks are more associated with receptor tyrosine kinase pathways, while the Class IB PI3K is linked more with GPCR signalling.

**Class II PI3Ks** (EC 2.7.1.154) phosphorylate phosphatidylinositol to generate phosphatidylinositol 3‐phosphate (and possibly phosphatidylinositol 4‐phosphate to generate phosphatidylinositol 3,4‐bisphosphate). Three monomeric members exist, PI3K‐C2*α*, *β* and *γ*, and include Ras‐binding, Phox homology and two C2domains.

The only **class III PI3K** isoform (EC 2.7.1.137) is a heterodimer formed of a catalytic subunit (VPS34) and regulatory subunit (VPS15).

**Phosphatidylinositol 4‐kinases**Phosphatidylinositol 4‐kinases (EC 2.7.1.67) generate phosphatidylinositol 4‐phosphate and may be divided into higher molecular weight type III and lower molecular weight type II forms.

5. [1‐phosphatidylinositol 4‐kinase family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=638) {#bph13354-sec-0166}
======================================================================================================================

Nomenclature[phosphatidylinositol 4‐kinase, catalytic, alpha](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2148)[phosphatidylinositol 4‐kinase, catalytic, beta](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2149)Common abreviationPI4KIII*α*/PIK4CAPI4KIII*β*/PIK4CBHGNC, UniProt[*PI4KA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8983), [P42356](http://www.uniprot.org/uniprot/P42356)[*PI4KB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8984), [Q9UBF8](http://www.uniprot.org/uniprot/Q9UBF8)EC number[2.7.1.67](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.1.67)[2.7.1.67](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.1.67)Endogenous activation--PKD‐mediated phosphorylation \[[199](http://www.ncbi.nlm.nih.gov/pubmed/16100512?dopt=AbstractPlus)\](Sub)family‐selective inhibitors[wortmannin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6060) (pIC~50~ 6.7--6.8) \[[170](http://www.ncbi.nlm.nih.gov/pubmed/10101268?dopt=AbstractPlus), [329](http://www.ncbi.nlm.nih.gov/pubmed/9020160?dopt=AbstractPlus)\][wortmannin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6060) (pIC~50~ 6.7--6.8) \[[170](http://www.ncbi.nlm.nih.gov/pubmed/10101268?dopt=AbstractPlus), [329](http://www.ncbi.nlm.nih.gov/pubmed/9020160?dopt=AbstractPlus)\]Selective inhibitors--[PIK‐93](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6062) \[[259](http://www.ncbi.nlm.nih.gov/pubmed/16647110?dopt=AbstractPlus)\]

6. [Phosphatidylinositol‐4‐phosphate 3‐kinase family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=671) {#bph13354-sec-0167}
================================================================================================================================

Nomenclature[phosphatidylinositol‐4‐phosphate 3‐kinase,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2150)[phosphatidylinositol‐4‐phosphate 3‐kinase,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2151)[phosphatidylinositol‐4‐phosphate 3‐kinase,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2288)[catalytic subunit type 2 alpha](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2150)[catalytic subunit type 2 beta](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2151)[catalytic subunit type 2 gamma](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2288)Common abreviationC2*α*/PIK3C2AC2*β*/PIK3C2BC2*γ*/PIK3C2GHGNC, UniProt[*PIK3C2A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8971), [O00443](http://www.uniprot.org/uniprot/O00443)[*PIK3C2B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8972), [O00750](http://www.uniprot.org/uniprot/O00750)[*PIK3C2G*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8973), [O75747](http://www.uniprot.org/uniprot/O75747)EC number[2.7.1.154](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.1.154)[2.7.1.154](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.1.154)[2.7.1.154](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.1.154)

7. [Phosphatidylinositol 3‐kinase family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=672) {#bph13354-sec-0168}
====================================================================================================================

Nomenclature[phosphatidylinositol 3‐kinase, catalytic subunit type 3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2152)Common abreviationVPS34/PIK3C3HGNC, UniProt[*PIK3C3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8974), [Q8NEB9](http://www.uniprot.org/uniprot/Q8NEB9)EC number[2.7.1.137](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.1.137)

8. [Phosphatidylinositol‐4,5‐bisphosphate 3‐kinase family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=673) {#bph13354-sec-0169}
=====================================================================================================================================

Nomenclature[phosphatidylinositol‐4,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2153)[phosphatidylinositol‐4,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2154)[phosphatidylinositol‐4,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2156)[phosphatidylinositol‐4,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155)[5-bisphosphate 3-kinase,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)[5-bisphosphate 3-kinase,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)[5-bisphosphate 3-kinase,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)[5-bisphosphate 3-kinase,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)[catalytic subunit alpha](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)[catalytic subunit beta](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)[catalytic subunit gamma](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)[catalytic subunit delta](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)Common abreviationp110*α*/PIK3CAp110*β*/PIK3CBp110*γ*/PIK3CGp110*δ*/PIK3CDHGNC, UniProt[*PIK3CA*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8975), [P42336](http://www.uniprot.org/uniprot/P42336)[*PIK3CB*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8976), [P42338](http://www.uniprot.org/uniprot/P42338)[*PIK3CG*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8978), [P48736](http://www.uniprot.org/uniprot/P48736)[*PIK3CD*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8977), [O00329](http://www.uniprot.org/uniprot/O00329)EC number[2.7.1.153](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.1.153)[2.7.1.153](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.1.153)[2.7.1.153](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.1.153)[2.7.1.153](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.1.153)[2.7.11.1](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.11.1)Inhibitors[PIK‐75](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8012) (pIC~50~ 9.5) \[[200](http://www.ncbi.nlm.nih.gov/pubmed/17601739?dopt=AbstractPlus)\], [gedatolisib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7940) (pIC~50~ 9.4) \[[500](http://www.ncbi.nlm.nih.gov/pubmed/20166697?dopt=AbstractPlus)\], [PF‐04691502](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7936) (p*K* ~i~ 9.2) \[[290](http://www.ncbi.nlm.nih.gov/pubmed/24900269?dopt=AbstractPlus)\], [PI‐103](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701) (pIC~50~ 8.7) \[[404](http://www.ncbi.nlm.nih.gov/pubmed/19584227?dopt=AbstractPlus)\], [BGT‐226](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7951) (pIC~50~ 8.4) \[[315](http://www.ncbi.nlm.nih.gov/pubmed/22357447?dopt=AbstractPlus)\], [KU‐0060648](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8011) (pIC~50~ 8.4) \[[60](http://www.ncbi.nlm.nih.gov/pubmed/23855836?dopt=AbstractPlus)\], [dactolisib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950) (pIC~50~ 8.4) \[[310](http://www.ncbi.nlm.nih.gov/pubmed/18606717?dopt=AbstractPlus)\], [apitolisib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888) (pIC~50~ 8.3) \[[467](http://www.ncbi.nlm.nih.gov/pubmed/21981714?dopt=AbstractPlus)\], [alpelisib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7955) (pIC~50~ 8.3) \[[155](http://www.ncbi.nlm.nih.gov/pubmed/23726034?dopt=AbstractPlus)\], [PIK‐75](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8012) (pIC~50~ 8.2) \[[259](http://www.ncbi.nlm.nih.gov/pubmed/16647110?dopt=AbstractPlus)\], [buparlisib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7878) (pIC~50~ 7.5) \[[49](http://www.ncbi.nlm.nih.gov/pubmed/24900266?dopt=AbstractPlus)\], [PP121](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8013) (pIC~50~ 7.3) \[[14](http://www.ncbi.nlm.nih.gov/pubmed/18849971?dopt=AbstractPlus)\][KU‐0060648](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8011) (pIC~50~ 9.3) \[[60](http://www.ncbi.nlm.nih.gov/pubmed/23855836?dopt=AbstractPlus)\], [PI‐103](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701) (pIC~50~ 8.5) \[[404](http://www.ncbi.nlm.nih.gov/pubmed/19584227?dopt=AbstractPlus)\], [AZD6482](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8059) (pIC~50~ 8) \[[355](http://www.ncbi.nlm.nih.gov/pubmed/22906130?dopt=AbstractPlus)\], [ZSTK474](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7965) (pIC~50~ 7.8) \[[535](http://www.ncbi.nlm.nih.gov/pubmed/16622124?dopt=AbstractPlus)\], [apitolisib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888) (pIC~50~ 7.6) \[[467](http://www.ncbi.nlm.nih.gov/pubmed/21981714?dopt=AbstractPlus)\], [BGT‐226](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7951) (pIC~50~ 7.2) \[[315](http://www.ncbi.nlm.nih.gov/pubmed/22357447?dopt=AbstractPlus)\][dactolisib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950) (pIC~50~ 8.3) \[[310](http://www.ncbi.nlm.nih.gov/pubmed/18606717?dopt=AbstractPlus)\], [apitolisib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888) (pIC~50~ 7.8) \[[467](http://www.ncbi.nlm.nih.gov/pubmed/21981714?dopt=AbstractPlus)\], [PI‐103](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701) (pIC~50~ 7.8) \[[404](http://www.ncbi.nlm.nih.gov/pubmed/19584227?dopt=AbstractPlus)\], [BGT‐226](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7951) (pIC~50~ 7.4) \[[315](http://www.ncbi.nlm.nih.gov/pubmed/22357447?dopt=AbstractPlus)\], [ZSTK474](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7965) (pIC~50~ 7.3) \[[535](http://www.ncbi.nlm.nih.gov/pubmed/16622124?dopt=AbstractPlus)\], [TG‐100‐115](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5715) (pIC~50~ 7.1) \[[369](http://www.ncbi.nlm.nih.gov/pubmed/17685602?dopt=AbstractPlus)\], [alpelisib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7955) (pIC~50~ 6.6) \[[155](http://www.ncbi.nlm.nih.gov/pubmed/23726034?dopt=AbstractPlus)\], [KU‐0060648](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8011) (pIC~50~ 6.2) \[[60](http://www.ncbi.nlm.nih.gov/pubmed/23855836?dopt=AbstractPlus)\][KU‐0060648](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8011) (pIC~50~\>10) \[[60](http://www.ncbi.nlm.nih.gov/pubmed/23855836?dopt=AbstractPlus)\], [idelalisib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6741) (*in vitro* activity against recombinant enzyme) (pIC~50~ 8.6) \[[276](http://www.ncbi.nlm.nih.gov/pubmed/20959606?dopt=AbstractPlus)\], [PI‐103](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5701) (pIC~50~ 8.5) \[[404](http://www.ncbi.nlm.nih.gov/pubmed/19584227?dopt=AbstractPlus)\], [ZSTK474](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7965) (pIC~50~ 8.2) \[[535](http://www.ncbi.nlm.nih.gov/pubmed/16622124?dopt=AbstractPlus)\], [apitolisib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7888) (pIC~50~ 8.2) \[[467](http://www.ncbi.nlm.nih.gov/pubmed/21981714?dopt=AbstractPlus)\], [dactolisib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7950) (pIC~50~ 8.1) \[[310](http://www.ncbi.nlm.nih.gov/pubmed/18606717?dopt=AbstractPlus)\], [alpelisib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7955) (pIC~50~ 6.5) \[[155](http://www.ncbi.nlm.nih.gov/pubmed/23726034?dopt=AbstractPlus)\](Sub)family‐selective inhibitors[pictilisib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5682) (pIC~50~ 8.5) \[[141](http://www.ncbi.nlm.nih.gov/pubmed/18754654?dopt=AbstractPlus)\][pictilisib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5682) (pIC~50~ 7.5) \[[141](http://www.ncbi.nlm.nih.gov/pubmed/18754654?dopt=AbstractPlus)\][pictilisib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5682) (pIC~50~ 7.1) \[[141](http://www.ncbi.nlm.nih.gov/pubmed/18754654?dopt=AbstractPlus)\][pictilisib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5682) (pIC~50~ 8.5) \[[141](http://www.ncbi.nlm.nih.gov/pubmed/18754654?dopt=AbstractPlus)\]Selective inhibitors----[CZC 24832](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6653) (p*K* ~d~ 7.7) \[[30](http://www.ncbi.nlm.nih.gov/pubmed/22544264?dopt=AbstractPlus)\], [CZC 24832](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6653) (pIC~50~ 7.6) \[[30](http://www.ncbi.nlm.nih.gov/pubmed/22544264?dopt=AbstractPlus)\]--

9. [1‐phosphatidylinositol‐3‐phosphate 5‐kinase family](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=913) {#bph13354-sec-0170}
==================================================================================================================================

Nomenclature[phosphoinositide kinase, FYVE finger containing](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2857)HGNC, UniProt[*PIKFYVE*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23785), [Q9Y2I7‐4](http://www.uniprot.org/uniprot/Q9Y2I7-4)EC number[2.7.1.150](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.1.150): ATP + 1‐phosphatidyl‐1D‐myo‐inositol 3‐phosphate = ADP + 1‐phosphatidyl‐1D‐myo‐inositol 3,5‐bisphosphate

10. [Type I PIP kinases (1‐phosphatidylinositol‐4‐phosphate 5‐kinase family)](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=675) {#bph13354-sec-0171}
========================================================================================================================================================

Overview {#bph13354-sec-0172}
--------

Type I PIP kinases are required for the production of the second messenger phosphatidylinositol 4,5‐bisphosphate (PtdIns(4,5)P2) by phosphorylating PtdIns(4)P \[[397](http://www.ncbi.nlm.nih.gov/pubmed/9367159?dopt=AbstractPlus)\]. This enzyme family is also known as type I PIP(5)Ks.

Nomenclature[phosphatidylinositol‐4‐phosphate 5‐kinase, type I, alpha](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2164)[phosphatidylinositol‐4‐phosphate 5‐kinase, type I, gamma](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2165)Common abreviationPIP5K1APIP5K1CHGNC, UniProt[*PIP5K1A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8994), [Q99755](http://www.uniprot.org/uniprot/Q99755)[*PIP5K1C*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8996), [O60331](http://www.uniprot.org/uniprot/O60331)EC number[2.7.1.68](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.1.68)[2.7.1.68](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.1.68)Inhibitors[ISA‐2011B](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8444) \[[428](http://www.ncbi.nlm.nih.gov/pubmed/25071204?dopt=AbstractPlus)\]--

11. [Type II PIP kinases (1‐phosphatidylinositol‐5‐phosphate 4‐kinase family)](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=674) {#bph13354-sec-0173}
=========================================================================================================================================================

Overview {#bph13354-sec-0174}
--------

Type II PIP kinases are essential for the production of the second messenger phosphatidylinositol 4,5‐bisphosphate (PtdIns(4,5)P2) by phosphorylating PtdIns(5)P \[[397](http://www.ncbi.nlm.nih.gov/pubmed/9367159?dopt=AbstractPlus)\]. This enzyme family is also known as type II PIP(5)Ks.

Nomenclature[phosphatidylinositol‐5‐phosphate 4‐kinase,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2858)[phosphatidylinositol‐5‐phosphate 4‐kinase,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2162)[phosphatidylinositol‐5‐phosphate 4‐kinase,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2163)[type II, alpha](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)[type II, beta](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)[type II, gamma](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)Common abreviation--PIP4K2BPIP4K2CHGNC, UniProt[*PIP4K2A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8997), [P48426](http://www.uniprot.org/uniprot/P48426)[*PIP4K2B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8998), [P78356](http://www.uniprot.org/uniprot/P78356)[*PIP4K2C*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23786), [Q8TBX8](http://www.uniprot.org/uniprot/Q8TBX8)EC number[2.7.1.149](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.1.149)[2.7.1.149](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.1.149)[2.7.1.149](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.1.149)ATP + 1‐phosphatidyl‐1D‐*m* *y* *o*‐inositol 5‐phosphate \<=\> ADP + 1‐phosphatidyl‐1D‐*m* *y* *o*‐inositol 4,5‐bisphosphate

Further Reading {#bph13354-sec-0175}
---------------

Neubauer HA *et al*. (2013) Roles, regulation and inhibitors of sphingosine kinase 2. *FEBS J.* **280**: 5317‐36 [\[PMID:23638983\]](http://www.ncbi.nlm.nih.gov/pubmed/23638983?dopt=AbstractPlus)

Truman JP *et al*. (2014) Evolving concepts in cancer therapy through targeting sphingolipid metabolism. *Biochim. Biophys. Acta* **1841**: 1174‐88 [\[PMID:24384461\]](http://www.ncbi.nlm.nih.gov/pubmed/24384461?dopt=AbstractPlus)

12. [Phosphoinositide‐specific phospholipase C](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=274) {#bph13354-sec-0176}
==========================================================================================================================

Overview {#bph13354-sec-0177}
--------

Phosphoinositide‐specific phospholipase C (PLC, EC 3.1.4.11), catalyses the hydrolysis of [PIP~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387) to [IP~3~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222) and 1,2‐diacylglycerol, each of which have major second messenger functions. Two domains, X and Y, essential for catalytic activity, are conserved in the different forms of PLC. Isoforms of PLC‐*β* are activated primarily by G protein‐coupled receptors through members of the G~q/11~ family of G proteins. The receptor‐mediated activation of PLC‐*γ* involves their phosphorylation by [receptor tyrosine kinases (RTK)](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=304) in response to activation of a variety of growth factor receptors and immune system receptors. PLC‐*ε*1 may represent a point of convergence of signalling via both G protein‐coupled and catalytic receptors. Ca^2+^ ions are required for catalytic activity of PLC isoforms and have been suggested to be the major physiological form of regulation of PLC‐*δ* activity. PLC has been suggested to be activated non‐selectively by the small molecule [*m*3M3FBS](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5097)\[[21](http://www.ncbi.nlm.nih.gov/pubmed/12695532?dopt=AbstractPlus)\], although this mechanism of action has been questioned \[[271](http://www.ncbi.nlm.nih.gov/pubmed/15302681?dopt=AbstractPlus)\]. The aminosteroid [U73122](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5283) has been described as an inhibitor of phosphoinositide‐specific PLC \[[447](http://www.ncbi.nlm.nih.gov/pubmed/2338654?dopt=AbstractPlus)\], although its selectivity among the isoforms is untested and it has been reported to occupy the H1 histamine receptor \[[222](http://www.ncbi.nlm.nih.gov/pubmed/11138848?dopt=AbstractPlus)\].

Nomenclature[PLC*β*1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1403)[PLC*β*2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1404)[PLC*β*3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1405)[PLC*β*4](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1406)[PLC*γ*1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1407)[PLC*γ*2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1408)HGNC, UniProt[*PLCB1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=15917), [Q9NQ66](http://www.uniprot.org/uniprot/Q9NQ66)[*PLCB2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9055), [Q00722](http://www.uniprot.org/uniprot/Q00722)[*PLCB3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9056), [Q01970](http://www.uniprot.org/uniprot/Q01970)[*PLCB4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9059), [Q15147](http://www.uniprot.org/uniprot/Q15147)[*PLCG1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9065), [P19174](http://www.uniprot.org/uniprot/P19174)[*PLCG2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9066), [P16885](http://www.uniprot.org/uniprot/P16885)Endogenous activatorsG*α*q, G*α*11, G*β* *γ* \[[207](http://www.ncbi.nlm.nih.gov/pubmed/8314796?dopt=AbstractPlus), [374](http://www.ncbi.nlm.nih.gov/pubmed/8383116?dopt=AbstractPlus), [449](http://www.ncbi.nlm.nih.gov/pubmed/1846707?dopt=AbstractPlus)\]G*α*16, G*β* *γ*, [Rac2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5251) ([*RAC2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9802), [P15153](http://www.uniprot.org/uniprot/P15153)) \[[59](http://www.ncbi.nlm.nih.gov/pubmed/1465133?dopt=AbstractPlus), [223](http://www.ncbi.nlm.nih.gov/pubmed/12441352?dopt=AbstractPlus), [224](http://www.ncbi.nlm.nih.gov/pubmed/12509427?dopt=AbstractPlus), [281](http://www.ncbi.nlm.nih.gov/pubmed/1322889?dopt=AbstractPlus), [374](http://www.ncbi.nlm.nih.gov/pubmed/8383116?dopt=AbstractPlus)\]G*α*q, G*β* *γ* \[[65](http://www.ncbi.nlm.nih.gov/pubmed/8380773?dopt=AbstractPlus), [281](http://www.ncbi.nlm.nih.gov/pubmed/1322889?dopt=AbstractPlus), [374](http://www.ncbi.nlm.nih.gov/pubmed/8383116?dopt=AbstractPlus)\]G*α*q \[[237](http://www.ncbi.nlm.nih.gov/pubmed/8454637?dopt=AbstractPlus)\][PIP~3~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2353) \[[20](http://www.ncbi.nlm.nih.gov/pubmed/9468499?dopt=AbstractPlus)\][PIP~3~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2353), [Rac1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5250) ([*RAC1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9801), [P63000](http://www.uniprot.org/uniprot/P63000)), [Rac2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5251) ([*RAC2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9802), [P15153](http://www.uniprot.org/uniprot/P15153)), [Rac3](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5252) ([*RAC3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9803), [P60763](http://www.uniprot.org/uniprot/P60763)) \[[20](http://www.ncbi.nlm.nih.gov/pubmed/9468499?dopt=AbstractPlus), [384](http://www.ncbi.nlm.nih.gov/pubmed/16172125?dopt=AbstractPlus), [507](http://www.ncbi.nlm.nih.gov/pubmed/18728011?dopt=AbstractPlus)\]

Nomenclature[PLC*δ*1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1409)[PLC*δ*3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1410)[PLC*δ*4](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1411)[PLC*ε*1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1412)[PLC*ζ*1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1413)[PLC*η*1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1414)[PLC*η*2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1415)HGNC, UniProt[*PLCD1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9060), [P51178](http://www.uniprot.org/uniprot/P51178)[*PLCD3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9061), [Q8N3E9](http://www.uniprot.org/uniprot/Q8N3E9)[*PLCD4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9062), [Q9BRC7](http://www.uniprot.org/uniprot/Q9BRC7)[*PLCE1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17175), [Q9P212](http://www.uniprot.org/uniprot/Q9P212)[*PLCZ1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19218), [Q86YW0](http://www.uniprot.org/uniprot/Q86YW0)[*PLCH1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=29185), [Q4KWH8](http://www.uniprot.org/uniprot/Q4KWH8)[*PLCH2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=29037), [O75038](http://www.uniprot.org/uniprot/O75038)Endogenous activatorsTransglutaminase II, [p122‐RhoGAP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5237) {Rat}, [spermine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=710), G*β* *γ* \[[187](http://www.ncbi.nlm.nih.gov/pubmed/1654825?dopt=AbstractPlus), [214](http://www.ncbi.nlm.nih.gov/pubmed/7835339?dopt=AbstractPlus), [344](http://www.ncbi.nlm.nih.gov/pubmed/10518533?dopt=AbstractPlus), [374](http://www.ncbi.nlm.nih.gov/pubmed/8383116?dopt=AbstractPlus)\]----Ras, rho \[[452](http://www.ncbi.nlm.nih.gov/pubmed/11022048?dopt=AbstractPlus), [525](http://www.ncbi.nlm.nih.gov/pubmed/14993441?dopt=AbstractPlus)\]----G*β* *γ* \[[551](http://www.ncbi.nlm.nih.gov/pubmed/16107206?dopt=AbstractPlus)\]Endogenous inhibitorsSphingomyelin \[[378](http://www.ncbi.nlm.nih.gov/pubmed/1497353?dopt=AbstractPlus)\]------------

Comments {#bph13354-sec-0178}
--------

A series of PLC‐like proteins ([*PLCL1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9063), [Q15111](http://www.uniprot.org/uniprot/Q15111); [*PLCL2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9064), [Q9UPR0](http://www.uniprot.org/uniprot/Q9UPR0) and [*PLCH1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=29185), [Q4KWH8](http://www.uniprot.org/uniprot/Q4KWH8)) form a family with PLC*δ* and PLC*ζ*1 isoforms, but appear to lack catalytic activity.

PLC‐*δ*2 has been cloned from bovine sources \[[328](http://www.ncbi.nlm.nih.gov/pubmed/1848183?dopt=AbstractPlus)\].

13. [Phospholipase A~2~](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=275) {#bph13354-sec-0179}
===================================================================================================

Overview {#bph13354-sec-0180}
--------

Phospholipase A~2~(PLA~2~, EC 3.1.1.4) cleaves the *sn*‐2 fatty acid of phospholipids, primarily phosphatidylcholine, to generate [lysophosphatidylcholine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2508) and [arachidonic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2391). Most commonly‐used inhibitors (*e.g.* [bromoenol lactone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5149), [arachidonyl trifluoromethyl ketone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5142) or [methyl arachidonyl fluorophosphonate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5218)) are either non‐selective within the family of phospholipase A~2~ enzymes or have activity against other eicosanoid‐metabolising enzymes.

**Secreted or extracellular forms:** sPLA~2~‐1B, sPLA~2~‐2A, sPLA~2~‐2D, sPLA~2~‐2E, sPLA~2~‐2F, sPLA~2~‐3, sPLA~2~‐10 and sPLA~2~‐12A

**Cytosolic, calcium‐dependent forms:** cPLA~2~‐4A, cPLA~2~‐4B, cPLA~2~‐4C, cPLA~2~‐4D, cPLA~2~‐4E and cPLA~2~‐4F

**Other forms:** PLA~2~‐G5, iPLA~2~‐G6, PLA~2~‐G7 and PAFAH2 (platelet‐activating factor acetylhydrolase 2)

Nomenclature[sPLA~2~‐1B](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1416)[sPLA~2~‐2A](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1417)[sPLA~2~‐2D](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1418)[sPLA~2~‐2E](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1419)[sPLA~2~‐2F](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1420)HGNC, UniProt[*PLA2G1B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9030), [P04054](http://www.uniprot.org/uniprot/P04054)[*PLA2G2A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9031), [P14555](http://www.uniprot.org/uniprot/P14555)[*PLA2G2D*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9033), [Q9UNK4](http://www.uniprot.org/uniprot/Q9UNK4)[*PLA2G2E*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13414), [Q9NZK7](http://www.uniprot.org/uniprot/Q9NZK7)[*PLA2G2F*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30040), [Q9BZM2](http://www.uniprot.org/uniprot/Q9BZM2)

Nomenclature[sPLA~2~‐3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1421)[sPLA~2~‐10](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1422)[sPLA~2~‐12A](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1423)[cPLA~2~‐4A](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1424)[cPLA~2~‐4B](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1425)HGNC, UniProt[*PLA2G3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17934), [Q9NZ20](http://www.uniprot.org/uniprot/Q9NZ20)[*PLA2G10*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9029), [O15496](http://www.uniprot.org/uniprot/O15496)[*PLA2G12A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18554), [Q9BZM1](http://www.uniprot.org/uniprot/Q9BZM1)[*PLA2G4A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9035), [P47712](http://www.uniprot.org/uniprot/P47712)[*PLA2G4B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9036), [P0C869](http://www.uniprot.org/uniprot/P0C869)Comments------cPLA~2~‐4A also expresses lysophospholipase ([EC 3.1.1.5](http://www.genome.jp/kegg-bin/search_brite?option=-a&search_string=3.1.1.5)) activity \[[435](http://www.ncbi.nlm.nih.gov/pubmed/8083230?dopt=AbstractPlus)\].--

Nomenclature[cPLA~2~‐4C](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1426)[cPLA~2~‐4D](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1427)[cPLA~2~‐4E](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1428)[cPLA~2~‐4F](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1429)HGNC, UniProt[*PLA2G4C*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9037), [Q9UP65](http://www.uniprot.org/uniprot/Q9UP65)[*PLA2G4D*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=30038), [Q86XP0](http://www.uniprot.org/uniprot/Q86XP0)[*PLA2G4E*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=24791), [Q3MJ16](http://www.uniprot.org/uniprot/Q3MJ16)[*PLA2G4F*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=27396), [Q68DD2](http://www.uniprot.org/uniprot/Q68DD2)

Nomenclature[PLA~2~‐G5](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1430)[iPLA~2~‐G6](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1431)[PLA~2~‐G7](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1432)[platelet‐activating factor](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2508)[acetylhydrolase 2, 40kDa](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2508)HGNC, UniProt[*PLA2G5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9038), [P39877](http://www.uniprot.org/uniprot/P39877)[*PLA2G6*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9039), [O60733](http://www.uniprot.org/uniprot/O60733)[*PLA2G7*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9040), [Q13093](http://www.uniprot.org/uniprot/Q13093)[*PAFAH2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=8579), [Q99487](http://www.uniprot.org/uniprot/Q99487)Inhibitors----[darapladib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6696) (pIC~50~ 10) \[[39](http://www.ncbi.nlm.nih.gov/pubmed/12643913?dopt=AbstractPlus)\]--Selective inhibitors----[rilapladib](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7376) (Competitive) (pIC~50~ 9.6) \[[523](http://www.ncbi.nlm.nih.gov/pubmed/19667981?dopt=AbstractPlus)\]--Comments------PAFAH2 also expresses PAF hydrolase activity (EC 3.1.1.47)

Comments {#bph13354-sec-0181}
--------

The sequence of PLA~2~‐2C suggests a lack of catalytic activity, while PLA~2~‐12B (GXIIB, GXIII sPLA~2~‐like) appears to be catalytically inactive \[[413](http://www.ncbi.nlm.nih.gov/pubmed/14516201?dopt=AbstractPlus)\]. A further fragment has been identified with sequence similarities to Group II PLA~2~ members. Otoconin 90 (OC90) shows sequence homology to PLA~2~‐G10.

A binding protein for secretory phospholipase A~2~ has been identified which shows modest selectivity for sPLA~2~‐1B over sPLA~2~‐2A, and also binds snake toxin phospholipase A~2~\[[12](http://www.ncbi.nlm.nih.gov/pubmed/7548076?dopt=AbstractPlus)\]. The binding protein appears to have clearance function for circulating secretory phospholipase A~2~, as well as signalling functions, and is a candidate antigen for idiopathic membraneous nephropathy \[[27](http://www.ncbi.nlm.nih.gov/pubmed/19571279?dopt=AbstractPlus)\].

PLA~2~‐G7 and PAFAH2 also express platelet‐activating factor acetylhydrolase activity ([EC 3.1.1.47](http://www.genome.jp/kegg-bin/search_brite?option=-a&search_string=3.1.1.47)).

14. [Phosphatidylcholine‐specific phospholipase D](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=276) {#bph13354-sec-0182}
=============================================================================================================================

Overview {#bph13354-sec-0183}
--------

Phosphatidylcholine‐specific phospholipase D (PLD, EC 3.1.1.4) catalyses the formation of phosphatidic acid from phosphatidylcholine. In addition, the enzyme can make use of alcohols, such as butanol in a transphosphatidylation reaction \[[399](http://www.ncbi.nlm.nih.gov/pubmed/2186929?dopt=AbstractPlus)\].

Nomenclature[PLD1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1433)[PLD2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1434)HGNC, UniProt[*PLD1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9067), [Q13393](http://www.uniprot.org/uniprot/Q13393)[*PLD2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9068), [O14939](http://www.uniprot.org/uniprot/O14939)Endogenous activators[ADP‐ribosylation factor 1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5305) ([*ARF1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=652), [P84077](http://www.uniprot.org/uniprot/P84077)), [PIP~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387), RhoA, PKC evoked phosphorylation, RalA \[[189](http://www.ncbi.nlm.nih.gov/pubmed/9013646?dopt=AbstractPlus), [303](http://www.ncbi.nlm.nih.gov/pubmed/9207251?dopt=AbstractPlus)\]--Endogenous inhibitorG*β* *γ* \[[391](http://www.ncbi.nlm.nih.gov/pubmed/16638972?dopt=AbstractPlus)\]G*β* *γ* \[[391](http://www.ncbi.nlm.nih.gov/pubmed/16638972?dopt=AbstractPlus)\]Endogenous activators--[ADP‐ribosylation factor 1](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5305) ([*ARF1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=652), [P84077](http://www.uniprot.org/uniprot/P84077)), [PIP~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387) \[[298](http://www.ncbi.nlm.nih.gov/pubmed/9582313?dopt=AbstractPlus)\], [oleic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1054) \[[418](http://www.ncbi.nlm.nih.gov/pubmed/12374567?dopt=AbstractPlus)\]Selective inhibitors--[VU0364739](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5287) (pIC~50~ 7.7) \[[279](http://www.ncbi.nlm.nih.gov/pubmed/20735042?dopt=AbstractPlus)\]

Comments {#bph13354-sec-0184}
--------

A lysophospholipase D activity ([*ENPP2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3357), [Q13822](http://www.uniprot.org/uniprot/Q13822), also known as ectonucleotide pyrophosphatase/phosphodiesterase 2, phosphodiesterase I, nucleotide pyrophosphatase 2, autotaxin) has been described, which not only catalyses the production of lysophosphatidic acid ([LPA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2906)) from [lysophosphatidylcholine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2508), but also cleaves [ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713) (see Goding *et al*., 2003 \[[175](http://www.ncbi.nlm.nih.gov/pubmed/12757929?dopt=AbstractPlus)\]). Additionally, an N‐acylethanolamine‐specific phospholipase D ([*NAPEPLD*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=21683), [Q6IQ20](http://www.uniprot.org/uniprot/Q6IQ20)) has been characterized, which appears to have a role in the generation of [endocannabinoids](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=273)/endovanilloids, including [anandamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364)\[[362](http://www.ncbi.nlm.nih.gov/pubmed/14634025?dopt=AbstractPlus)\]. This enzyme activity appears to be enhanced by polyamines in the physiological range \[[292](http://www.ncbi.nlm.nih.gov/pubmed/12047899?dopt=AbstractPlus)\] and fails to transphosphatidylate with alcohols \[[381](http://www.ncbi.nlm.nih.gov/pubmed/10428468?dopt=AbstractPlus)\].

Three further, less well‐characterised isoforms are PLD3 ([*PLD3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17158), [Q8IV08](http://www.uniprot.org/uniprot/Q8IV08), other names Choline phosphatase 3, HindIII K4L homolog, Hu‐K4), PLD4 ([*PLD4*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23792), [Q96BZ4](http://www.uniprot.org/uniprot/Q96BZ4), other names Choline phosphatase 4, Phosphatidylcholine‐hydrolyzing phospholipase, D4C14orf175 UNQ2488/PRO5775) and PLD5 ([*PLD5*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=26879), [Q8N7P1](http://www.uniprot.org/uniprot/Q8N7P1)). PLD3 has been reported to be involved in myogenesis \[[365](http://www.ncbi.nlm.nih.gov/pubmed/22428023?dopt=AbstractPlus)\]. PLD4 is described not to have phospholipase D catalytic activity \[[539](http://www.ncbi.nlm.nih.gov/pubmed/21085684?dopt=AbstractPlus)\], but has been associated with inflammatory disorders \[[360](http://www.ncbi.nlm.nih.gov/pubmed/22446963?dopt=AbstractPlus), [468](http://www.ncbi.nlm.nih.gov/pubmed/23577190?dopt=AbstractPlus), [484](http://www.ncbi.nlm.nih.gov/pubmed/23124809?dopt=AbstractPlus)\]. Sequence analysis suggests that PLD5 is catalytically inactive.

15. [Lipid phosphate phosphatases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=277) {#bph13354-sec-0185}
=============================================================================================================

Overview {#bph13354-sec-0186}
--------

Lipid phosphate phosphatases, divided into phosphatidic acid phosphatases or lipins catalyse the dephosphorylation of phosphatidic acid (and other phosphorylated lipid derivatives) to generate inorganic phosphate and diacylglycerol. PTEN, a phosphatase and tensin homolog (BZS, MHAM, MMAC1, PTEN1, TEP1) is a phosphatidylinositol 3,4,5‐trisphosphate 3‐phosphatase which acts as a tumour suppressor by reducing cellular levels of PI 3,4,5‐P, thereby toning down activity of PDK1 and PKB. Loss‐of‐function mutations are frequently identified as somatic mutations in cancers.

Nomenclature[Lipin1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1435)[Lipin2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1436)[Lipin3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1437)[PPA2A](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1438)[PPA2B](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1439)[PPA3A](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1440)[phosphatase and](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2497)[tensin homolog](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2497)HGNC, UniProt[*LPIN1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=13345), [Q14693](http://www.uniprot.org/uniprot/Q14693)[*LPIN2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14450), [Q92539](http://www.uniprot.org/uniprot/Q92539)[*LPIN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14451), [Q9BQK8](http://www.uniprot.org/uniprot/Q9BQK8)[*PPAP2A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9228), [O14494](http://www.uniprot.org/uniprot/O14494)[*PPAP2B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9229), [O14495](http://www.uniprot.org/uniprot/O14495)[*PPAP2C*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9230), [O43688](http://www.uniprot.org/uniprot/O43688)[*PTEN*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9588), [P60484](http://www.uniprot.org/uniprot/P60484)EC number[3.1.3.4](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.3.4)[3.1.3.4](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.3.4)[3.1.3.4](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.3.4)[3.1.3.4](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.3.4)[3.1.3.4](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.3.4)[3.1.3.4](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.3.4)[3.1.3.67](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.3.67)[3.1.3.48](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.3.48)[3.1.3.16](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.3.16)Substrates--phosphatidic acid----phosphatidic acid--phosphatidylinositol (3,4,5)‐trisphosphate
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---------------
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16. [Haem oxygenase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=278) {#bph13354-sec-0188}
===============================================================================================

Overview {#bph13354-sec-0189}
--------

Haem oxygenase (heme,hydrogen‐donor:oxygen oxidoreductase (*α*‐methene‐oxidizing, hydroxylating)), [E.C. 1.14.99.3](http://www.genome.jp/kegg-bin/search_brite?option=-a&search_string=1.14.99.3), converts [heme](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4349) into [biliverdin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5153) and carbon monoxide, utilizing [NADPH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041) as cofactor.

Nomenclature[Haem oxygenase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1441)[Haem oxygenase 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1442)Common abreviationHO1HO2HGNC, UniProt[*HMOX1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5013), [P09601](http://www.uniprot.org/uniprot/P09601)[*HMOX2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5014), [P30519](http://www.uniprot.org/uniprot/P30519)EC number[1.14.99.3](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.99.3)[1.14.99.3](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.99.3)

Comments {#bph13354-sec-0190}
--------

The existence of a third non‐catalytic version of haem oxygenase, HO3, has been proposed, although this has been suggested to be a pseudogene \[[202](http://www.ncbi.nlm.nih.gov/pubmed/15246535?dopt=AbstractPlus)\]. The chemical [tin protoporphyrin IX](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5279) acts as a haem oxygenase inhibitor in rat liver with an IC~50~ value of 11 nM \[[120](http://www.ncbi.nlm.nih.gov/pubmed/6947237?dopt=AbstractPlus)\].

Further Reading {#bph13354-sec-0191}
---------------
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17. [Hydrogen sulphide synthesis](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=279) {#bph13354-sec-0192}
============================================================================================================

Overview {#bph13354-sec-0193}
--------

Hydrogen sulfide is a putative gasotransmitter, with similarities to nitric oxide and carbon monoxide. Although the enzymes indicated have multiple enzymatic activities, the focus here is the generation of hydrogen sulphide and the enzymatic characteristics are described accordingly. Cystathionine *β*‐synthase and cystathionine *γ*‐lyase are pyridoxal phosphate‐dependent enzymes, while 3‐mercaptopyruvate sulfurtransferase functions as a pyridoxal phosphate‐independent pathway.

Nomenclature[Cystathionine *β*‐synthase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1443)[Cystathionine *γ*‐lyase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1444)[L‐Cysteine:2‐oxoglutarate](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1445)[3‐Mercaptopyruvate](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1446)[aminotransferase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1445)[sulfurtransferase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1445)Common abreviationCBSCSECATMPSTHGNC, UniProt[*CBS*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1550), [P35520](http://www.uniprot.org/uniprot/P35520)[*CTH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2501), [P32929](http://www.uniprot.org/uniprot/P32929)[*CCBL1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1564), [Q16773](http://www.uniprot.org/uniprot/Q16773)[*MPST*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7223), [P25325](http://www.uniprot.org/uniprot/P25325)EC number[4.2.1.22](http://www.genome.jp/dbget-bin/www_bget?ec:4.2.1.22)[4.4.1.1](http://www.genome.jp/dbget-bin/www_bget?ec:4.4.1.1)[4.4.1.13](http://www.genome.jp/dbget-bin/www_bget?ec:4.4.1.13)[2.8.1.2](http://www.genome.jp/dbget-bin/www_bget?ec:2.8.1.2)Endogenous substrates[L‐cysteine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4782) (*K* ~m~6 × 10^−3^M) \[[74](http://www.ncbi.nlm.nih.gov/pubmed/15520012?dopt=AbstractPlus)\], [L‐homocysteine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5198)[L‐cysteine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4782)[L‐cysteine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4782)[3‐mercaptopyruvic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5118) (*K* ~m~1.2 × 10^−3^M) \[[345](http://www.ncbi.nlm.nih.gov/pubmed/7608189?dopt=AbstractPlus)\]Products[cystathionine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5173)NH~3~, [pyruvic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809)NH~3~, [pyruvic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809)[pyruvic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4809)Cofactors[pyridoxal phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249)[pyridoxal phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249)[pyridoxal phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249)[Zn^2+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=566)Inhibitors[aminooxyacetic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5136)[propargylglycine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5247)----

Further Reading {#bph13354-sec-0194}
---------------
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Li L *et al*. (2011) Hydrogen sulfide and cell signaling. *Annu. Rev. Pharmacol. Toxicol.* **51**: 169‐87 [\[PMID:21210746\]](http://www.ncbi.nlm.nih.gov/pubmed/21210746?dopt=AbstractPlus)
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Wallace JL *et al*. (2015) Hydrogen sulfide‐based therapeutics: exploiting a unique but ubiquitous gasotransmitter. *Nat Rev Drug Discov* **14**: 329‐45 [\[PMID:25849904\]](http://www.ncbi.nlm.nih.gov/pubmed/25849904?dopt=AbstractPlus)

Wang R *et al*. (2015) The role of H2S bioavailability in endothelial dysfunction. *Trends Pharmacol. Sci.* [\[PMID:26071118\]](http://www.ncbi.nlm.nih.gov/pubmed/26071118?dopt=AbstractPlus)

18. [Hydrolases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=799) {#bph13354-sec-0195}
===========================================================================================

Overview {#bph13354-sec-0196}
--------

listed in this section are hydrolases not accumulated in other parts of the Concise Guide, such as monoacylglycerol lipase and acetylcholinesterase. Pancreatic lipase is the predominant mechanism of fat digestion in the alimentary system; its inhibition is associated with decreased fat absorption. CES1 is present at lower levels in the gut than CES2 (P23141), but predominates in the liver, where it is responsible for the hydrolysis of many aliphatic, aromatic and steroid esters. Hormone‐sensitive lipase is also a relatively non‐selective esterase associated with steroid ester hydrolysis and triglyceride metabolism, particularly in adipose tissue. Endothelial lipase is secreted from endothelial cells and regulates circulating cholesterol in high density lipoproteins.

Nomenclature[pancreatic lipase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2590)[lipase, endothelial](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2591)[carboxylesterase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2592)[lipase, hormone‐sensitive](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2593)Common abreviationPNLIPLIPGCES1LIPEHGNC, UniProt[*PNLIP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9155), [P16233](http://www.uniprot.org/uniprot/P16233)[*LIPG*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6623), [Q9Y5X9](http://www.uniprot.org/uniprot/Q9Y5X9)[*CES1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1863), [P23141](http://www.uniprot.org/uniprot/P23141)[*LIPE*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6621), [Q05469](http://www.uniprot.org/uniprot/Q05469)EC number[3.1.1.3](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.1.3)[3.1.1.3](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.1.3)[3.1.1.1](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.1.1)[3.1.1.79](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.1.79)Inhibitors[orlistat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5277) (pIC~50~ 8.9) \[[51](#bph13354-bib-0051){ref-type="ref"}\]------

Further Reading {#bph13354-sec-0197}
---------------

Markey, G.M. (2011) Carboxylesterase 1 (Ces1): from monocyte marker to major player. *J Clin Pathol* **64**: 107‐109 [\[PMID:21177752\]](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids)

19. [Inositol phosphate turnover](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=245) {#bph13354-sec-0198}
============================================================================================================

Overview {#bph13354-sec-0199}
--------

The sugar alcohol D‐*myo*‐inositol is a component of the [phosphatidylinositol signalling cycle](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=244), where the principal second messenger is inositol 1,4,5‐trisphosphate, [IP~3~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222), which acts at intracellular ligand‐gated ion channels, [IP~3~ receptors](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=123) to elevate intracellular calcium. [IP~3~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222) is recycled to inositol by phosphatases or phosphorylated to form other active inositol polyphosphates. Inositol produced from dephosphorylation of [IP~3~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222) is recycled into membrane phospholipid under the influence of phosphatidyinositol synthase activity (CDP‐diacylglycerol‐inositol 3‐phosphatidyltransferase \[[EC 2.7.8.11](http://www.genome.jp/kegg-bin/search_brite?option=-a&search_string=2.7.8.11)\]).

20. [Inositol 1,4,5‐trisphosphate 3‐kinases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=280) {#bph13354-sec-0200}
=======================================================================================================================

Overview {#bph13354-sec-0201}
--------

Inositol 1,4,5‐trisphosphate 3‐kinases ([E.C. 2.7.1.127](http://www.genome.jp/kegg-bin/search_brite?option=-a&search_string=2.7.1.127), [ENSFM00250000001260](http://www.ensembl.org/Homo_sapiens/Gene/Family/Genes?family=ENSFM00250000001260)) catalyse the generation of inositol 1,3,4,5‐tetrakisphosphate ([IP~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5202)) from [IP~3~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222). IP~3~ kinase activity is enhanced in the presence of calcium/[calmodulin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2351)([*CALM1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1442) [*CALM2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1445) [*CALM3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1449), [P62158](http://www.uniprot.org/uniprot/P62158)) \[[91](http://www.ncbi.nlm.nih.gov/pubmed/2559811?dopt=AbstractPlus)\].

21. [Inositol polyphosphate phosphatases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=281) {#bph13354-sec-0202}
====================================================================================================================

Overview {#bph13354-sec-0203}
--------

Members of this family exhibit phosphatase activity towards IP~3~, as well as towards other inositol derivatives, including the phospholipids [PIP~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387) and [PIP~3~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2353). With [IP~3~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222) as substrate, 1‐phosphatase ([EC 3.1.3.57](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.3.57)) generates [4,5,‐IP~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5119), 4‐phosphatases ([EC 3.1.3.66](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.3.66), [ENSFM00250000001432](http://www.ensembl.org/Homo_sapiens/Gene/Family/Genes?family=ENSFM00250000001432)) generate [1,5,‐IP~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5099) and 5‐phosphatases ([E.C. 3.1.3.36](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.3.36) or [3.1.3.56](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.3.56)) generate [1,4,‐IP~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5098).

Comments {#bph13354-sec-0204}
--------

*In vitro* analysis suggested [IP~3~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4222) and [IP~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5202) were poor substrates for SKIP, synaptojanin 1 and synaptojanin 2, but suggested that [PIP~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2387) and [PIP~3~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2353) were more efficiently hydrolysed \[[422](http://www.ncbi.nlm.nih.gov/pubmed/15474001?dopt=AbstractPlus)\].

22. [Inositol monophosphatase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=282) {#bph13354-sec-0205}
=========================================================================================================

Overview {#bph13354-sec-0206}
--------

Inositol monophosphatase ([E.C. 3.1.3.25](http://www.genome.jp/kegg-bin/search_brite?option=-a&search_string=3.1.3.25), IMPase, *myo*‐inositol‐1(or 4)‐phosphate phosphohydrolase) is a magnesium‐dependent homodimer which hydrolyses *myo*‐inositol monophosphate to generate [*myo*‐inositol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4495) and phosphate. [Glycerol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5195) may be a physiological phosphate acceptor. [Li^+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5212) is a nonselective un‐competitive inhibitor more potent at IMPase 1 (*p*K~i~ *ca*. 3.5, \[[324](http://www.ncbi.nlm.nih.gov/pubmed/1377913?dopt=AbstractPlus)\]; *p*IC~50~ 3.2, \[[359](http://www.ncbi.nlm.nih.gov/pubmed/17068342?dopt=AbstractPlus)\]) than IMPase 2 (*p*IC~50~ 1.8‐2.1, \[[359](http://www.ncbi.nlm.nih.gov/pubmed/17068342?dopt=AbstractPlus)\]). IMPase activity may be inhibited competitively by [L690330](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5208)(*p*K~i~ 5.5, \[[324](http://www.ncbi.nlm.nih.gov/pubmed/1377913?dopt=AbstractPlus)\]), although the enzyme selectivity is not yet established.

Nomenclature[IMPase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1463)[IMPase 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1464)HGNC, UniProt[*IMPA1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6050), [P29218](http://www.uniprot.org/uniprot/P29218)[*IMPA2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6051), [O14732](http://www.uniprot.org/uniprot/O14732)EC number[3.1.3.25](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.3.25)[3.1.3.25](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.3.25)Rank order of affinity[inositol 4‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5205)\>[inositol 3‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5204)\>[inositol 1‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5203) \[[324](http://www.ncbi.nlm.nih.gov/pubmed/1377913?dopt=AbstractPlus)\]--Inhibitors[Li^+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5212) (p*K* ~i~ 3.5) \[[324](http://www.ncbi.nlm.nih.gov/pubmed/1377913?dopt=AbstractPlus)\]--

Comments {#bph13354-sec-0207}
--------

Polymorphisms in either of the genes encoding these enzymes have been linked with bipolar disorder \[[443](http://www.ncbi.nlm.nih.gov/pubmed/10822345?dopt=AbstractPlus), [444](http://www.ncbi.nlm.nih.gov/pubmed/9339367?dopt=AbstractPlus), [540](http://www.ncbi.nlm.nih.gov/pubmed/9322233?dopt=AbstractPlus)\]. Disruption of the gene encoding IMPase 1, but not IMPase 2, appears to mimic the effects of [Li^+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5212) in mice \[[97](http://www.ncbi.nlm.nih.gov/pubmed/16841073?dopt=AbstractPlus), [98](http://www.ncbi.nlm.nih.gov/pubmed/17460611?dopt=AbstractPlus)\].

Further Reading {#bph13354-sec-0208}
---------------

Barker CJ *et al*. (2013) New horizons in cellular regulation by inositol polyphosphates: insights from the pancreatic *β*‐cell. *Pharmacol. Rev.* **65**: 641‐69 [\[PMID:23429059\]](http://www.ncbi.nlm.nih.gov/pubmed/23429059?dopt=AbstractPlus)

Billcliff PG *et al*. (2014) Inositol lipid phosphatases in membrane trafficking and human disease. *Biochem. J.* **461**: 159‐75 [\[PMID:24966051\]](http://www.ncbi.nlm.nih.gov/pubmed/24966051?dopt=AbstractPlus)

Chiu CT *et al*. (2010) Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. *Pharmacol. Ther.* **128**: 281‐304 [\[PMID:20705090\]](http://www.ncbi.nlm.nih.gov/pubmed/20705090?dopt=AbstractPlus)

Pirruccello M *et al*. (2012) Inositol 5‐phosphatases: insights from the Lowe syndrome protein OCRL. *Trends Biochem. Sci.* **37**: 134‐43 [\[PMID:22381590\]](http://www.ncbi.nlm.nih.gov/pubmed/22381590?dopt=AbstractPlus)

Schell MJ. (2010) Inositol trisphosphate 3‐kinases: focus on immune and neuronal signaling. *Cell. Mol. Life Sci.* **67**: 1755‐78 [\[PMID:20066467\]](http://www.ncbi.nlm.nih.gov/pubmed/20066467?dopt=AbstractPlus)

23. [Lanosterol biosynthesis pathway](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=104) {#bph13354-sec-0209}
================================================================================================================

Overview {#bph13354-sec-0210}
--------

Lanosterol is a precursor for cholesterol, which is synthesized primarily in the liver in a pathway often described as the mevalonate or HMG‐CoA reductase pathway. The first two steps (formation of [acetoacetyl CoA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3039) and the mitochondrial generation of [(S)‐3‐hydroxy‐3‐methylglutaryl‐CoA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3040)) are also associated with oxidation of fatty acids.

Nomenclature[acetyl‐CoA acetyltransferase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2435), [acetyl‐CoA acetyltransferase 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2436)[hydroxymethylglutaryl‐CoA synthase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=638), [hydroxymethylglutaryl‐CoA synthase 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2432)HGNC, UniProt[*ACAT1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=93), [P24752](http://www.uniprot.org/uniprot/P24752), [*ACAT2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=94), [Q9BWD1](http://www.uniprot.org/uniprot/Q9BWD1)[*HMGCS1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5007), [Q01581](http://www.uniprot.org/uniprot/Q01581), [*HMGCS2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5008), [P54868](http://www.uniprot.org/uniprot/P54868)EC number[2.3.1.9](http://www.genome.jp/dbget-bin/www_bget?ec:2.3.1.9): 2[acetyl CoA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038) = [acetoacetyl CoA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3039) + [coenzyme A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044)[2.3.3.10](http://www.genome.jp/dbget-bin/www_bget?ec:2.3.3.10): [acetyl CoA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3038) + H~2~O + [acetoacetyl CoA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3039) ‐\>[(S)‐3‐hydroxy‐3‐methylglutaryl‐CoA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3040) + [coenzyme A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044)Comments--HMGCoA synthase is found in cytosolic (HMGCoA synthase 1) and mitochondrial (HMGCoA synthase 2) versions; the former associated with [(R)‐mevalonate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3042) synthesis and the latter with ketogenesis.

Nomenclature[hydroxymethylglutaryl‐CoA](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=639)[mevalonate kinase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=640)[phosphomevalonate kinase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=641)[diphosphomevalonate](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=642)[reductase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=639)[decarboxylase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=642)HGNC, UniProt[*HMGCR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5006), [P04035](http://www.uniprot.org/uniprot/P04035)[*MVK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7530), [Q03426](http://www.uniprot.org/uniprot/Q03426)[*PMVK*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=9141), [Q15126](http://www.uniprot.org/uniprot/Q15126)[*MVD*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7529), [P53602](http://www.uniprot.org/uniprot/P53602)EC number[1.1.1.34](http://www.genome.jp/dbget-bin/www_bget?ec:1.1.1.34): [(S)‐3‐hydroxy‐3‐methylglutaryl‐CoA](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3040) + [NADPH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041) ‐\>[(R)‐mevalonate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3042) + [coenzyme A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3044) + [NADP^+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045) Reaction mechanism:: **First step:** (S)‐3‐hydroxy‐3‐methylglutaryl‐CoA + NADPH ‐\> mevaldyl‐CoA + NADP^+^ **Second step:** mevaldyl‐CoA + H2O ‐\> (R)‐mevalonate + NADP^+^[2.7.1.36](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.1.36): [ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713) + [(R)‐mevalonate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3042) ‐\>[adenosine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712) + [(R)‐5‐phosphomevalonate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3046)[2.7.4.2](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.4.2): [ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713) + [(R)‐5‐phosphomevalonate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3046) = [adenosine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712) + [(R)‐5‐diphosphomevalonate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3047)[4.1.1.33](http://www.genome.jp/dbget-bin/www_bget?ec:4.1.1.33): [ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713) + [(R)‐5‐diphosphomevalonate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3047) ‐\>[adenosine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712) + [isopentenyl diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048) + CO~2~ + PO~3~ ^4‐^Inhibitors[lovastatin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2739) (Competitive) (p*K* ~i~ 9.2) \[[8](http://www.ncbi.nlm.nih.gov/pubmed/6933445?dopt=AbstractPlus)\], [rosuvastatin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2954) (Competitive) (pIC~50~ 8.3) \[[228](http://www.ncbi.nlm.nih.gov/pubmed/11349148?dopt=AbstractPlus)\], [cerivastatin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2950) (Competitive) (p*K* ~i~ 8.2) \[[61](http://www.ncbi.nlm.nih.gov/pubmed/16128575?dopt=AbstractPlus)\], [atorvastatin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2949) (Competitive) (pIC~50~ 8.1) \[[228](http://www.ncbi.nlm.nih.gov/pubmed/11349148?dopt=AbstractPlus)\], [cerivastatin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2950) (Competitive) (pIC~50~ 8) \[[486](http://www.ncbi.nlm.nih.gov/pubmed/15686906?dopt=AbstractPlus)\], [simvastatin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2955) (Competitive) (pIC~50~ 8) \[[228](http://www.ncbi.nlm.nih.gov/pubmed/11349148?dopt=AbstractPlus)\], [fluvastatin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2951) (Competitive) (pIC~50~ 7.6) \[[228](http://www.ncbi.nlm.nih.gov/pubmed/11349148?dopt=AbstractPlus)\]------CommentsHMGCoA reductase is associated with intracellular membranes; enzymatic activity is inhibited by phosphorylation by AMP‐activated kinase. The enzymatic reaction is a three‐step reaction involving the intermediate generation of mevaldehyde‐CoA and mevaldehyde.Mevalonate kinase activity is regulated by the downstream products [farnesyl diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2910) and [geranyl diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3051) as an example of feedback inhibition.----

Nomenclature[isopentenyl‐diphosphate](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=646)[isopentenyl‐diphosphate](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=647)[geranylgeranyl diphosphate synthase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=643)[farnesyl diphosphate synthase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=644)[Δ‐isomerase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=646)[Δ‐isomerase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=646)HGNC, UniProt[*IDI1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=5387), [Q13907](http://www.uniprot.org/uniprot/Q13907)[*IDI2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=23487), [Q9BXS1](http://www.uniprot.org/uniprot/Q9BXS1)[*GGPS1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4249), [O95749](http://www.uniprot.org/uniprot/O95749)[*FDPS*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3631), [P14324](http://www.uniprot.org/uniprot/P14324)EC number[5.3.3.2](http://www.genome.jp/dbget-bin/www_bget?ec:5.3.3.2): [isopentenyl diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048) = [dimethylallyl diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3049)[5.3.3.2](http://www.genome.jp/dbget-bin/www_bget?ec:5.3.3.2): [isopentenyl diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048) = [dimethylallyl diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3049)[2.5.1.29](http://www.genome.jp/dbget-bin/www_bget?ec:2.5.1.29): [trans,trans‐farnesyl diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3050) + [isopentenyl diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048) ‐\>[geranylgeranyl diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3052) + diphosphate [2.5.1.10](http://www.genome.jp/dbget-bin/www_bget?ec:2.5.1.10): [geranyl diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3051) + [isopentenyl diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048) ‐\>[trans,trans‐farnesyl diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3050) + diphosphate [2.5.1.1](http://www.genome.jp/dbget-bin/www_bget?ec:2.5.1.1): [dimethylallyl diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3049) + [isopentenyl diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048) = [geranyl diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3051) + diphosphate[2.5.1.10](http://www.genome.jp/dbget-bin/www_bget?ec:2.5.1.10): [geranyl diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3051) + [isopentenyl diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048) ‐\>[trans,trans‐farnesyl diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3050) + diphosphate [2.5.1.1](http://www.genome.jp/dbget-bin/www_bget?ec:2.5.1.1): [dimethylallyl diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3049) + [isopentenyl diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3048) = [geranyl diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3051) + diphosphateInhibitors------[risedronate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3176) (pIC~50~ 8.4) \[[31](http://www.ncbi.nlm.nih.gov/pubmed/10620343?dopt=AbstractPlus)\], [zoledronic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3177) (p*K* ~i~ 7.1) \[[121](http://www.ncbi.nlm.nih.gov/pubmed/18327899?dopt=AbstractPlus)\], [alendronate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3141) (pIC~50~ 6.3) \[[31](http://www.ncbi.nlm.nih.gov/pubmed/10620343?dopt=AbstractPlus)\]Selective inhibitors------[ibandronic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3059) (p*K* ~i~ 6.7) \[[121](http://www.ncbi.nlm.nih.gov/pubmed/18327899?dopt=AbstractPlus)\], [pamidronic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7259) (pIC~50~ 6.7) \[[121](http://www.ncbi.nlm.nih.gov/pubmed/18327899?dopt=AbstractPlus)\]

Nomenclature[squalene synthase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=645)[squalene monooxygenase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2433)[lanosterol synthase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2434)HGNC, UniProt[*FDFT1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3629), [P37268](http://www.uniprot.org/uniprot/P37268)[*SQLE*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11279), [Q14534](http://www.uniprot.org/uniprot/Q14534)[*LSS*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6708), [P48449](http://www.uniprot.org/uniprot/P48449)EC number[2.5.1.21](http://www.genome.jp/dbget-bin/www_bget?ec:2.5.1.21): 2[trans,trans‐farnesyl diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3050) ‐\>[presqualene diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3053) + diphosphate [presqualene diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3053) + NAD(P)H + H^+^ ‐\>[squalene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3054) + diphosphate + NAD(P)^+^[1.14.13.132](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.13.132): H^+^ + [NADPH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041) + O~2~ + [squalene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3054) = H~2~O + [NADP^+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3045) + [(*S*)‐2,3‐epoxysqualene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6551)[5.4.99.7](http://www.genome.jp/dbget-bin/www_bget?ec:5.4.99.7): [(*S*)‐2,3‐epoxysqualene](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6551) = [lanosterol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2746)Cofactors[NADPH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041)----Inhibitors[zaragozic acid A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3057) (p*K* ~i~ 10.1) \[[32](http://www.ncbi.nlm.nih.gov/pubmed/8419946?dopt=AbstractPlus)\] -- Rat, [zaragozic acid A](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3057) (pIC~50~ 9.2) \[[488](http://www.ncbi.nlm.nih.gov/pubmed/9473303?dopt=AbstractPlus)\]----

Further Reading {#bph13354-sec-0211}
---------------
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Seiki S *et al*. (2009) Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia. *Cardiol Rev* **17**: 70‐6 [\[PMID:19367148\]](http://www.ncbi.nlm.nih.gov/pubmed/19367148?dopt=AbstractPlus)
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24. [Nucleoside synthesis and metabolism](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=920) {#bph13354-sec-0212}
====================================================================================================================

Overview {#bph13354-sec-0213}
--------

The *de novo* synthesis and salvage of nucleosides have been targetted for therapeutic advantage in the treatment of particular cancers and gout. Dihydrofolate reductase produces tetrahydrofolate, a cofactor required for synthesis of purines, pyrimidines and amino acids. GART allows formylation of phosphoribosylglycinamide, an early step in purine biosynthesis. Dihydroorotate dehydrogenase produces orotate, a key intermediate in pyrimidine synthesis. IMP dehydrogenase generates xanthosine monophosphate, an intermediate in GTP synthesis.

Nomenclature[dihydrofolate reductase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2603)[dihydroorotate dehydrogenase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2604)[IMP (inosine 5\'‐monophosphate)](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2624)[IMP (inosine 5\'‐monophosphate)](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2625)[(quinone)](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)[dehydrogenase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)[dehydrogenase 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)HGNC, UniProt[*DHFR*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2861), [P00374](http://www.uniprot.org/uniprot/P00374)[*DHODH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2867), [Q02127](http://www.uniprot.org/uniprot/Q02127)[*IMPDH1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6052), [P20839](http://www.uniprot.org/uniprot/P20839)[*IMPDH2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6053), [P12268](http://www.uniprot.org/uniprot/P12268)EC number[1.5.1.3](http://www.genome.jp/dbget-bin/www_bget?ec:1.5.1.3)[1.3.5.2](http://www.genome.jp/dbget-bin/www_bget?ec:1.3.5.2)[1.1.1.205](http://www.genome.jp/dbget-bin/www_bget?ec:1.1.1.205)[1.1.1.205](http://www.genome.jp/dbget-bin/www_bget?ec:1.1.1.205)Inhibitors[pemetrexed](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6837) (p*K* ~i~ 8.1) \[[161](http://www.ncbi.nlm.nih.gov/pubmed/16078850?dopt=AbstractPlus), [436](http://www.ncbi.nlm.nih.gov/pubmed/9762351?dopt=AbstractPlus)\], [pralatrexate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6840) (p*K* ~i~ 7.3) \[[231](http://www.ncbi.nlm.nih.gov/pubmed/19221750?dopt=AbstractPlus)\][teriflunomide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6844) (p*K* ~i~ 7.5) \[[204](http://www.ncbi.nlm.nih.gov/pubmed/17228860?dopt=AbstractPlus)\], [leflunomide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6825) (p*K* ~i~ 4.9) \[[372](http://www.ncbi.nlm.nih.gov/pubmed/9719606?dopt=AbstractPlus)\][mycophenolic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6832) (pIC~50~ 7.7) \[[351](http://www.ncbi.nlm.nih.gov/pubmed/1967654?dopt=AbstractPlus)\], [ribavirin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6842) (pIC~50~ 5.6--6) \[[526](http://www.ncbi.nlm.nih.gov/pubmed/22555152?dopt=AbstractPlus)\], [mycophenolate mofetil](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6831), [thioguanine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6845) \[[124](http://www.ncbi.nlm.nih.gov/pubmed/14529546?dopt=AbstractPlus), [502](http://www.ncbi.nlm.nih.gov/pubmed/18609073?dopt=AbstractPlus)\][mycophenolic acid](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6832) (pIC~50~ 7.7) \[[351](http://www.ncbi.nlm.nih.gov/pubmed/1967654?dopt=AbstractPlus)\], [ribavirin](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6842) (pIC~50~ 5.6--6) \[[526](http://www.ncbi.nlm.nih.gov/pubmed/22555152?dopt=AbstractPlus)\], [mycophenolate mofetil](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6831) (See **Inhibitor Comment** below), [thioguanine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6845) \[[124](http://www.ncbi.nlm.nih.gov/pubmed/14529546?dopt=AbstractPlus), [502](http://www.ncbi.nlm.nih.gov/pubmed/18609073?dopt=AbstractPlus)\]Selective inhibitors[methotrexate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4815) (p*K* ~i~ 8.9) \[[412](http://www.ncbi.nlm.nih.gov/pubmed/7877140?dopt=AbstractPlus)\]------

Nomenclature[xanthine dehydrogenase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2646)[ribonucleotide reductase M1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2630)[ribonucleotide reductase M2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2631)[ribonucleotide reductase M2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2754)[B (TP53 inducible)](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=)HGNC, UniProt[*XDH*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12805), [P47989](http://www.uniprot.org/uniprot/P47989)[*RRM1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10451), [P23921](http://www.uniprot.org/uniprot/P23921)[*RRM2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10452), [P31350](http://www.uniprot.org/uniprot/P31350)[*RRM2B*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17296), [Q7LG56](http://www.uniprot.org/uniprot/Q7LG56)EC number[1.17.1.4](http://www.genome.jp/dbget-bin/www_bget?ec:1.17.1.4)[1.17.14.1](http://www.genome.jp/dbget-bin/www_bget?ec:1.17.14.1)[1.17.4.1](http://www.genome.jp/dbget-bin/www_bget?ec:1.17.4.1)[1.17.1.4](http://www.genome.jp/dbget-bin/www_bget?ec:1.17.1.4)Inhibitors[febuxostat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6817) (p*K* ~i~ 9.9) \[[361](http://www.ncbi.nlm.nih.gov/pubmed/12421831?dopt=AbstractPlus)\] -- Bovine, [febuxostat](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6817) (pIC~50~ 7.5) \[[255](http://www.ncbi.nlm.nih.gov/pubmed/23122864?dopt=AbstractPlus)\] -- Bovine, [allopurinol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6795) (pIC~50~ 5.4) \[[34](http://www.ncbi.nlm.nih.gov/pubmed/8691450?dopt=AbstractPlus)\], [allopurinol](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6795) (p*K* ~i~ 5.2) \[[34](http://www.ncbi.nlm.nih.gov/pubmed/8691450?dopt=AbstractPlus)\][clofarabine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6802) (pIC~50~ 8.3) \[[375](http://www.ncbi.nlm.nih.gov/pubmed/1707752?dopt=AbstractPlus)\], [fludarabine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4802) (pIC~50~ 6) \[[491](http://www.ncbi.nlm.nih.gov/pubmed/7048062?dopt=AbstractPlus)\], [hydroxyurea](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6822) (pIC~50~ 3.8) \[[433](http://www.ncbi.nlm.nih.gov/pubmed/15670581?dopt=AbstractPlus)\], [gemcitabine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4793) \[[205](http://www.ncbi.nlm.nih.gov/pubmed/2233693?dopt=AbstractPlus)\][clofarabine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6802) (pIC~50~ 8.3) \[[375](http://www.ncbi.nlm.nih.gov/pubmed/1707752?dopt=AbstractPlus)\], [fludarabine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4802) (pIC~50~ 6) \[[491](http://www.ncbi.nlm.nih.gov/pubmed/7048062?dopt=AbstractPlus)\], [hydroxyurea](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6822) (pIC~50~ 3.8) \[[433](http://www.ncbi.nlm.nih.gov/pubmed/15670581?dopt=AbstractPlus)\], [gemcitabine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4793) \[[205](http://www.ncbi.nlm.nih.gov/pubmed/2233693?dopt=AbstractPlus)\]--

Nomenclature[thymidylate synthetase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2642)[phosphoribosylglycinamide formyltransferase,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2612)[purine nucleoside phosphorylase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2841)[phosphoribosylglycinamide synthetase,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2612)[phosphoribosylaminoimidazole synthetase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2612)Common abreviation--GART--HGNC, UniProt[*TYMS*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12441), [P04818](http://www.uniprot.org/uniprot/P04818)[*GART*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=4163), [P22102](http://www.uniprot.org/uniprot/P22102)[*PNP*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7892), [P00491](http://www.uniprot.org/uniprot/P00491)EC number[2.1.1.45](http://www.genome.jp/dbget-bin/www_bget?ec:2.1.1.45)[2.1.2.2](http://www.genome.jp/dbget-bin/www_bget?ec:2.1.2.2)--[6.3.3.1](http://www.genome.jp/dbget-bin/www_bget?ec:6.3.3.1)[6.3.4.13](http://www.genome.jp/dbget-bin/www_bget?ec:6.3.4.13)Inhibitors[pemetrexed](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6837) (p*K* ~i~ 7) \[[436](http://www.ncbi.nlm.nih.gov/pubmed/9762351?dopt=AbstractPlus)\], [capecitabine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6799) \[[63](http://www.ncbi.nlm.nih.gov/pubmed/15709193?dopt=AbstractPlus), [373](http://www.ncbi.nlm.nih.gov/pubmed/10631692?dopt=AbstractPlus)\][pemetrexed](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6837) (p*K* ~i~ 5) \[[436](http://www.ncbi.nlm.nih.gov/pubmed/9762351?dopt=AbstractPlus)\] -- Mouse--Selective inhibitors[raltitrexed](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7403) (pIC~50~ 6.5) \[[162](http://www.ncbi.nlm.nih.gov/pubmed/22739090?dopt=AbstractPlus)\]----

Comments {#bph13354-sec-0214}
--------

Thymidylate synthetase allows the interconversion of dUMP and dTMP, thereby acting as a crucial step in DNA synthesis. Purine nucleoside phosphorylase allows separation of a nucleoside into the nucleobase and ribose phosphate for nucleotide salvage. Xanthine dehydrogenase generates urate in the purine degradation pathway. Post‐translational modifications of xanthine dehydrogenase convert the enzymatic reaction to a xanthine oxidase, allowing the interconversion of hypoxanthine and xanthine, with the production (or consumption) of reactive oxygen species. Ribonucleotide reductases allow the production of deoxyribonucleotides from ribonucleotides.

Further Reading {#bph13354-sec-0215}
---------------

Battelli MG *et al*. (2014) Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi‐tasking enzyme. *Biochim. Biophys. Acta* **1842**: 1502‐17 [\[PMID:24882753\]](http://www.ncbi.nlm.nih.gov/pubmed/24882753?dopt=AbstractPlus)

Cantu‐Medellin N *et al*. (2013) Xanthine oxidoreductase‐catalyzed reduction of nitrite to nitric oxide: insights regarding where, when and how. *Nitric Oxide* **34**: 19‐26 [\[PMID:23454592\]](http://www.ncbi.nlm.nih.gov/pubmed/23454592?dopt=AbstractPlus)

Glander P *et al*. (2012) Inosine 5\'‐monophosphate dehydrogenase activity as a biomarker in the field of transplantation. *Clin. Chim. Acta* **413**: 1391‐7 [\[PMID:21889500\]](http://www.ncbi.nlm.nih.gov/pubmed/21889500?dopt=AbstractPlus)

Munier‐Lehmann H *et al*. (2013) On dihydroorotate dehydrogenases and their inhibitors and uses. *J. Med. Chem.* **56**: 3148‐67 [\[PMID:23452331\]](http://www.ncbi.nlm.nih.gov/pubmed/23452331?dopt=AbstractPlus)

26. [Sphingosine 1‐phosphate turnover](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=776) {#bph13354-sec-0218}
=================================================================================================================

Overview {#bph13354-sec-0219}
--------

S1P ([sphingosine 1‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911)) is a pro‐survival signal, in contrast to ceramide. It is formed by the sphingosine kinase‐catalysed phosphorylation of [sphingosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452). S1P can be released from cells to act as an agonist at a family of five G protein‐coupled receptors (S1P~1‐5~) but also has intracellular targets. S1P can be dephosphorylated back to sphingosine or hydrolysed to form [hexadecanal](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6627) and [phosphoethanolamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6628). Sphingosine choline phosphotransferase (EC 2.7.8.10) generates sphingosylphosphocholine from [sphingosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452) and CDP‐choline. Sphingosine *β*‐galactosyltransferase (EC 2.4.1.23) generates [psychosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5548) from [sphingosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452) in the presence of UDP‐*α*‐D‐galactose. The molecular identities of these enzymes have not been confirmed.

Further Reading {#bph13354-sec-0220}
---------------

Chan H *et al*. (2013) Post‐translational regulation of sphingosine kinases. *Biochim. Biophys. Acta* **1831**: 147‐56 [\[PMID:22801036\]](http://www.ncbi.nlm.nih.gov/pubmed/22801036?dopt=AbstractPlus)

Khavandgar Z *et al*. (2015) Sphingolipid metabolism and its role in the skeletal tissues. *Cell. Mol. Life Sci.* **72**: 959‐69 [\[PMID:25424644\]](http://www.ncbi.nlm.nih.gov/pubmed/25424644?dopt=AbstractPlus)

Maceyka M *et al*. (2014) Sphingolipid metabolites in inflammatory disease. *Nature* **510**: 58‐67 [\[PMID:24899305\]](http://www.ncbi.nlm.nih.gov/pubmed/24899305?dopt=AbstractPlus)

Plano D *et al*. (2014) Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors. *J. Med. Chem.* **57**: 5509‐24 [\[PMID:24471412\]](http://www.ncbi.nlm.nih.gov/pubmed/24471412?dopt=AbstractPlus)

Pyne S *et al*. (2011) Translational aspects of sphingosine 1‐phosphate biology. *Trends Mol Med* **17**: 463‐72 [\[PMID:21514226\]](http://www.ncbi.nlm.nih.gov/pubmed/21514226?dopt=AbstractPlus)

Rosen H *et al*. (2013) Sphingosine‐1‐phosphate and its receptors: structure, signaling, and influence. *Annu. Rev. Biochem.* **82**: 637‐62 [\[PMID:23527695\]](http://www.ncbi.nlm.nih.gov/pubmed/23527695?dopt=AbstractPlus)

Schwalm S *et al*. (2014) Targeting the sphingosine kinase/sphingosine 1‐phosphate pathway to treat chronic inflammatory kidney diseases. *Basic Clin. Pharmacol. Toxicol.* **114**: 44‐9 [\[PMID:23789924\]](http://www.ncbi.nlm.nih.gov/pubmed/23789924?dopt=AbstractPlus)

27. [Sphingosine kinase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=787) {#bph13354-sec-0221}
===================================================================================================

Nomenclature[sphingosine kinase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2204) [sphingosine kinase 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2205)Common abreviationSPHK1, SPHK2HGNC, UniProt[*SPHK1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11240), [Q9NYA1](http://www.uniprot.org/uniprot/Q9NYA1) [*SPHK2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=18859), [Q9NRA0](http://www.uniprot.org/uniprot/Q9NRA0)EC number[2.7.1.91](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.1.91): [sphingosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452) + [ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713) = [sphingosine 1‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911) + [adenosine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712) [ATP](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1713) + [sphinganine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2453) = [sphinganine 1‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6621) + [adenosine diphosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1712)Cofactors[Mg^2+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=708) \[[432](http://www.ncbi.nlm.nih.gov/pubmed/22677141?dopt=AbstractPlus)\]Inhibitors[PF‐543](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6623) (pIC~50~ 8.7) \[[425](http://www.ncbi.nlm.nih.gov/pubmed/22397330?dopt=AbstractPlus)\], [SK1‐I](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6622) \[[377](http://www.ncbi.nlm.nih.gov/pubmed/18511810?dopt=AbstractPlus)\], [ABC294640](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6624) \[[148](http://www.ncbi.nlm.nih.gov/pubmed/20061445?dopt=AbstractPlus)\], [ROMe](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6625) \[[287](http://www.ncbi.nlm.nih.gov/pubmed/21620961?dopt=AbstractPlus)\](Sub)family‐selective inhibitors[sphingosine kinase inhibitor](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6041) (pIC~50~ 6.3) \[[147](http://www.ncbi.nlm.nih.gov/pubmed/14522923?dopt=AbstractPlus)\]

Further Reading {#bph13354-sec-0222}
---------------

Neubauer HA *et al*. (2013) Roles, regulation and inhibitors of sphingosine kinase 2. *FEBS J.* **280**: 5317‐36 [\[PMID:23638983\]](http://www.ncbi.nlm.nih.gov/pubmed/23638983?dopt=AbstractPlus)

Truman JP *et al*. (2014) Evolving concepts in cancer therapy through targeting sphingolipid metabolism. *Biochim. Biophys. Acta* **1841**: 1174‐88 [\[PMID:24384461\]](http://www.ncbi.nlm.nih.gov/pubmed/24384461?dopt=AbstractPlus)

28. [Sphingosine 1‐phosphate phosphatase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=778) {#bph13354-sec-0223}
====================================================================================================================

Nomenclature[sphingosine‐1‐phosphate phosphatase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2523)[sphingosine‐1‐phosphate phosphatase 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2524)Common abreviationSGPP1SGPP2HGNC, UniProt[*SGPP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=17720), [Q9BX95](http://www.uniprot.org/uniprot/Q9BX95)[*SGPP2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=19953), [Q8IWX5](http://www.uniprot.org/uniprot/Q8IWX5)EC number[3.1.3.‐](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.3.-): [sphingosine 1‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911) ‐\>[sphingosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452) + inorganic phosphate[3.1.3.‐](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.3.-): [sphingosine 1‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911) ‐\>[sphingosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2452) + inorganic phosphateCommentsDepletion of S1P phosphohydrolase‐1 (SPP1), which degrades intracellular S1P, induces the unfolded protein response and endoplasmic reticulum stress‐induced autophagy \[[307](http://www.ncbi.nlm.nih.gov/pubmed/22052905?dopt=AbstractPlus)\].--

29. [Sphingosine 1‐phosphate lyase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=777) {#bph13354-sec-0224}
==============================================================================================================

Nomenclature[sphingosine‐1‐phosphate lyase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2522)HGNC, UniProt[*SGPL1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=10817), [O95470](http://www.uniprot.org/uniprot/O95470)EC number[4.1.2.27](http://www.genome.jp/dbget-bin/www_bget?ec:4.1.2.27): [sphingosine 1‐phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=911) ‐\>[phosphoethanolamine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6628) + [hexadecanal](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6627)Cofactors[pyridoxal phosphate](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5249)Inhibitors[compound 31 \[PMID: 24809814\]](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8465) (pIC~50~ 6.7) \[[519](http://www.ncbi.nlm.nih.gov/pubmed/24809814?dopt=AbstractPlus)\]Comments[THI](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6626) (2‐Acetyl‐5‐tetrahydroxybutyl imidazole) inhibits the enzyme activity in intact cell preparations \[[426](http://www.ncbi.nlm.nih.gov/pubmed/16151014?dopt=AbstractPlus)\].

Further Reading {#bph13354-sec-0225}
---------------

Bigaud M *et al*. (2014) Second generation S1P pathway modulators: research strategies and clinical developments. *Biochim. Biophys. Acta* **1841**: 745‐58 [\[PMID:24239768\]](http://www.ncbi.nlm.nih.gov/pubmed/24239768?dopt=AbstractPlus)

Van Veldhoven PP *et al*. (2000) Human sphingosine‐1‐phosphate lyase: cDNA cloning, functional expression studies and mapping to chromosome 10q22(1). *Biochim. Biophys. Acta* **1487**: 128‐34 [\[PMID:11018465\]](http://www.ncbi.nlm.nih.gov/pubmed/11018465?dopt=AbstractPlus)

30. [Thyroid hormone turnover](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=779) {#bph13354-sec-0226}
=========================================================================================================

Overview {#bph13354-sec-0227}
--------

The thyroid hormones triiodothyronine and thyroxine, usually abbreviated as [triiodothyronine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634) and [T~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635), respectively, are synthesized in the thyroid gland by sequential metabolism of tyrosine residues in the glycosylated homodimeric protein thyroglobulin ([*TG*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11764), [P01266](http://www.uniprot.org/uniprot/P01266)) under the influence of the haem‐containing protein iodide peroxidase. Iodide peroxidase/TPO is a haem‐containing enzyme, from the same structural family as eosinophil peroxidase ([*EPX*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=3423), [P11678](http://www.uniprot.org/uniprot/P11678)), lactoperoxidase ([LPO](http://www.genenames.org/data/hgnc_data.php?hgnc_id=6678), [P22079](http://www.uniprot.org/uniprot/P22079)) and myeloperoxidase ([MPO](http://www.genenames.org/data/hgnc_data.php?hgnc_id=7218), [P05164](http://www.uniprot.org/uniprot/P05164)). Circulating thyroid hormone is bound to thyroxine‐binding globulin ([SERPINA7](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11583), [P05543](http://www.uniprot.org/uniprot/P05543)).

**Tissue deiodinases**These are 1 TM selenoproteins that remove an iodine from [T~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635)(3,3\',5,5\'‐tetraiodothyronine) to generate [triiodothyronine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634)(3,3\',5‐triiodothyronine, a more potent agonist at thyroid hormone receptors) or [rT~3~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2636)(rT3, 3,3\',5\'‐triiodothyronine, a relatively inactive analogue). DIO1 is also able to deiodinate RT3 to form 3,3\'‐diidothyronine ([T~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6648)). Iodotyrosine deiodinase is a 1TM homodimeric enzyme.

Nomenclature[thyroid peroxidase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2526)[deiodinase, iodothyronine,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2481)[deiodinase, iodothyronine,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2482)[deiodinase, iodothyronine,](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2483)[iodotyrosine deiodinase](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2488)[type I](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2481)[type II](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2482)[type III](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2483)Common abreviationTPODIO1DIO2DIO3IYDHGNC, UniProt[*TPO*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=12015), [P07202](http://www.uniprot.org/uniprot/P07202)[*DIO1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2883), [P49895](http://www.uniprot.org/uniprot/P49895)[*DIO2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2884), [Q92813](http://www.uniprot.org/uniprot/Q92813)[*DIO3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=2885), [P55073](http://www.uniprot.org/uniprot/P55073)[*IYD*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=21071), [Q6PHW0](http://www.uniprot.org/uniprot/Q6PHW0)EC number[1.11.1.8](http://www.genome.jp/dbget-bin/www_bget?ec:1.11.1.8): \[Thyroglobulin\]‐L‐tyrosine + [H~2~O~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2448) + H^+^ + I^‐^ ‐\> \[Thyroglobulin\]‐3,5,3\'‐triiodo‐L‐thyronine + \[thyroglobulin\]‐aminoacrylate + H~2~O[1.97.1.10](http://www.genome.jp/dbget-bin/www_bget?ec:1.97.1.10): [T~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635) ‐\>[triiodothyronine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634) [rT~3~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2636) ‐\>[T~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6648)[1.97.1.10](http://www.genome.jp/dbget-bin/www_bget?ec:1.97.1.10): [T~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635) ‐\>[triiodothyronine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634) [rT~3~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2636) ‐\>[T~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6648)[1.97.1.11](http://www.genome.jp/dbget-bin/www_bget?ec:1.97.1.11): [T~4~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2635) ‐\>[triiodothyronine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2634) [rT~3~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2636) ‐\>[T~2~](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6648)[1.22.1.1](http://www.genome.jp/dbget-bin/www_bget?ec:1.22.1.1): [3‐iodotyrosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5117) ‐\>[L‐tyrosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4791) + I^‐^ [3,5‐diiodo‐L‐tyrosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6651) ‐\>[3‐iodotyrosine](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5117) + I^‐^Cofactors[Ca^2+^](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=707)------[flavin adenine dinucleotide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5184), [NADPH](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3041)Inhibitors[methimazole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6649) \[[349](http://www.ncbi.nlm.nih.gov/pubmed/748042?dopt=AbstractPlus)\], [propylthiouracil](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6650) \[[349](http://www.ncbi.nlm.nih.gov/pubmed/748042?dopt=AbstractPlus)\]--------CommentsCarbimazole is a pro‐drug for [methimazole](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6649)--------

Further Reading {#bph13354-sec-0228}
---------------

Arrojo E Drigo R *et al*. (2013) Role of the type 2 iodothyronine deiodinase (D2) in the control of thyroid hormone signaling. *Biochim. Biophys. Acta* **1830**: 3956‐64 [\[PMID:22967761\]](http://www.ncbi.nlm.nih.gov/pubmed/22967761?dopt=AbstractPlus)

Darras VM *et al*. (2015) Intracellular thyroid hormone metabolism as a local regulator of nuclear thyroid hormone receptor‐mediated impact on vertebrate development. *Biochim. Biophys. Acta* **1849**: 130‐41 [\[PMID:24844179\]](http://www.ncbi.nlm.nih.gov/pubmed/24844179?dopt=AbstractPlus)

Darras VM *et al*. (2012) Iodothyronine deiodinase structure and function: from ascidians to humans. *J. Endocrinol.* **215**: 189‐206 [\[PMID:22825922\]](http://www.ncbi.nlm.nih.gov/pubmed/22825922?dopt=AbstractPlus)

Gereben B *et al*. (2008) Cellular and molecular basis of deiodinase‐regulated thyroid hormone signaling. *Endocr. Rev.* **29**: 898‐938 [\[PMID:18815314\]](http://www.ncbi.nlm.nih.gov/pubmed/18815314?dopt=AbstractPlus)

Waung JA *et al*. (2012) Thyroid hormone metabolism in skeletal development and adult bone maintenance. *Trends Endocrinol. Metab.* **23**: 155‐62 [\[PMID:22169753\]](http://www.ncbi.nlm.nih.gov/pubmed/22169753?dopt=AbstractPlus)

31. [1.14.11.29 2‐oxoglutarate oxygenases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=900) {#bph13354-sec-0229}
=====================================================================================================================

Overview {#bph13354-sec-0230}
--------

The hypoxia inducible factor (HIF) is a transcriptional complex that is involved in oxygen homeostasis \[[429](http://www.ncbi.nlm.nih.gov/pubmed/11595178?dopt=AbstractPlus)\]. At normal oxygen levels, the alpha subunit of HIF (HIF‐1*α*) is targeted for degradation by prolyl hydroxylation by the PHD proteins 1‐3 (HIF‐PHs) whch are 2‐oxoglutarate (2OG) oxygenases responsible for the post‐translational modification of a specific proline in each of the oxygen‐dependent degradation (ODD) domains of HIF‐1*α*. Hydroxylated HIFs are then targeted for proteasomal degradation *via* the von Hippel‐Lindau ubiquitination complex \[[232](http://www.ncbi.nlm.nih.gov/pubmed/11292861?dopt=AbstractPlus)\]. Under hypoxic conditions, the hydroxylation reaction is blunted which results in decreased HIF degradation. The surviving HIFs are then available to translocate to the nucleus where they heterodimerize with HIF‐1*β*, effecting increased expression of hypoxia‐inducible genes.

HIF‐PH enzymes are being investigated as pharmacological targets as their inhibition mimics the hypoxic state and switches on transcription of genes associated with processes such as erythropoiesis and vasculogenesis \[[142](http://www.ncbi.nlm.nih.gov/pubmed/24371328?dopt=AbstractPlus)\]. Small molecule HIF‐PH inhibitors are in clinical trial as novel therapies for the amelioration of anemia associated with chronic kidney disease \[[46](http://www.ncbi.nlm.nih.gov/pubmed/24213751?dopt=AbstractPlus)\].

Nomenclature[egl‐9 family hypoxia‐inducible factor 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2832)[egl‐9 family hypoxia‐inducible factor 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2833)[egl‐9 family hypoxia‐inducible factor 3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2834)Common abreviationPHD1PHD2PHD3HGNC, UniProt[*EGLN2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14660), [Q96KS0](http://www.uniprot.org/uniprot/Q96KS0)[*EGLN1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1232), [Q9GZT9](http://www.uniprot.org/uniprot/Q9GZT9)[*EGLN3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=14661), [Q9H6Z9](http://www.uniprot.org/uniprot/Q9H6Z9)EC number--[1.14.11.29](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.11.29)[1.14.11.29](http://www.genome.jp/dbget-bin/www_bget?ec:1.14.11.29)Inhibitors--[IOX2](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8229) (pIC~50~ 7.7) \[[84](http://www.ncbi.nlm.nih.gov/pubmed/23683440?dopt=AbstractPlus)\]--

32. [2.4.2.30 poly(ADP‐ribose)polymerases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=883) {#bph13354-sec-0231}
=====================================================================================================================

Overview {#bph13354-sec-0232}
--------

The Poly ADP‐ribose polymerase family is a series of enzymes, where the best characterised members are nuclear proteins which are thought to function by binding to single strand breaks in DNA, allowing the recruitment of repair enzymes by the synthesis of NAD‐derived ADP‐ribose polymers, which are subsequently degraded by a glycohydrolase ([*PARG*](http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=HGNC:8605), [Q86W56](http://www.uniprot.org/uniprot/Q86W56)).

Nomenclature[poly (ADP‐ribose) polymerase 1](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2771)[poly (ADP‐ribose) polymerase 2](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2772)[poly (ADP‐ribose) polymerase 3](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2864)Common abreviationPARP1PARP2PARP3HGNC, UniProt[*PARP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=270), [P09874](http://www.uniprot.org/uniprot/P09874)[*PARP2*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=272), [Q9UGN5](http://www.uniprot.org/uniprot/Q9UGN5)[*PARP3*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=273), [Q9Y6F1](http://www.uniprot.org/uniprot/Q9Y6F1)EC number[2.4.2.30](http://www.genome.jp/dbget-bin/www_bget?ec:2.4.2.30)[2.4.2.30](http://www.genome.jp/dbget-bin/www_bget?ec:2.4.2.30)--Selective inhibitors[AG14361](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8094) (p*K* ~i~ 8.2) \[[445](http://www.ncbi.nlm.nih.gov/pubmed/12519059?dopt=AbstractPlus)\]----

Further Reading {#bph13354-sec-0233}
---------------

Bürkle A *et al*. (2013) Poly(ADP‐ribose): PARadigms and PARadoxes. *Mol. Aspects Med.* **34**: 1046‐65 [\[PMID:23290998\]](http://www.ncbi.nlm.nih.gov/pubmed/23290998?dopt=AbstractPlus)

De Vos M *et al*. (2012) The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. *Biochem. Pharmacol.* **84**: 137‐46 [\[PMID:22469522\]](http://www.ncbi.nlm.nih.gov/pubmed/22469522?dopt=AbstractPlus)

Lord CJ *et al*. (2012) The DNA damage response and cancer therapy. *Nature* **481**: 287‐94 [\[PMID:22258607\]](http://www.ncbi.nlm.nih.gov/pubmed/22258607?dopt=AbstractPlus)

Sonnenblick A *et al*. (2015) An update on PARP inhibitors--moving to the adjuvant setting. *Nat Rev Clin Oncol* **12**: 27‐41 [\[PMID:25286972\]](http://www.ncbi.nlm.nih.gov/pubmed/25286972?dopt=AbstractPlus)

33. [2.5.1.58 Protein farnesyltransferase](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=898) {#bph13354-sec-0234}
=====================================================================================================================

Overview {#bph13354-sec-0235}
--------

Farnesyltransferase is a member of the prenyltransferases family which also includes geranylgeranyltransferase types I (EC 2.5.1.59) and II (EC 2.5.1.60) \[[66](http://www.ncbi.nlm.nih.gov/pubmed/8621375?dopt=AbstractPlus)\]. Protein farnesyltransferase catalyses the post‐translational formation of a thioether linkage between the C‐1 of an isoprenyl group and a cysteine residue fourth from the C‐terminus of a protein (*ie* to the CaaX motif, where \'a\' is an aliphatic amino acid and \'X\' is usually serine, methionine, alanine or glutamine; leucine for EC 2.5.1.59) \[[156](http://www.ncbi.nlm.nih.gov/pubmed/7756316?dopt=AbstractPlus)\]. Farnesyltransferase is a dimer, composed of an alpha and beta subunit and requires Mg^2+^ and Zn^2+^ ions as cofactors. The active site is located between the subunits. Prenylation creates a hydrophobic domain on protein tails which acts as a membrane anchor.

Substrates of the prenyltransferases include Ras, Rho, Rab, other Ras‐related small GTP‐binding proteins, G‐protein *γ*‐subunits, nuclear lamins, centromeric proteins and many proteins involved in visual signal transduction.

In relation to the causative association between oncogenic Ras proteins and cancer, farnesyltransferase has become an important mechanistic drug discovery target.

35. [3.5.3.15 Peptidyl arginine deiminases (PADI)](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=918) {#bph13354-sec-0238}
=============================================================================================================================

Overview {#bph13354-sec-0239}
--------

In humans, the peptidyl arginine deiminases (PADIs; [HGNC family link](http://www.genenames.org/cgi-bin/genefamilies/set/677)) are a family of five enzymes, PADI1‐4 and PADI6. PADIs catalyze the deimination of protein L‐arginine residues to L‐citrulline and ammonia. The human isozymes exhibit tissue‐specific expression patterns \[[244](http://www.ncbi.nlm.nih.gov/pubmed/12606753?dopt=AbstractPlus)\].

36. [RAS subfamily](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=897) {#bph13354-sec-0240}
==============================================================================================

Overview {#bph13354-sec-0241}
--------

The RAS proteins (HRAS, NRAS and KRAS) are small membrane‐localised G protein‐like molecules of 21 kd. They act as an on/off switch linking receptor and non‐receptor tyrosine kinase activation to downstream cytoplasmic or nuclear events. Binding of GTP activates the switch, and hydrolysis of the GTP to GDP inactivates the switch.

The RAS proto‐oncogenes are the most frequently mutated class of proteins in human cancers. Common mutations compromise the GTP‐hydrolysing ability of the proteins causing constitutive activation \[[457](http://www.ncbi.nlm.nih.gov/pubmed/7900159?dopt=AbstractPlus)\], which leads to increased cell proliferation and decreased apoptosis \[[550](http://www.ncbi.nlm.nih.gov/pubmed/17721087?dopt=AbstractPlus)\]. Because of their importance in oncogenic transformation these proteins have become the targets of intense drug discovery effort \[[23](http://www.ncbi.nlm.nih.gov/pubmed/22004085?dopt=AbstractPlus)\].

37. [4.2.1.1 Carbonate dehydratases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=842) {#bph13354-sec-0242}
===============================================================================================================

Overview {#bph13354-sec-0243}
--------

Carbonic anhydrases facilitate the interconversion of water and carbon dioxide with bicarbonate ions and protons (EC 4.2.1.1), with over a dozen gene products identified in man. The enzymes function in acid‐base balance and the movement of carbon dioxide and water. They are targetted for therapeutic gain by particular antiglaucoma agents and diuretics.

Nomenclature[carbonic anhydrase I](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2597)[carbonic anhydrase VII](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2749)[carbonic anhydrase XII](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2747)HGNC, UniProt[*CA1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1368), [P00915](http://www.uniprot.org/uniprot/P00915)[*CA7*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1381), [P43166](http://www.uniprot.org/uniprot/P43166)[*CA12*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=1371), [O43570](http://www.uniprot.org/uniprot/O43570)EC number[4.2.1.1](http://www.genome.jp/dbget-bin/www_bget?ec:4.2.1.1)[4.2.1.1](http://www.genome.jp/dbget-bin/www_bget?ec:4.2.1.1)[4.2.1.1](http://www.genome.jp/dbget-bin/www_bget?ec:4.2.1.1)Inhibitors[chlorthalidone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7147) (p*K* ~i~ 6.5)[methazolamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6828) (p*K* ~i~ 8.7) \[[430](http://www.ncbi.nlm.nih.gov/pubmed/23965175?dopt=AbstractPlus)\], [acetazolamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6792) (p*K* ~i~ 8.6) \[[18](http://www.ncbi.nlm.nih.gov/pubmed/20605094?dopt=AbstractPlus)\], [brinzolamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6797) (p*K* ~i~ 8.6) \[[430](http://www.ncbi.nlm.nih.gov/pubmed/23965175?dopt=AbstractPlus)\], [chlorthalidone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7147) (p*K* ~i~ 8.6) \[[482](http://www.ncbi.nlm.nih.gov/pubmed/19119014?dopt=AbstractPlus)\][chlorthalidone](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7147) (p*K* ~i~ 8.4) \[[482](http://www.ncbi.nlm.nih.gov/pubmed/19119014?dopt=AbstractPlus)\], [diclofenamide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6807) (p*K* ~i~ 7.3) \[[504](http://www.ncbi.nlm.nih.gov/pubmed/15686894?dopt=AbstractPlus)\]

Further Reading {#bph13354-sec-0244}
---------------

Alterio V *et al*. (2012) Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? *Chem. Rev.* **112**: 4421‐68 [\[PMID:22607219\]](http://www.ncbi.nlm.nih.gov/pubmed/22607219?dopt=AbstractPlus)
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Imtaiyaz Hassan M *et al*. (2013) Structure, function and applications of carbonic anhydrase isozymes. *Bioorg. Med. Chem.* **21**: 1570‐82 [\[PMID:22607884\]](http://www.ncbi.nlm.nih.gov/pubmed/22607884?dopt=AbstractPlus)

Sjöblom M. (2011) Duodenal epithelial sensing of luminal acid: role of carbonic anhydrases. *Acta Physiol (Oxf)* **201**: 85‐95 [\[PMID:20632999\]](http://www.ncbi.nlm.nih.gov/pubmed/20632999?dopt=AbstractPlus)

38. [5.99.1.2 DNA Topoisomerases](http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=851) {#bph13354-sec-0245}
============================================================================================================

Overview {#bph13354-sec-0246}
--------

DNA topoisomerases regulate the supercoiling of nuclear DNA to influence the capacity for replication or transcription. The enzymatic function of this series of enzymes involves cutting the DNA to allow unwinding, followed by re‐attachment to reseal the backbone. Members of the family are targetted in anti‐cancer chemotherapy.

Nomenclature[topoisomerase (DNA) I](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636)[topoisomerase (DNA) II alpha 170kDa](http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2637)HGNC, UniProt[*TOP1*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11986), [P11387](http://www.uniprot.org/uniprot/P11387)[*TOP2A*](http://www.genenames.org/data/hgnc_data.php?hgnc_id=11989), [P11388](http://www.uniprot.org/uniprot/P11388)EC number[5.99.1.2](http://www.genome.jp/dbget-bin/www_bget?ec:5.99.1.2)[5.99.1.2](http://www.genome.jp/dbget-bin/www_bget?ec:5.99.1.2)Inhibitors[irinotecan](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6823) \[[117](http://www.ncbi.nlm.nih.gov/pubmed/9655905?dopt=AbstractPlus), [477](http://www.ncbi.nlm.nih.gov/pubmed/8182764?dopt=AbstractPlus)\] -- Bovine[etoposide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6815) (pIC~50~ 7.3), [teniposide](http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6843) \[[119](http://www.ncbi.nlm.nih.gov/pubmed/2557897?dopt=AbstractPlus)\] -- Mouse

Further Reading {#bph13354-sec-0247}
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